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Somatic mutation is a natural process in healthy human tissues but has significant 
implications in a range of disorders and diseases with cancer being the most 
prominent example. In the last decade, genomics research generated big data 
resources that contributed tremendously to our understanding how genetic mutations 
and evolutionary processes shape cancer initiation and progression. More recently, 
sequencing efforts have shifted towards normal human tissues to explore their somatic 
mutational landscapes in order to understand the processes before cancer initiation. 
Here, data from large-scale cancer sequencing efforts is utilized as well as new data 
is generated to explore somatic mutation in healthy human tissues. Firstly, a 
mutational process that associates translocations with long-ranging epigenetic 
silencing is discovered in pan-cancer data. After somatic translocations involving the 
naturally inactivated X-chromosome in women, the RNA expression pattern of the 
partner chromosome indicated the spread of X-inactivation onto the autosomal partner 
in glioblastoma and bladder cancer. This recurrent finding highlights a novel rare 
mechanism how translocations contribute to genome instability and gene expression 
modulation in cancer. Secondly, G&T-seq, a single cell multiomics technique, is 
extended to single nucleotide variant analysis. When applied to cortical neurons, it 
suggested a substantial level of technical artefacts in previously published mutational 
spectra. Thus, this multiomic approach offers an alternative method in a field that is 
still under active development and identifies a basic but refined mutational spectrum 
in individual cortical neurons. Thirdly, hundreds of targeted microdissections of 
prostate epithelium were sequenced to investigate the lineage relationships and clonal 
dynamics within prostatic ductal structures. Through combination of genetic and 
morphological relationship between the epithelial microdissections, long-ranging 
developmental clones could be detected throughout the ductal structures. A 
secondary, more spatially confined expansion was indicated during puberty followed 
by tissue maintenance through local progenitor proliferation. This is the most 
comprehensive insight into the somatic point mutation landscape of healthy human 
prostate and generates valuable insight into the clonal dynamics of prostatic ductal 
epithelium. Collectively, this thesis contributes to the characterisation and our 
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This thesis contributes to the characterisation of somatic mutation and mutational 
mechanisms in cancerous and healthy human tissues. Since the biological context in 
which somatic mutation is studied in differs between the individual chapters, this thesis 
starts with a brief summary about genetic mutations and their relevance in health and 
disease and a more specific introduction is presented at the start of each chapter. 
 
Genetic Mutations 
A mutation is any change in the DNA sequence of an organism. Genetic mutations 
appear across a large range of scales from aneuploidies over structural variations 
(SVs) such gross chromosomal rearrangements or focal copy number alterations 
down to point mutations at individual base pairs 1. Mutations are essential to increase 
the genetic variability and form the basis for Darwinian evolution to act upon. The 
gradual and repeated selection for and removal of mutations over several generations 
are a main driver for speciation together with other necessary factors such as 
reproductive isolation 2. 
 
Since natural selection is a gradual process and the cost or conferred advantage of 
any mutation can vary as widely as the genomic scale affected, pronounced genetic 
variability can already be observed within one species. The human genome between 
any two individuals is identical to at least 99.5% but naturally contains high variability 
in the remaining fraction 3-5. While mutations that are present in more than one percent 
of the population are usually referred to as polymorphisms, they can be used to 
illustrate how common changes are in the human genome 6. Large-scale sequencing 
efforts estimate that every human carries a single nucleotide polymorphism (SNP) 
every 1 – 2 kilobases (kb) as well as up to over 600,000 small insertions or deletions 
in the range of up to 50 base pairs (bp) compared to the reference genome 7-9. 
However, not only base pair-level and small aberrations are common but each 
individual is estimated to carry over 2,000 larger SV events that can sometimes reach 
the scale of megabases (Mb) 9. 
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The Origins of Mutations and Mutational Processes 
Mutations are caused by several endogenous and exogenous factors. They can arise 
at very low frequencies due to the molecular instability of DNA bases and spontaneous 
reactions 10,11. Metabolic by-products such as reactive oxygen species (ROS), DNA 
replication before cell division as well as unwinding of the DNA double-helix during 
transcription all pose steady threats to DNA integrity 12-14. Additionally, cells can be 
exposed to environmental mutagens such as tobacco smoke and aflatoxin or UV and 
ionising radiation 15,16. However, the accumulation of mutations is not always a gradual 
process as catastrophic events such as chromothripsis and kataegis can cause 
thousands of clustered chromosomal rearrangements or vast numbers of point 
mutations across a relatively short stretch of DNA 17,18. 
 
It is estimated that every single cell is facing between 70,000 – 100,000 incidences of 
DNA damage per day, while the relative contribution of different intrinsic and extrinsic 
factors is still a matter of debate 19-23. To deal with this overwhelming amount of DNA 
damage and to maintain genomic integrity, eukaryotes have developed a DNA 
damage response. This response comprises several pathways that among others 
include base-excision repair for the correction of base modifications, nucleotide-
excision repair for the correction of helix-distorting DNA lesions as well as non-
homologous end-joining or homologous recombination to repair double-strand 
breaks 24-26. Furthermore, heavy DNA damage can also result in the induction of 
apoptosis to remove these genomes completely 27. 
 
Given that an adult human body consists of 10-100 trillion of cells and the daily 
average of DNA lesions, these repair mechanisms could face up to 1019 mutations per 
day 28. Arguably, even extremely accurate repair mechanisms will fail to deal with all 
of these lesions correctly and will allow some mutations to manifest themselves. While 
the occurrence of an individual mutation is a stochastic event and can be caused by 
any of the factors outlined above, the type and context of mutations is not random. 
Each of the endogenous or exogenous factors and their associated repair 
mechanisms promote particular molecular reactions and thus, are associated with a 
spectrum of mutations. The first formalised approach to detect the association 
between different underlying mutational processes and their corresponding footprint 
was performed on the point mutation profiles of a large sequencing cohort of cancer 
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patients 29,30. Since then, this concept has been extended using different mathematical 
approaches for the deconvolution of the observed spectrum into individual mutational 
signatures and can also consider doublet base substitutions, small insertions and 
deletions (indels), SVs or integrated frameworks 31-37. It is important to note that for 
many of the mutational processes established in this way, the aetiology still remains 
unknown and is only linked to the independent observation of a distinct mutational 
signature across multiple individuals. The concept that mutations manifest themselves 
in a non-random context that can be linked to mutational signatures will be used in 
several analyses in this thesis. 
 
Germline and Somatic Mutations 
In multicellular organisms, it is important to distinguish between germinal and somatic 
mutations. Any germline mutation has the chance to be passed on to the progeny and 
will be present in all cells of the newborn. The germline mutation rate must correspond 
to the rate of natural selection as a too high mutation rate can cause accumulating 
deleterious effects while excessive fidelity is a fitness cost in itself and prevents 
adaptability to environmental changes. Therefore, the mutation rate can vary widely 
between species 38-41. The germline point mutation rate in humans was estimated to 
be about 1-1.2x10-8 per nucleotide per generation using trio-sequencing approaches, 
which corresponds to roughly 60 new mutations per generation 42,43. 
 
In contrast to germline mutations, somatic mutations are not necessarily required for 
evolution since they cannot be passed on to the next generation. The evolutionary 
argument for their existence is that excessive fidelity in the soma would represent a 
fitness cost with little added benefit past the reproductive age 39,41,44. Although somatic 
mutations cannot be passed on through sexual reproduction, any somatic mutation 
occurring in a dividing cell will be present in all of its cellular progeny. This 
corresponding population of cells is called a clone and the parallel existence of many 
of such clones within one individual was termed somatic mosaicism 45,46. Since the 
concept of somatic mosaicism is central to this thesis, I will give a brief perspective 
about its relevance in the human body and the impact on earlier studies exploring 
somatic mutation. 
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Somatic Mosaicism in Human Tissues 
While early studies already indicated that the somatic mutation rate is orders of 
magnitude higher than in the germline, the initial efforts were confined to observations 
at reporter loci for technical reasons 47-49. Several years later, the advent of next-
generation sequencing technologies allowed for a genome-wide detection of 
mutations 50. However, as the DNA of up to one million cells is used as input material 
for classic bulk genome sequencing approaches, mutations can only be found if their 
clonality exceeds the detection limit 51.  
 
Clone sizes depend on the proliferative capacity of the cell a mutation originally occurs 
in. Thus, the corresponding clone sector is usually larger the earlier the mutation is 
acquired in development 52. Several studies have explored developmental somatic 
mutations in monozygotic twins and successfully challenged the view that any 
phenotypic difference in these twins has to be due to environmental factors 53-59.  
Another study used the relative frequencies of blood cells carrying different 
developmental mutations and could show that many early embryonic cell doubling 
events contribute to the adult blood in an asymmetric 2:1 ratio, further increasing the 
evidence of how pronounced developmental somatic mosaicism is in humans 60. 
 
While the most pronounced somatic mosaicism is established during development, 
postnatal tissue maintenance and environmental exposure steadily increases the 
genetic variability and can give rise to new clones 61. However, somatic mutations 
acquired in this period are usually only present in few cells and lack sufficient clonality 
to be detected by classic bulk sequencing approaches 51. To circumvent this issue, 
initial efforts focussed on clonal haematopoiesis and cancer as a large number of cells 
deriving from a single or few somatic progenitors can be sampled in these instances 
62-66. The studies focussed on clonal haematopoiesis could demonstrate that clonal 
detectability of mutations becomes more common as the age of the donor increases. 
Although the risk for cancer increases with this observed clonal haematopoiesis, most 
of the mutations were not predicted to have any functional impact 62-64. An even more 
striking association with age and a first quantitative estimate of the inter-tissue 
variability of somatic mutation rates and spectra was derived by investigating 
mutational signatures in a large cancer sequencing cohort of various tissue origins. In 
nearly all tissues, two clock-like mutational signatures could be demonstrated. 
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Remarkably, the total and relative burden introduced by these processes varied 
greatly between tissues. The authors suggested that one signature was due to mitotic 
division while the other signature was the footprint of an unrelated clock-like 
process 66.  
 
In summary, somatic mosaicism is continuously shaped and increases during an 
individual’s developmental and postnatal lifetime. Initial efforts seeking to characterise 
somatic mutations on sub-microscopic detail were restricted to developmental 
mutations or clonal syndromes and diseases to circumvent technical detection limits. 
 
Detection Methods for Somatic Mutations in Normal Tissues 
Several approaches have been developed to overcome heterogeneity in normal 
human tissues and the technical detection limit of classic bulk genome sequencing 
(reviewed in 51,67). These approaches can be divided into error-corrected ultra-deep 
sequencing, in-vitro clonal culture or (oligo-)clonal microbiopsies followed by regular 
sequencing or single cell sequencing. 
 
Since the detection limit of genome sequencing data is a function of the obtained read 
depth, ultra-deep sequencing can uncover normal tissue heterogeneity to a certain 
extent. Estimates of variant allele fractions (VAFs) can be used to estimate clone sizes 
and thus, the clonal architecture of patches of tissues could be reconstructed in skin 
and oesophagus 68-70. However, deep sequencing approaches are eventually limited 
by the rate of technical artefacts during library preparation and sequencing. To 
improve the detection limits, several DNA barcoding approaches have been 
developed. The barcode introduction allows for the assembly of read families that 
originate from the same DNA molecule or even from the corresponding Watson or 
Crick strands. Stochastic PCR and sequencing errors will only be present in part of 
the read family, which allows for more reliable variant calls 71-73. Further enrichment of 
these read families by rolling replication of the barcoded DNA molecules or a limiting 
dilution step before library amplification finally allow for variant detection at frequencies 
as low as 10-7 – 10-9 mutations per base pair 74,75. For economic and technical reasons, 
these approaches are limited to targeted or randomly sampled regions of the genome 
and thus, do not allow an unbiased genome-wide investigation of somatic mutations.  
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Clonal culture approaches reduce the detection-limiting heterogeneity within normal 
tissues by culturing single cell-derived clones. Since all somatic mutations of the 
founder cell are now clonal, their mutational landscape can reliably be revealed using 
classic bulk genome sequencing. Since sufficient clonal culture sizes are difficult or 
impossible to obtain for several terminally differentiated human tissues, several 
studies have used reprogramming approaches to derive induced-pluripotent stem 
cells (iPSCs) before clonal expansion. However, the creation of iPSCs is inherently 
mutagenic 76-79. This mutagenic process can be circumvented by somatic nuclear cell 
transfer (SNCT) into enucleated oocytes. This cloning approach depends on the 
epigenetic plasticity of the transferred nucleus and was criticized to preferentially work 
in cells carrying favourable mutations, which would result in a biased estimate of 
mutational burden and processes 80,81. A more direct approach is to utilize tissue-
resident stem or progenitor cells to proliferate in culture. While this process can be 
very inefficient for some tissues, clonal patches or organoids can be derived for a wide 
range of tissues including stomach, small and large bowel, prostate, skin, liver, 
myeloid and lymphoid lineages and even neurons 82-87. However, even these 
approaches might suffer from an inherent selection bias and some of the cell culture-
induced mutations are difficult to distinguish from the original in-vivo acquired somatic 
mutations. 
 
Genetic heterogeneity can also be reduced by using targeted microdissections as 
input for bulk sequencing. Laser-capture microdissection (LCM) is a powerful 
technology to restrict the input material to a morphological subunit or a defined cell 
type within a heterogeneous tissue 88. With sufficient morphological constraints, it is 
possible to derive samples that share a very recent common ancestor and thus, are 
clonal for all mutations present at that time. Colonic crypts are a particularly well-suited 
example to illustrate this since all cells in individual crypts are derived from a single 
progenitor 89,90. Recent studies have used this technology to study somatic mutation 
in colorectal and endometrial epithelial cells 91-93. In this thesis, all insights into somatic 
mutation in the human prostate and clonal dynamics within individual ductal trees are 
derived on the basis of targeted microdissections using LCM. 
 
The most obvious way to circumvent genetic variability within a sample is to sequence 
the DNA of single cells. In theory, this approach is suitable to study any cell type, is 
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not dependent on tissue architecture and cells can be selected at random to avoid any 
bias towards epigenetic or mutational status. Several studies have explored different 
classes of somatic mutations, including single nucleotide variants (SNVs), 
retrotranspositions and copy-number variations (CNVs) in skin, heart and 
predominantly in brain 94-104. However, genome sequencing of single cells requires 
whole-genome amplification (WGA) and can result in uneven and incomplete genome 
coverage, substantial error rates and thus, suboptimal sensitivity and specificity 105,106. 
As single cell sequencing is used to characterise the somatic SNV spectrum in human 
neurons in this thesis, a more detailed discussion of single cell sequencing and the 
differences in sensitivity for different types of mutations follows in the relevant 
chapters.  
 
Using the methods explained in the previous section, several studies have recently 
unveiled surprising findings about somatic mutations in healthy human cells while 
highlighting both common features as well as great differences between tissues 
(summarised in 67,107). Most of these studies were motivated by cancer research and 
to fully appreciate the findings in normal tissues, understanding of the relevance of 
somatic mutation in disease is necessary.  
 
Somatic Mutations in Cancer and Disease 
DNA mutations are essential for evolution and genetic variation is common in healthy 
tissues. However, particular germline and somatic mutations are linked to several 
disorders and diseases. A plethora of syndromes, diseases and disorders are 
associated with inherited and de-novo germline mutations. While they are highly 
relevant to human health, this thesis contributes to the research of somatic mutations. 
As outlined above, methods to study germline and somatic variation differ as do their 
implications. Therefore, this section only aims to give a brief summary about the 
history and relevance of somatic mutations in disease. 
 
Cancer is the most well-characterised example of a disease that is caused by somatic 
mutation 108. The relationship between mutations and cancer emerged in the late 
nineteenth and early twentieth century, when the German biologists David von 
Hansemann and Theodor Boveri observed abnormalities in mitotic divisions and 
corresponding chromosomal aberrations in cancerous epithelial cells 109,110. 
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Extensive research over several decades identified several chemical and 
environmental factors that were epidemiologically associated with cancer and could 
induce neoplasms in animal models. After the discovery of DNA as the inheritable 
substance and its structure in the forties and fifties, these mutagens were shown to 
cause chemical changes in the DNA, further strengthening the link between genetic 
alterations and the occurrence of cancer (reviewed in 15).  
 
Refined chromosomal analyses in the sixties and seventies could demonstrate the 
association between a recurrent chromosomal translocation and a particular cancer 
type. The translocation between chromosomes 9 and 22 and the correspondingly 
derived Philadelphia chromosome is a hallmark of chronic myeloid leukaemia (CML) 
that can also be present in rare subtypes of other leukaemias 111-113. Although the 
concept was only defined much later, this recurrent structural variation was the first 
identification of a driver mutation. Driver mutations are deemed to be the driving force 
for cancer initiation and progression as they confer a selective growth advantage to its 
carrier. Contrary to this, so-called passenger mutations have either negligible minor or 
neutral effects 108,114. It is important to note that the vast majority of mutations detected 
in cancer are passenger mutations. On average, a cancer genome is estimated to 
have four driver mutations with substantial variation depending on the tissue type of 
origin 115-117. 
 
Without a precise definition of driver and passenger mutations, several important 
cancer genes and concepts were discovered in the seventies and eighties. By 
comparing the age-incidence-relationship of familial and sporadic retinoblastoma, the 
requirement for two independent hits in particular genes was postulated for cancer 
progression and the corresponding RB1 gene was identified as the first tumour 
suppressor gene 118,119. Additionally, oncogenes were discovered through the 
neoplastic potential of viral oncogene homologs 120,121. Finally, it could be shown that 
the introduction of genomic DNA from cancerous cells into phenotypically normal cell 
lines caused their transformation, which was the final proof for the causal relationship 
of genetic mutations and cancer 122,123. 
 
In the following decades until today, a myriad of individual studies as well as several 
large-scale consortium projects such as the International Cancer Genome Consortium 
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(ICGC), The Cancer Genome Atlas (TCGA) and the Pan-Cancer Analysis of Whole 
Genomes Project (PCAWG) have contributed to our extensive knowledge about 
genetic mutations in cancer 124-126. Currently, 719 genes are included in the Cancer 
Gene Census and COSMIC, the largest cancer-related database, describes nearly 6 
million coding mutations across 1.4 million cancer samples that have been curated 
from a total of over 26,000 publications 127. 
 
The most extensive research of somatic mutation as a cause for disease was 
performed in the context of cancer but several other examples have been identified. 
Since only a subset of cells within one organism is affected by any particular somatic 
mutation, somatic mosaicism can result in attenuated phenotypes of well-established 
Mendelian diseases. Moreover, some diseases can only manifest in this mosaic state 
when the corresponding constitutional mutation is lethal during development 128. 
Especially developmentally acquired somatic mutations were shown to be associated 
with a range of diseases including psychiatric disorders, autoimmune and 
cardiovascular diseases as well as complex syndromes 55,58,107,128-132.  In recent years, 
ample evidence has also been found for the relevance of somatic mutations in 
neurodegeneration and this is briefly summarised in the chapter addressing somatic 
base substitutions in single human neurons. 
 
Somatic Mutations in the Context of Ageing 
Somatic mutations are more frequently occurring during development but also 
manifest later in life and over the course of aging 61. Several recent studies could 
demonstrate this age-dependent increase of somatic mutation directly in normal 
human tissues while it was already implicated by their corresponding cancerous 
genomes as previously explained 66,68,70,84,86,91,92,102. This accumulation of mutations 
and the functional decline of tissues and organs with ageing, has previously been 
associated with each other in the mutation theory of aging 133,134. Originally, this model 
was criticised as the somatic burden in normal cells was not thought to be substantial 
enough to cause functional decline of a whole tissue 85,107,135. However, the recent 
genomic surveys of normal tissues have revolutionised our understanding of their 
mutational landscape and the resulting clonal architecture. Sun-exposed skin cells 
were shown to carry more than 10,000 mutations in total and a positively selected 
mutation in known cancer genes was present in every fourth cell 69. While the total 
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mutational burden was found to be much lower in normal epithelium of the 
oesophagus, an even higher prevalence of known driver genes and convoluted clonal 
architecture was discovered 68,70. However, there is also great disparity between 
tissues as the high prevalence of driver mutations in skin, oesophagus and 
endometrium is contrasted with their near absence in normal blood and colon 86,91-93. 
 
The universal presence of selection in normal tissues and the complex clonal 
architecture discovered within them, yields new insight into the relationship between 
somatic mutations and the functional decline with age 68-70,86,91-93,107,117. While it is 
unlikely that enough normal cells acquire independent mutations that lead to a 
progressive loss of function, positively selected clones can overtake larger parts of the 
tissue. In essence, this reduces clonality and diversity within a tissue and is similar in 
nature to what had already been observed in clonal haematopoiesis 62-64,85. This less 




On the one hand, this thesis leverages large pan-cancer data sets to explore somatic 
mutational mechanisms. On the other hand, it also contributes to and applies recent 
methods to explore somatic mutation in normal human tissues. 
 
The presented work is divided into four main chapters. The first chapter utilizes the 
PCAWG pan-cancer data set to uncover a mutational mechanism that links somatic 
translocations to long-ranging epigenetic silencing on the translocated chromosomes. 
The second chapter demonstrates that a method for the characterisation of point 
mutations in single cells can be used within a multi-omics technique that allows parallel 
genome and transcriptome sequencing of single cells. The third chapter applies this 
technique to characterise the mutational burden and spectrum in individual neurons 
from normal human brains. The fourth chapter explores somatic mutations within the 
healthy human prostate and provides a qualitative assessment of the clonal dynamics 







Autosomal Spread of X-Inactivation After Somatic 
Translocations in the PCAWG Pan-cancer Data Set 
 
Introduction 
This chapter describes the spread of epigenetic silencing from the inactivated X 
chromosome to autosomes involved in somatic translocations in the Pan-Cancer 
Analysis of Whole-Genomes (PCAWG) data set. Two examples from different cancer 
types are identified that show overall decreased and allele-specific expression (ASE) 
of whole chromosome arms from translocation partners of the inactive X chromosome. 
Due to the resemblance to X chromosomal expression patterns and in absence of any 
further structural variations, these examples are suggested to represent autosomal 
spread of X-inactivation. 
 
The importance and role of translocations in human cancer as well as X-inactivation 
and the known cases of autosomal spread are briefly summarised in this chapter. 
 
The Role of Translocations in Human Cancer 
Genome instability and mutation is one of the hallmarks of cancer 136. While most 
classes of mutations also occur in normal somatic tissue as explained in the general 
introduction, the acquisition of structural driver events is suggested to be a rate-limiting 
step in tumorigenesis 137. Notably, the Philadelphia chromosome as consequence of 
a recurrent translocation between chromosome 9 and 22 was the first discovered 
cancer driver gene 111,112. In general, translocations have a crucial role in cancer 
initiation and progression and are estimated to drive about 20% of all cancer cases 138.  
 
Traditionally, translocations are classified as unbalanced (associated with large-scale 
copy number change) or balanced (copy number-neutral) and distinguished between 
intra- and inter-chromosomal translocation involving two loci of the same or of two 
distinct chromosomes 139. Unbalanced translocations typically exert their oncogenic 
effects through gene expression dosage consequences of the copy number 
changes 116. Balanced translocations can generate chimeric fusion genes or affect 
gene expression through juxtaposition with promoters or other regulatory 
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elements 138,140. Notably, most cancer-relevant translocations are thought to increase 
expression of deregulated genes and the vast majority of fusion genes are associated 
with oncogenic function 138,140. However, rare examples for a suppressive function on 
gene expression or activity such as TTC28 fusions in some colorectal cancer patients 
exist 141. 
 
While translocations can be caused by mechanisms like chromothripsis and 
chromoplexy or be part of other complex structural variations, traditionally defined 
translocations are caused by the erroneous repair of two simultaneously occurring 
double-strand breaks (DSBs) 17,35,140,142. While the exact process is not fully resolved 
yet, it has been shown that several epigenetic modifications are involved in this repair 
process, highlighting the importance of dynamic chromatin modification for the 
generation of translocations 143. While these local changes around the breakpoints are 
dynamic and temporary, the resulting translocation has the potential to join genomic 
regions with different chromatin states. Chromatin states can largely be divided into 
condensed and transcriptionally inactive heterochromatin as well as lightly packed and 
accessible euchromatin 144. A multitude of epigenetic mechanisms influence the 
chromatin state including binding of non-coding RNAs, DNA methylation, histone 
modification and nucleosome positioning 145. Several of these marks are mediated by 
DNA-bound chromatin remodelers that create local gradients around their own 
position and can facilitate spreading by recruiting similar chromatin remodelers in a 
positive feedback loop 145,146. Therefore, translocations between heterochromatic and 
euchromatic regions of the genome have the potential for epigenetic dysregulation of 
the translocation partner. 
 
X-Inactivation as Dosage Compensation Mechanism 
Different dosage compensation mechanisms have evolved in the animal kingdom to 
account for the different amount of gonosomes between the sexes of the same 
species 147. In humans, one of the two X chromosomes in females is randomly 
selected for X chromosome inactivation (XCI) in the late blastocyst stage that causes 
life-long epigenetic silencing of the selected copy in all somatic cells 148,149. For the 
initiation of XCI, the expression of the long non-coding RNA XIST from the cis-acting 
Xist locus of the inactive X chromosome plays a central role 149,150. During the XCI 
process, Xist progressively coats the whole inactive X chromosome and a facultative 
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heterochromatic state is promoted by several additional chromatin modifications, 
including repressive histone tail modifications, DNA hypermethylation and 
nucleosome positioning 151,152. While about 15% of X-chromosomal genes consistently 
escape the epigenetic silencing to a certain extent and about 10% display a variable 
pattern of inactivation, the facultative heterochromatin is maintained throughout life 
and re-established on the same copy in progenitor cells 147,151,153. Notably, XCI 
initiation and maintenance are at least partially dependent on different mechanisms 
since deletion of Xist does not interfere with XCI maintenance after the initial 
establishment 152,154.  
 
Autosomal Spread of X-Inactivation 
While only additional copies of the X chromosome are subject to physiological 
chromosome-wide silencing, spreading of the heterochromatic features and 
concomitant gene silencing has been shown for several cases with germline 
X;autosome translocations 155-161. For all of these cases, the autosome silencing is 
thought to arise from spreading of physiological X chromosome inactivation during 
development and subsequent maintenance. While more genes on affected autosomes 
seem to escape the complete silencing compared to the inactive X chromosome, 
expression levels of whole chromosome arms are affected and were associated with 
developmental disorder or increased cancer risk 156-158,160-162.   
 
While these studies highlight the potential for autosomal spread of XCI for germline 
translocations before the physiological establishment of the inactive X chromosome, 
only one case study describes the autosomal spread of XCI after a somatic 
translocation. In this case, gene silencing of chromosome 5 close after a somatically 
acquired X;5 translocation could be identified as one of the driver mutations for 
essential thrombocythemia 163. Given the differences for developmental establishment 
and adult maintenance of XCI, corresponding differences in the efficiency of 
autosomal spread of XCI after somatic translocation compared to germline events are 
reasonable. Here, the frequency of this largely unexplored mutational mechanism is 
considered in a pan-cancer data set comprising whole-genome and transcriptome 




Data Set Description 
The PCAWG data set is currently the largest collection of whole-genome sequencing 
data for cancer research with a total of 2,834 donors from 39 distinct tumor types 126. 
Additionally, transcriptome data is available for 1,188 from 27 cancer types 164.  
 
Considered samples were restricted to female patients with whole-genome and whole-
transcriptome data that passed the PCAWG consortium quality control (QC) 
standards 165. For genome sequencing, main QC criteria assessed were the mean 
depth and the evenness of coverage, the ratio of paired reads mapping to different 
chromosomes, and the ratio of substitutions between forward and reverse reads. For 
RNA-seq, the QC metrics included sequence quality scores such as base-wise quality 
scores and GC content, mapping quality scores including a minimum fraction of 50% 
mapped reads and an assessment of the 3’/5’ bias. While transcriptome data is 
available as Tophat2 and STAR alignments, only the STAR alignments were 
considered for the presented analyses. In total, data for 620 patients from 26 cancer 
subtypes was obtained. 
 
Structural Variant Calls and Annotation 
Structural variant calls from the BRASS algorithm generated by the PCAWG Structural 
Variation Working Group were downloaded for the same female cancer patients 
described above 35,166. The downloaded SV calls included annotation that 
distinguished classes of structural variants such as deletions, inversions or 
translocations. Only structural variants annotated as translocations were considered. 
 
Inference of Allele-specific Expression 
Unphased germline variants for the same female cancer patients were downloaded 
as generated by the PCAWG Germline Working Group 167. Allele-specific counts for 
these variants were generated for the genome and transcriptome data. For allele-
specific counts, only bases with phred-scaled quality score of at least 20 on reads with 
a phred-scaled mapping quality of at least 20 were considered. Subsequently, 
computation of ASE was restricted to loci with at least eight counts each in WGS and 
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RNA-seq data. Both WGS and RNA-seq data were considered to account for potential 
DNA copy number related changes in expression. 
 
The per-variant odds ratio and significance for allele-specific expression were 
computed using Fisher’s exact test. To analyse allele-specific expression on a gene 
level, the significance for all variants within protein-coding genes according to the 
GENCODE 19 annotation was combined using Fisher’s method and corrected for 
multiple testing using the Benjamini-Hochberg procedure. 
 
Impact of Autosome;Autosome and X;Autosome Translocations on ASE 
All translocations can interfere with physiological gene expression of their new 
genomic environment. Thus, potentially observed ASE is not necessarily due to 
autosomal spread of XCI and a uniformly distributed test statistic is not expected when 
testing genes for ASE in adjacency to X;autosome translocations. 
 
To reveal differences with respect to ASE in vicinity to autosome;autosome or 
X;autosome translocations, ASE was computed for all autosomal protein-coding 
genes as defined in the GENCODE 19 annotation within a maximum distance of 4 Mb 
from annotated breakpoints of heterologous chromosome translocations. In case one 
gene was within the distance and correct orientation of several translocation 
breakpoints, the gene was associated with the closest translocation. A bootstrap 
hypothesis test of equality was performed to compare the p-value distributions for 
autosomal genes in vicinity of X-chromosomal or autosomal translocations using the 
R package sm 168. 
 
Inference of X-Activity Status via Phasing 
All reads supporting the annotated X-chromosomal translocations were screened for 
the presence of heterozygous germline variants from the respective sample. In case 
one SNP allele could be associated with a translocation breakpoint, the X 
chromosome was phased for this sample using SHAPEIT v2.r837 against the 1000 
genomes reference panel 169. To improve the quality and reduce branching of the 
haplotype tree structure, the read-aware phasing option was used 170. Phasing 
uncertainty of the breakpoint-supported variant with the three closest expressed 
heterozygous SNPs both upstream and downstream was computed using 
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SHAPEIT v2.r837 169. A total of 1,000 discrete haplotype sets were sampled from the 
phasing graph structure emitted by SHAPEIT v2.r837 and the probability for all 
haplotype combinations of the selected germline variants was calculated. Phasing with 
the breakpoint-supporting variant was considered sufficient if a haplotype block of at 
least three of the seven considered variants displayed a phasing likelihood greater 
than 0.9. For these cases, the X-activity status was derived by comparing the 
haplotype for the breakpoint-associated allele with the haplotype expression status 
and assigned accordingly. 
 
Inference of X-Activity Status Using Copy Number and Expression Information 
For some translocations, the activity status of the X chromosome could be inferred 
using copy number information. Copy number analyses were generated by the 
PCAWG Structural Variation Working Group using ascatNgs and downloaded for the 
patients considered in this study 35,166. 
 
By definition, all unbalanced translocations coincide with a change in copy number. 
However, also reciprocal translocations frequently lead to a small deletion in at least 
one of the chromosomes involved in the translocation 171. For two different scenarios, 
ploidy information and copy number changes were used to assign the activity status 
to the X chromosome involved in an X;autosome translocation. 
 
In case of a single copy of the X chromosome, samples were checked for X-
chromosomal ASE. In case the single X chromosome copy in the tumour would be 
silenced, any X-chromosomal expression must have derived from the non-clonal 
normal contamination in the tumour sample. In this case, most loci would show 
expression of both X-chromosomal alleles. However, if substantial ASE was observed 
across the whole X chromosome, the single X-chromosomal copy was actively 
expressed in the tumour sample. Therefore, all X-chromosomal translocation in this 
sample were assigned to involve the active X chromosome. As ASE was always 
maintained for samples with a single copy of the X chromosome, only active 
X;autosome translocations were identified for these cases. 
 
In case two X-chromosomal copies were observed, large coinciding deletions were 
necessary to assign the activity status to the X chromosome involved in the 
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translocation. Notably, it was necessary to assume the most parsimonious explanation 
of nearly identical breakpoints for deletions and translocation, in which the deletion 
and the translocation involve the same DNA molecule and not both homologous 
chromosomes. Similar to the example above, ASE of the X chromosome across the 
deleted regions was used to assign the X-activity status. If ASE was maintained for 
the monosomic segment, the inactive copy must have been lost and thus, been the 
one involved in the translocation. Accordingly, if ASE was lost for the monosomic 
segment, the active X chromosome must have been involved in the translocation. 
Notably, only X;autosome translocations involving the inactive copy were detected 
using this method. 
 
Manual Curation of Relevant Translocations 
All breakpoints annotated as X;autosome translocation with assigned X-activity status 
were manually curated. All structural variants and copy numbers of the X chromosome 
and the autosomal translocation partner were visualised as described by the PCAWG 
Structural Variation Working Group 35. Any translocations similar to templated 
insertions, chromothripsis, chromoplexy or other complex structural variation on the 
involved chromosome arms were excluded from further analyses. Templated 
insertions were characterised by a focal copy number gain of the donor chromosome, 
a focal deletion of the receiving chromosome and the corresponding orientation of two 
inter-chromosomal breakpoints 35. Chromothripsis was defined as high translocation 
breakpoints to various chromosomes. Chromoplexy was assumed if at least three 
interlinked translocations were observed. Any translocation involving more than two 
chromosomes or coinciding deletion or duplication was considered to be a complex 




Comparison of Gene Expression 
Autosomal spread after translocations involving the inactive X-chromosome was 
indicated in a glioblastoma (GBM) and bladder urothelial cancer (BLCA). Gene 
expression information for 28 additional GBM and 21 BLCA patients were downloaded 
as FPKM values as generated by the PCAWG Transcriptome Working Group 164. All 
genes with FPKM values of at least 0.1 in the sample with X;autosome translocation 
were considered as expressed and the cancer-specific mean expression for these 




All statistical analysis was performed in R version 3.5.0 using core distribution 





Adjacency to X-chromosomal Translocations More Frequently Induces ASE 
Than Proximity to Autosomal Translocations 
Physiological XCI in women is necessary for dosage compensation and results in ASE 
for most X-chromosomal genes. Since XCI is initially randomly established per cell in 
the human blastocyst and then clonally maintained throughout life, normal tissues do 
not display ASE for X-chromosomal expression in bulk RNA-seq 149. However, all cells 
within one tumour originally derive from a single somatic cell and thus, display 
repression of the same X chromosome. Since no epigenetic information was available 
for most donors from PCAWG, ASE was used as one proxy for XCI. 
 
All structural variants, including autosome;autosome translocations, can cause ASE 
in their adjacency by disrupting gene boundaries or regulatory elements. To ensure 
that ASE marks the autosomal spread of XCI above this random background, I 
compared the frequency of autosomal genes displaying ASE adjacent to X-
chromosomal or autosomal translocations as described in the methods section.  
 
In the 620 appropriate samples from PCAWG, we identified a total of 85,584 inter-
chromosomal breakpoints, with 2,077 (2.4%) from 158 donors being X;autosome inter-
chromosomal breakpoints. ASE was evaluated for 8,606 and 229,087 autosomal 
genes in proximity to X;autosome and autosome;autosome inter-chromosomal 
breakpoints, respectively. After correction for multiple hypothesis testing using the 
Benjamini-Hochberg procedure, a total of 1,574 (17.9%) and 35,124 (15.3%) 
autosomal genes adjacent to X;autosome and autosome;autosome inter-
chromosomal breakpoints, respectively, displayed significant ASE (defined by 
q < 0.05). While significant ASE was also detected near autosomal translocation 
breakpoints, genes associated with X-chromosomal translocation breakpoints were 
more significantly affected (see Figure1; bootstrap hypothesis test of equality, 
p < 1e-3). This indicated that ASE is more common in proximity of X-chromosomal 
translocations compared to a general translocation background and suggested a 




Figure 1: Autosomal Genes Near X-Chromosomal Translocations are More 
Significantly Affected by ASE than Genes Near Autosomal Translocations. The 
probability for ASE was calculated for autosomal protein coding genes and associated 
with translocation breakpoints as called by BRASS. Genes were associated with the 
closest translocations within a 4 MB window and annotated as being affected by either 
an autosome;autosome or an X;autosome translocation. The QQ-plot demonstrates 
that autosomal genes in proximity to an X-chromosomal translocation are more 
significantly affected by ASE compared to a background defined by autosomal 
translocations. 
 
Activity Inference for the Translocation-involved X Chromosome Without 
Epigenetic Sequencing Information is Possible in a Subset of Donors  
To further explore this apparent bias in skewed allele expression, it was important to 
establish whether the inactive or the active X chromosome was involved in the 
breakpoint. Since there was no epigenetic information available for any of the 158 
samples with X;autosome translocations, three different approaches relying on copy 
number, expression and phasing data were used to infer the X-activity status, which 
are described in the methods section in more detail: i) In cases where only a single 
copy of the X chromosome was present, all translocations in this sample could be 
assigned to involve the active copy (Figure 2A); ii) If a translocation breakpoint on the 
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X chromosome coincided with a copy number loss from two to one copy of the X 
chromosome and ASE was maintained in the lost segment, the inactive copy was 
implied to be involved in the translocation (Figure 2B); iii) If at least one of the reads 
supporting the breakpoint on the X chromosome featured a heterozygous germline 
variant, haplotype-phasing with other expressed variants on the X chromosome was 
performed and the activity status of the X chromosome involved in the translocation 
assigned accordingly if high phasing quality was indicated. In total, the X-activity status 
could be assigned for 61 X;autosome breakpoints from 23 samples. Of these 61 
translocation breakpoints, 40 breakpoints in 9 samples were assigned to involve the 
active X chromosome, with the remaining 21 breakpoints in 14 samples were 
associated with translocations of the inactive X chromosome. 
 
 
Figure 2: Copy Number and Expression Information Can be Used to Infer the 
X-Activity Status. TD: Tandem duplication. D: Deletion. HH: Head-to-head inversion. 
TT: Tail-to-tail inversion. (A) A single copy of the X chromosome with chromosome-
wide ASE indicates the involvement of the active X chromosome in the three 
X;autosome translocations in this sample. (B) Large scale deletions resulting in loss 
of one of the two X-chromosome copies that coincide with an autosomal translocation 
characterize unbalanced X;autosome translocations. ASE in the monoallelic region 
indicates that the inactive copy was lost. The 11;X translocation in this sample involved 
the inactive X chromosome. 
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Subsequent to X-activity inference, the subset of translocation breakpoints with 
assigned status was further curated to exclude all translocation-annotated variants 
that did not represent single large-scale translocations. Two breakpoints within one 
sample were interpreted to derive from chromothripsis, which would obscure any 
inference about autosomal spread of X-silencing. Moreover, a total of 37 breakpoints 
from 16 samples represented templated insertions. Templated insertions are a 
common SV in cancer, where short chromosomal segments are copied and inserted 
into distant regions of the genome, presumably during replication 35. Since these short 
replication-based events are unlikely to confer any spread of their epigenetic status, 
they were also excluded from further analyses. 
 
The remaining 22 X;autosome breakpoints with assigned X-activity status could be 
confirmed to represent genuine translocation events. Considering that one balanced 
translocation is marked by two and unbalanced translocations by one X-chromosomal 
breakpoint, a total of 17 large-scale translocations with inferred X-activity status could 
be identified. From the total of 17 curated X;autosome translocations, eleven events 
in six donors were identified to involve the active copy and six translocations from 
another six donors were associated with the inactive copy of the X chromosome. 
 
Somatic Translocations of the Inactive X Chromosome Can Cause Long-ranging 
ASE on Autosomal Partner Chromosomes 
Autosomal spread of XCI after germline X;autosome translocations was previously 
shown to be long-ranging but discontinuous 162. To assess ASE potentially caused by 
autosomal spread of XCI in the presented data set, the odds ratio for ASE was 
computed for all autosomes involved in the 17 manually curated X;autosome 
translocations with inferred activity status of the X chromosome. 
 
In the six donors that featured the 17 events with active X translocations, the 
corresponding autosomes only displayed ASE on chromosome segments that were 
affected by additional structural variations such as copy number loss or loss of 
heterozygosity (LOH) (Figure 3). Hence, no substantially elevated odds ratio for ASE 
on translocation partners of the active X-chromosome could be observed. 
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The six translocations involving the inactive X chromosome were detected in three 
patients with ovarian serous carcinoma (OSC) as well as in one hepatocellular 
carcinoma (HCC), GBM and BLCA. The three OSC as well as the one HCC case did 
not display substantially elevated odds ratios for ASE on the autosomal part of the 
chromosome that was adjacent to the inactive X chromosome following the 
translocation (Figure 4). 
 
 
Figure 3: Translocations of the Active X Chromosome Do Not Induce ASE. The 
alternative allele fraction detected in RNA-seq and WGS as well as the corresponding 
log odds ratio for ASE were computed for all heterozygous germline SNPs on the 
autosomal partner chromosome of active X-chromosomal translocations. The average 
log odds ratio is indicated by the purple spline fit and the breakpoint of X-chromosomal 
translocations is highlighted in black. (A) No elevated ASE is detected on either side 
of chromosome 2 after a balanced translocation involving the active X chromosome in 
a malignant lymphoma sample. (B) ASE observed on chromosome 14 after an 
unbalanced X-chromosomal translocation is associated with LOH in a breast cancer 




Figure 4: Some Translocations of the inactive X chromosome Do Not Suggest 
Autosomal Spread of XCI. The alternative allele fraction detected in RNA-seq and 
WGS as well as the corresponding log odds ratio for ASE were computed for all 
heterozygous germline SNPs on the autosomal partner chromosome of active X-
chromosomal translocations. The average log odds ratio is indicated by the purple 
spline fit and the breakpoint of X-chromosomal translocations is highlighted in black. 
(A) LOH on chromosome 7 sufficiently explains the observed ASE after translocation 
of the inactive X chromosome in an OSC patient. (B) A copy number gain of 
chromosome 7 after translocation of the inactive X chromosome causes low levels of 
ASE in an HCC patient but does not suggest autosomal spread of XCI. 
 
For the GBM and BLCA patient, long-ranging ASE in absence of additional structural 
variants could be observed for the autosomal chromosome arms in adjacency to the 
inactive X chromosome (Figure 5 and 6). A balanced 1q;X translocation in the GBM 
patient resulted in strong ASE across most of chromosome 1q and only declined close 
to the centromeric region. Notably, no other structural variation was detected on 
chromosome 1q for this patient (Figure 5A and Figure 6A). For the BLCA patient, a 
21;X translocation but no other structural variation on chromosome 21 could be 
detected. Only a few protein-coding genes reside on chromosome 21, but a long-
ranging ASE signal was observed (Figure 5B and 6B). Since translocations involving 
the inactive X chromosome were the only events on the relevant autosomal segments 
for both of these patients and ASE could be detected up to 50 MB from the 
translocation breakpoint, these cases potentially represent autosomal spread of X-




Figure 5: Translocations in a Glioblastoma and a Bladder Urothelial Cancer 
Patient Involved the Inactive X-Chromosomal Copy. TD: Tandem duplication. 
D: Deletion. HH: Head-to-head inversion. TT: Tail-to-tail inversion. (A & B) 
Glioblastoma patient. (A) Translocation to chromosome 1 coinciding with copy number 
loss but maintained ASE identified the involvement of the inactive X-chromosomal 
copy in a balanced 1q;X translocation. (B) Reciprocal translocation to chromosome X 
was the only structural variant detected on chromosome 1q. (C & D) Bladder urothelial 
cancer patient. (C) Copy number loss coinciding with the 21;X translocation and 
maintained ASE on chromosome X suggested translocation of the inactive X-
chromosomal copy. (D) Translocation to chromosome X was the only structural event 




Figure 6: Autosomal Spread of XCI After Translocation of the Inactive X 
Chromosome is Suggested in a Glioblastoma and a Bladder Urothelial Cancer 
Patient. The alternative allele fraction detected in RNA-seq and WGS as well as the 
corresponding log odds ratio for ASE were computed for all heterozygous germline 
SNPs on the autosomal partner chromosome of inactive X-chromosomal 
translocations. The average log odds ratio is indicated by the purple spline fit and the 
breakpoint of X-chromosomal translocations is highlighted in black. (A) Substantially 
elevated ASE is detected on chromosome 1q after balanced translocation of the 
inactive X chromosome in a GBM patient. (B) Translocation of the inactive X 
chromosome causes chromosome-wide ASE on chromosome 21 in a BLCA patient 
after an unbalanced translocation of the inactive X chromosome. 
 
Autosomal Segments Affected by Long-ranging ASE Adjacent to Inactive 
X-Chromosomal Translocations Display Reduced Gene Expression 
Physiological inactivation of the X chromosome in women during development 
represents a dosage compensation mechanism 173. Consequently, chromosomal 
segments affected by autosomal spread of XCI were expected to be downregulated 
in addition to the observation of ASE. To corroborate the potential spread of XCI on 
chromosome 1q in a GBM patient and on chromosome 21 in a BLCA patient, the 
expression of these genomic regions was compared to the average expression of the 
corresponding cancer type. 
 
For all genes that were expressed for the corresponding sample with observed ASE, 
the average FPKM values were computed from all other PCAWG donors with 
RNA-seq data of the appropriate cancer subtype. When the subtype-specific gene 
expression was compared for the relevant genomic segments, significantly lower 
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levels of expression was observed for both the GBM and the BLCA patient (Figure 7; 
p = 1e-11 for GBM and p = 5e-4 for BLCA, Wilcoxon-Mann-Whitney test). Since the 
same regions were affected by reduced expression in addition to ASE after somatic 
translocation of the inactive X, this further substantiated the evidence for autosomal 
spread of X-silencing in the GBM and BLCA patient. 
 
 
Figure 7: The Glioblastoma and Bladder Urothelial Cancer Patient Display 
Significantly Reduced Expression in the Autosomal Segment Affected by ASE 
After Translocation of the Inactive X Chromosome. Expression of protein coding 
genes on chromosome 1q for the GBM patient and chromosome 21 for the BLCA 
patient were compared to the average expression of the corresponding cancer 
subtype. For both patients, the chromosomal segments affected by ASE after 
translocation of the inactive X chromosome displayed significantly lower expression 





Translocations are recognised as an important class of structural events in cancer that 
can impact genome stability in several ways 138,140. While disease-relevant 
translocations are typically linked to the generation of fusion genes, disruption of 
tumour suppressor genes or enhancer hijacking, the presented data highlights 
autosomal spread of XCI as additional mechanism for long-ranging dysregulation of 
gene expression. Autosomal spread of epigenetic silencing is established for germline 
disorders but only one case study could demonstrate this for a somatic translocation 
in a myeloproliferative neoplasm 155-161,163. Here, a large pan-cancer data set is 
systematically screened for X;autosome translocations and potential cases of 
autosomal spread of XCI. 
 
From 620 considered female cancer patients, X;autosome translocation events could 
be identified in 158 samples. An initial comparison of ASE in proximity of all 
translocation-annotated breakpoints suggested an enrichment in adjacency to 
X;autosome translocations (Figure 1). Notably, this difference was detected 
regardless of the activity status of the X chromosome involved in the translocation. 
The assignment of the X-activity status was only possible in a subset of twelve 
manually curated patients (Figure 2). The absence of epigenetic information and the 
small subset of patients that could eventually be considered for a detailed analysis, 
also represent the main limitations of this study. However, two cases in which somatic 
translocation of the inactive X chromosome caused long-ranging ASE and 
downregulation of gene expression on the autosomal translocation partner could be 
identified by combining genome and expression data (Figure 4-6). The similarity to 
physiological X-silencing and the absence of any other genomic alteration strongly 
suggests that these cases are genuine examples of autosomal spread of XCI. The 
occurrence in two different genomic regions and tumour types within a large pan-














Multiple Displacement Amplification (MDA) is one of several WGA methods that are 
necessary to generate sufficient input material from the DNA of single cells for 
sequencing experiments 105,174-176. G&T-seq is a modern multiomics technique that 
allows for the parallel analysis of the genome and the transcriptome from the same 
single cell 177,178. An initial nucleic acid separation step within G&T-seq necessitates 
the DNA amplification on magnetic beads and although several MDA kits with slightly 
different chemistries exist, none of them was optimised for this particular experimental 
design. Therefore, this chapter demonstrates the suitability of MDA for G&T-seq and 
selects the optimal available chemistry for this approach.  
 
A brief overview of single cell transcriptome and genome sequencing as well as 
relevant multiomics approaches is presented to provide a background for this rapidly 
evolving field and to highlight the importance of method and chemistry validation within 
new experimental designs. 
 
Single Cell Transcriptome Sequencing 
The transcriptome was the first entire molecular layer that single cell sequencing 
methods were presented for in 2009, only one year after corresponding bulk 
sequencing approaches were published 179-181. While many different methods with 
complementary features exist nowadays, they all comprise the initial isolation and lysis 
of the cell or nucleus, followed by reverse transcription (RT) of the RNA and a 
subsequent amplification of the cDNA 182. Over time, novel methods have substantially 
reduced the levels of technical noise through optimisation of the involved enzymes, 
primer sequences or reaction conditions and also increased the throughput by 
introducing cellular or molecular barcoding techniques that allow for pooled 
amplification (reviewed in 183). In general, the approaches can be divided into plate-
based and droplet-based methods. Plate-based approaches typically rely on the 
physical separation of cells by micromanipulation, limiting dilution or fluorescence-
 34 
activated cell sorting (FACS). The wells contain barcoded oligos that are added 
through RT, ligation or PCR, which improve the throughput by allowing for pooled 
reactions of subsequent steps 182,183. While plate-based formats are intrinsically limited 
in throughput, modern approaches using microwell-plates, droplet-containers or 
sequential combinatorial indexing can yield up to a few tens of thousands of cells per 
experiment 184,185. Droplet-based methods use microfluidics to capture individual cells 
in nanolitre emulsions in which the initial barcoding reactions are performed. In 
contrast to the plate-based methods, there is no intrinsic throughput limitation for 
droplet-based methods but typical experiments aim to profile thousands to tens of 
thousands of cells per run 183. Another important distinction of single cell RNA-seq 
(scRNA-seq) technologies that is also correlated to its throughput, is the difference 
between tag-based profiling and sequencing of full-length transcript structures 182. 
Sequencing of the complete transcript structure allows for the detection of alternative 
splicing, population-based genotyping as well as the estimation of RNA editing and 
allele-specific expression (ASE). However, despite a rapid decline of sequencing cost, 
full-length and high-depth analysis of the transcriptome from a large number of cells 
is still economically challenging and thus, several methods only aim to obtain short 
fragments from the 5’- or 3’-ends of the transcript. While losing some granularity, these 
tag-based methods enable the global characterisation of gene expression profiles of 
a large number of cells 182. 
 
The availability of scRNA-seq revolutionised the way cell types are defined nowadays. 
Traditionally, cell types were defined by their location within tissues and their 
morphological features. The advent of monoclonal antibodies and FACS as well as 
Fluorescence in situ hybridisation (FISH) made it possible to detect particular proteins 
and surface antigens, genomic features such as rearrangements as well as specific 
RNA transcripts and added further resolution to cell type definition (reviewed in 186). 
While these approaches already associated cell types with the presence of molecular 
markers, they are based on sporadic discoveries and not the result of systematic and 
comprehensive mapping of entire molecular layers. In contrast, scRNA-seq and 
genome-wide expression profiling allow for the unbiased classification of cells with 




Despite its great potential and widespread use, scRNA-seq comes with inherent 
limitations. For example, most techniques only achieve to capture 3 – 20% of all 
messenger RNA (mRNA) molecules per cell, leading to high technical variability 
between cells 187. Additional technical variation such as batch effects and amplification 
biases together with intrinsic biological variation such as stochastic gene expression 
or cell cycle-based fluctuations, pose additional challenges to the robust analysis of 
scRNA-seq data 182. However, these limitations are increasingly recognised and 
addressed with active bioinformatic method development 188-190. While several other 
molecular layers can be probed with single cell sequencing nowadays and some 
remaining limitations of scRNA-seq, transcriptome analysis is still considered the most 
mature single cell technology 191. 
 
Single Cell Genome Sequencing 
Single cell genome sequencing is a more recent technology compared to single cell 
transcriptomics. While it was already shown that amplifications of whole human 
genomes were feasible in 2002 and NGS technology became available in 2007, the 
first single cell whole-genome sequences from human cells were published in 
2011 50,175,192. In this work, 200 single nuclei from breast tumours and their liver 
metastases were isolated and despite only covering about 6% of the genome per cell, 
extensive subclonal copy number evolution could be demonstrated192. In the following 
years, single cell genomics contributed substantially to our understanding of genomic 
heterogeneity in cancerous and normal human tissues 67,107,176,193. 
 
Diverse classes of mutations such as retrotransposition, CNVs or SNVs have been 
analysed in various tissues with single cell genomics. Similar to single cell 
transcriptomics, many different single cell genome sequencing methods exist 176. In 
general, they all include the common steps of isolation and lysis of cells or nuclei, 
followed by WGA before sequencing library preparation. WGA is necessary as single 
cells only contain around six picograms of DNA, which is orders of magnitude below 
the required input for sequencing experiments 176. Several different WGA methods 
have been developed that all have unique benefits but also an associated spectrum 
of artefacts and technical limitations. Thus, the choice of the WGA method is crucial 
and limits the eventually generated sequencing data to certain downstream 
analyses 105,106,176. 
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Extensive efforts have been made to compare various WGA methods and 
chemistries 105,106,194-200. Usually, these comparisons are aiming to assess the 
suitability of a range of commercially available WGA methods for particular or several 
downstream analyses 105,106,197-199. Moreover, they are trying to assess the impact of 
the quality or different sample states such as fresh or frozen tissue on different WGA 
techniques or focus on a particular organism or tissue 194,195,200. WGA methods are 
often classified into three groups and while general trends for each class emerge from 
these comparisons, it is also evident that the obtained results differ based on the 
precise application and experimental conditions. Notably, differences can be detected 
between kits that rely on the same basic class of WGA but are from different 
commercial suppliers 105,197. Therefore, it is crucial to validate the WGA of choice for 
new experimental conditions. To provide a general overview about different WGA 
classes and their advantages and limitations, a brief summary is given below. 
 
First approaches completely relied on PCR amplification that target common or 
adaptor sequences or used degenerate-oligonucleotide primed PCR (DOP-PCR; 
Figure 8A) 105,201. While the first single cell genomics study successfully applied this 
WGA method on tetraploid nuclei to study large-scale copy number variation, DOP-
PCR generally suffers from poor genome coverage, high allelic dropout (ADO) and an 
elevated point mutation error rate compared to more recent approaches 105,106,176,202.  
 
To mitigate the low breadth of genome coverage when solely relying on PCR 
amplification, a more diverse class of methods uses an initial strand displacement 
amplification step to introduce an adaptor onto the copied strands. This limited 
isothermal amplification is commonly followed by several rounds of semi-linear 
amplification of the initial product to improve uniformity across the genome before a 
final PCR-based amplification 202,203. Since they combine isothermal displacement 
with PCR-based amplification, they are referred to as hybrid methods (Figure 8B). 
These hybrid methods have been shown to provide the highest coverage uniformity of 
currently available WGA methods with significantly increased breadth of coverage 
compared to DOP-PCR 105,106,176,197. 
 
The third class of WGA comprises multiple displacement amplification using 
isothermal reactions with the high-fidelity Φ29 DNA polymerase and random 
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primers 174,175,204. Through a continuous process of strand displacement and random 
priming, MDA generates highly branched structures in an exponential amplification 
process (Figure 8C). This exponential amplification can lead to pronounced non-
uniformity of the amplified DNA resulting in high levels of ADO and artificial biases for 
copy number detection 105,106,194,204. While less suitable for the detection of CNVs, 
MDA is preferred for genome-wide single cell SNV analyses due to its superior breadth 




Figure 8: Schematic Overview of WGA Methods. (A) Pure PCR Methods. PCR 
methods prime on naturally occurring or introduced common sequences and achieve 
WGA through continuous PCR amplification. (B) Hybrid Methods. Hybrid methods 
use initial (semi-)linear strand displacement amplification before a PCR-based 
amplification. (C) MDA. MDA solely relies on the isothermal strand displacement 
amplification. 
 
While MDA represents the preferred WGA method for the detection of base 
substitutions, it is important to note that heat-dependent cytosine deamination occurs 
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during common lysis protocol and the subsequent enzymatic amplification still 
introduces an average of 1000 erroneously paired bases for every complete 
amplification of the human genome 105,106,204. This remaining burden of technical 
artefacts can be aggravated by the non-uniform amplification of MDA, which can make 
it difficult to distinguish between early introduced artefacts and true biological 
variants 51. These limitations were targeted by several technical improvements of the 
method such as alkaline cell lysis on ice or the potential for molecular barcoding 104,205. 
Furthermore, several bioinformatic tools were developed  51,104,206. 
 
The first SNV studies in single cells used traditional variant callers that were designed 
for bulk sequencing that do not specifically address the technical limitations of single 
cell data 103,202,205,207. Since then, several single cell-specific SNV callers have been 
developed. One class of tools utilises shared information across several cells while 
either modelling single cell-specific error profiles or trying to reconstruct consistent 
phylogenies 208-211. However, these approaches are blind to private mutations and less 
applicable in highly heterogeneous or post-mitotic tissues. Other algorithms achieve 
improved accuracy through the integration of heterozygous germline SNPs. SCCaller 
derives a local estimate of the amplification non-uniformity and aims to threshold 
between artefacts and true variants based on this estimate and the observed variant 
allele fraction of potential SNVs 104. LiRA uses read-backed phasing and requires 
absolute concordance between the observed alleles of germline and potential somatic 
variants 206. While these approaches can detect private mutations, their thresholding 
approaches still fail to remove artefacts that were introduced in early rounds of MDA. 
Consequently, SNV calling in single cells is still a field under active development and 
in need for new approaches to distinguish between MDA-based artefacts and genuine 
biological mutations. 
 
Single Cell Multiomics 
Single cell sequencing methods have not only been developed to characterise the 
transcriptome or genome but also several epigenome layers such as the methylome 
and chromatin accessibility profile. Beyond that, several current technologies allow for 
the parallel measurement of two or even three molecular layers from the same single 
cell. These single cell multiomics methods allow for the direct correlation between the 
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measured layers without being obscured by cellular heterogeneity and have the 
potential to unravel their complex interaction networks (reviewed in 212,213).  
 
Currently, there are three main methods that enable transcriptome and whole-genome 
sequencing of the same single cell 177,214,215. All of these methods have primarily been 
used to investigate the impact of aneuploidies, CNVs and inter-chromosomal fusions 
on gene expression and could demonstrate a positive correlation between these 
measurements 178,214,215. While the demonstrated effects are similar, their approach to 
derive the whole genome and transcriptome differs. 
 
In DR-seq, cells are manually isolated, lysed and oligo-dT primed reverse transcription 
introduces cellular barcodes, an adapter sequence and a particular a T7 promoter on 
the first-strand copy DNA (cDNA) in the presence of genomic DNA (gDNA). 
Subsequently, the cDNA as well as the gDNA are subjected to a quasilinear 
amplification that introduces a second adapter. The amplified product is split before 
the cDNA is further amplified using in-vitro transcription to ensure the absence gDNA 
contamination. In parallel, the gDNA is amplified using a PCR priming on the adapter 
introduced during the quasilinear amplification. However, cDNA molecules that are 
present in the gDNA amplification reaction carry one or two adapters and thus, can be 
co-amplified with the targeted gDNA 214 (Figure 9A). While the amplification process 
is straightforward for DR-seq and loss of original gDNA and RNA molecules is 
minimised due to the initial co-amplification, the choice of the WGA method is not 
flexible, WGA-related artefacts are present in the cDNA, which only covers the 3’-ends 
due to in-vitro transcription and the genome sequencing data features cDNA 
contamination. 
 
The other methods both rely on physical separation of the DNA and RNA before their 
amplification. For SIDR-seq, isolated cells are incubated with antibody-conjugated 
magnetic beads that bind to the cellular membrane. The subsequent gentle lysis 
maintains the nuclear integrity. Thus, the nucleus can be precipitated in a magnetic 
field while the supernatant containing the cytoplasmic RNA can be removed. In theory, 
any whole transcriptome amplification (WTA) and WGA method available for single 
cells can be used afterwards due to their physical separation (Figure 9B) 215. While 
physical separation allows for a more flexible amplification approach, SIDR-seq loses 
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the nuclear RNA fraction and is dependent on tissues, where whole cell isolation is 
feasible.  
 
G&T-seq is the first method that utilised the idea of physical separation of the 
molecular layers before sequencing to allow for a flexible amplification approach. After 
cellular lysis, the mRNA is precipitated using oligo-dT-coated paramagnetic beads and 
the DNA-containing supernatant is transferred to an empty multi-well plate using liquid 
handling robotics. Following a bead-based precipitation of the DNA in the transferred 
supernatant, any WTA and WGA protocol can be applied in principle (Figure 9C) 
177,178. In contrast to DR-seq and SIDR-seq, G&T-seq is independent of a particular 
cellular isolation method and works equally well on whole cells or isolated nuclei. This 
is particularly useful for tissues or cell types, where isolation of whole cells is not 
feasible.  
 
While any WGA method is compatible with G&T-seq in theory, only hybrid class 
approaches have been tested thoroughly as previous efforts were focussed on CNV 
analyses 178. Furthermore, the precipitation and transfer of DNA before WGA could 
consistently lead to the loss of DNA molecules, preventing the amplification of 
homologous alleles and limiting the breadth of coverage. Any additional processing 
step also bears the potential to introduce technical artefacts, which could affect the 
observed mutational burden and spectrum. To extend the applicability of G&T-seq and 
to offer a multiomics approach to SNV calling in single cells, a comprehensive MDA 
chemistry comparison within the G&T-seq workflow was performed and is presented 




Figure 9: Parallel DNA-and-RNA Single Cell Sequencing Techniques. 
(A) DR-seq. DR-seq performs RT and a semi-linear amplification in presence of both 
nuclear acids before physically splitting the product. Therefore, the library submitted 
for WGS can contain cDNA amplicons. (B) SIDR-seq. SIDR-seq separates RNA from 
DNA through magnetic retention of the nucleus containing the genomic DNA. 
(C) G&T-seq. Both single cells or single nuclei can be used as input material to 
G&T-seq. Physical separation of DNA and RNA before amplification is achieved 
through magnetic retiontion of polyA-tailed mRNA. 
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Methods 
Cell Culture and Single Cell Isolation Using FACS 
Cell culturing was performed by Iraad Bronner within the Core Facility Pipelines at the 
Wellcome Sanger Institute (Sanger Pipelines) and single cell isolation was done in 
cooperation with Iraad Bronner and the Cytometry Core Facilities at the Wellcome 
Sanger Insitute. Low-passage aliquots from the cell line HCC38-BL were thawed from 
liquid nitrogen and maintained in standard cell culture conditions for a few days to 
allow one passage and subsequent outgrowth. Cells were suspended using a brief 
Trypsin digestion and cell clumps were removed using a cell strainer. Hoechst stain 
was added to the cell suspension and 50-cell controls as well as single cells were 
sorted into 96-well plates containing 1-2.5 µL of the lysis buffer or PBS as appropriate 
for the subsequent MDA method using the BD Influx Cell Sorter from BD Biosciences. 
Doublet discrimination was performed using a Forward-Scatter height versus Forward-
Scatter area approach. The cell cycle states G1 and G2 were discriminated by their 
DNA content as indicated by the Hoechst staining. A very narrow gate around the two 
peaks observed at DNA contents at 100% and 200% (arbitrary units) was chosen to 
specifically select for cells in G1 or G0 and G2 or M phase while avoiding cells that 
are undergoing DNA replication during S-phase. The 96-well plates were briefly spun 
down and stored at -80 °C until further processing. 
 
MDA Amplification and G&T-seq 
Three commercially available MDA chemistries were selected for the comparison 
between the G&T-seq and the respective original single cell genome sequencing 
version. The chemistries selected were the Single Cell GenomiPhi DNA Amplification 
kit from GE Healthcare Life Sciences (GenomiPhi), the Repli-g Single Cell Kit from 
Qiagen (RepliG) and the Trueprime Whole Genome Amplification Kit from Expedeon 
(Trueprime). All processing steps within G&T-seq and MDA amplifications were 
performed by Iraad Bronner. The commercial MDA kits were delivered with their 
individual lysis buffer, while the Buffer RLT Plus from Qiagen was used as lysis buffer 
within G&T-seq. The 96-well plates containing cells sorted into Buffer RLT Plus were 
subjected to the separation of mRNA and gDNA and the gDNA was transferred and 
precipitated as described in the original publications 177,178. Briefly, the polyadenylated 
mRNA was hybridized with paramagnetic beads carrying modified oligo-dT primers. 
 43 
During magnetic retention of the bead-bound mRNA, the original supernatant 
containing the gDNA and four washing step supernatants were pooled in a new 96-well 
plate. Subsequently, gDNA was precipitated within this new plate using AMPure 
Beads and washed with ethanol. After the ethanol dried off, the beads and gDNA were 
resuspended in the appropriate volumes of PBS and MDA reaction buffer as per the 
manufacturer’s instructions for the three different MDA chemistry kits. Similarly, the 
respective amounts of lysis or reaction buffers were added to the wells subjected to 
the original MDA process. For each of the considered commercial MDA kits, the MDA 
reactions were performed in parallel for the G&T-seq and the corresponding original 
version. Besides the mainly non-disclosed differences in buffer composition, the three 
MDA kits also differed in the suggested duration of MDA. MDA was performed at 30 °C 
for 2 h for GenomiPhi, for 3 h for Trueprime and for 8 h for RepliG followed by a brief 
enzyme inactivation at 65 °C for all three kits. Subsequently, the MDA products were 
purified using a standard Ampure SPRI bead clean-up and quantified using the 
spectroscopic PicoGreen method 216. 
 
Genotyping-by-Sequencing for MDA Product Quality Control 
The Genotyping-by-Sequencing (GbS) assay as developed within the Sanger 
Pipelines employs a bespoke miniaturised high-throughput amplicon sequencing 
protocol. All GbS-related lab work for the present samples was performed in 
cooperation or solely by Scott Goodwin and Naomi Park within the Sanger Pipelines. 
GbS is a high-multiplex two step PCR, with the first PCR stage employing bipartite 
primers to capture 126 SNP sites and their surrounding regions (190-250 bp typical 
size) and incorporate Illumina sequencing motifs, and the second PCR stage also 
employing bipartite primers which target the previously-introduced sequencing motifs 
and introduce dual-index barcodes and Illumina flowcell adaptor sequences. The 
assay is performed in a multi-well plate setup at a final volume of 5 µL and requires a 
minimum input of only 1 ng of DNA. 
 
The first PCR stage deviates significantly from standard PCR practice in order to 
ensure that targets are captured with approximately equal efficiency and with minimal 
off-target amplification. The primers were designed using the MPprimer software tool 
and feature 2'-OMe modifications at the penultimate 3' base to inhibit primer-dimer 
formation 217. They are included in the PCR at average concentrations of 300pM, with 
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the exact concentrations of individual primer pairs being slightly variable to 
compensate for amplification efficiency differences. The first PCR stage is composed 
of 5 elongated cycles of 40 minutes duration to permit efficient target capture in spite 
of the low primer concentration. At the end of this stage, the reactions are cooled to 
4°C to temporarily inhibit polymerase amplification and the second stage barcoding 
primers are introduced. Due to the low reaction volumes it is not possible to introduce 
the second stage primers into the PCR in solution form, therefore instead the entire 
reaction volume is transferred into another plate which contains pre-aliquoted dried 
barcoding primers in each well, and the reactions are mixed thoroughly to rehydrate 
and disperse the barcoding primers. 
 
The second PCR stage follows a conventional format and duration with 200nM primer 
concentration and typically 31 cycles for a total duration of approximately 1 hour. The 
barcoding primers amplify only those products generated in the first PCR by targeting 
the sequencing motifs introduced by the first stage primers. The PCR conditions have 
been chosen to achieve two aims; firstly that the carryover first stage primers no longer 
significantly participate in the PCR (there is approximately a 1000x excess of 
barcoding primer compared to each individual first stage primer pair, and annealing 
times are insufficient to allow efficient amplification by the first stage primers), and 
secondly that the amplification achieves plateau by effective exhaustion of the 
available barcoding primers over a wide range of input, therefore total yields per PCR 
are normalised to approximately the same level irrespective of the initial DNA 
concentration. 
 
Therefore, amplicons can be pooled in an equivolume manner without any further 
manipulation as normalisation for both amplicon yield and sample yield is achieved 
within the PCR. Pooling is done by inverting the open PCR plates over a specially-
designed reservoir and gentle centrifugation. Aliquots of this pool are purified using a 
standard Ampure SPRI bead clean-up on a liquid handling robot, followed by 
quantification by qPCR and sequencing on one Illumina MiSeq lane for 384 cells.  
 
The sequencing data was returned as cram files aligned to GRCh37. Computational 
evaluation of the GbS data was done by myself. A pileup across the 126 target regions 
was performed for the MDA products from this comparison experiment as well as for 
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HCC38-BL bulk sequencing data that was already available within the Wellcome 
Sanger Institute using bcftools mpileup and SNPs were called using bcftools call 218. 
Any calls with a total depth of less than six reads or phred-scaled quality score of less 
than 30 were flagged. To assess the quality of individual MDA products, their 
genotypes were compared to the reference genotypes that were called in the bulk 
sequencing data. For homozygous SNPs in the bulk sample, the MDA-derived 
genotypes were classified as concordant if they matched the SNP called in the bulk 
sample, as dropout if no sufficient coverage was obtained or as false positive if a non-
matching genotype was called. Additionally, ADO was classified for heterozygous 
SNPs in the bulk sample if the MDA-derived product was called to be homozygous for 
one of the respective alleles in the bulk sample. The GbS results were used to select 
high-quality MDA products for WGS. 
 
Sequencing Library Preparation and WGS Sequencing 
Amplification-free paired-end sequencing libraries for the selected MDA products were 
created in the Sanger Pipelines using standard Illumina protocols 219. Samples were 
multiplexed in equimolar amounts and submitted for 150 bp paired-end sequencing on 
the Illumina HiSeq X platform within the Sanger Pipelines. 
 
WGS Quality Control and Genome Alignment 
The WGS data was returned as de-multiplexed cram files per HiSeq X lane. The cram 
files were converted into FASTQ format using biobambam 220. FASTQ files from all 
HiSeq X lanes per MDA product were concatenated and Illumina sequencing adapter, 
unknown nucleotides and bases with phred-scaled quality scores less than 10 were 
removed from the read ends using TrimGalore and Cutadapt 221. Paired-end 
alignments to GRCh37 were performed using bwa mem with default parameters 222. 
Genome alignments were sorted and indexed using samtools and duplicates were 
removed using Picard v1.6 223,224. 
 
Computation of Depth, Breadth and Uniformity of Genome Coverage 
A genome-wide computation of sequencing depth per base was performed using 
samtools depth 223. The average depth as well as the cumulative fraction of the 
genome covered at various coverage thresholds was computed in R using this data. 
Lorenz curves to illustrate the uniformity of coverage were obtained using the R 
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package ineq and Gini coefficients were computed using the auc function from the R 
package MESS 225,226. 
 
Genotyping of MDA-derived Whole-Genome Sequences 
A list of 2,011,109 frequently polymorphic sites was used to obtain reference 
genotypes from the bulk sequencing data using the bcftools mpileup and call 
commands. A minimum coverage of six reads and a phred-scaled quality score of at 
least 30 was required to keep only high-quality reference genotypes. Genotypes of 
MDA-derived whole-genome sequences were obtained using similar commands but 
restricted to the 1,878,813 sites with known reference genotype and the minimum 
coverage was reduced to five reads and no quality-based filtering was performed to 
account for the lower average depth of MDA-derived whole-genome sequences. 
 
Genome-wide SNV Calling 
Genome-wide SNV calling was done using the single cell-specific caller SCCaller-
v1.2. SCCaller derives a local estimate of the MDA amplification bias using known 
heterozygous SNPs from a corresponding bulk sample 104. The approximately 
516,000 SNPs that were called as heterozygous in the bulk data during the previous 
genotyping assessment were used for this. The amplification bias estimates can be 
refined if the amplicon size distribution of MDA products is known, as this is used to 
define the width and shape of the kernel smoother within SCCaller. Estimates of the 
size distributions were taken from the single cell WGS quality package PaSD-qc 227. 
To obtain these size distributions, the alignments were down-sampled to an average 
coverage of 1x using samtools and compared to the categorical spectra at the same 
coverage within the PaSD-qc pipeline 223,227.  
 
Given the locally observed MDA amplification bias as well as the total depth and 
variant allele fraction, SCCaller computes a likelihood parameter that aims to 
distinguish between technical artefacts and true variants 104. All sites with a likelihood 
for being an artefact of greater than 0.01 as well as all variants present in dbSNP 
build 138 or the 1000 Genome Phase 1 panel were flagged and not considered in the 
final burden and mutational spectrum analysis. 
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Mutational spectrum analysis 
Every mutation is the result of a corresponding mutational process as explained in the 
general introduction for this thesis. As mutational processes leave unique footprints, 
the observation of mutational spectra can give insight into biological processes as well 
as processing steps that cause technical artefacts. Traditionally, SNV calling results 
are defined as the base change on the Watson strand. As it is impossible to distinguish 
on which strand the original base change occurred after Illumina sequencing without 
specific barcoding approaches, all SNV calls were classified given the pyrimidine base 
change of the Watson-Crick base pair for the mutational spectrum analysis. 
Consequently, both an originally annotated G>A and an originally annotated C>T 
mutation, will be classified as C>T mutations for this analysis. This results in a total of 
six classes of base substitutions, namely C>A, C>G, C>T, T>A, T>C, T>G. This 
spectrum can further be refined by incorporating information about the 5’- and 3’-
context of the mutated base. Here, a single base immediately prior and after the called 
SNV is considered, creating sixteen different permutations for a total of 96 substitution 
classes. This approach follows the commonly used pattern for mutational signatures 
of single base substitutions 18,29,36. The filtered genome-wide calls derived from 
SCCaller were classified accordingly and the resulting mutational spectrum plotted to 
illustrate any potential differences between the G&T-seq and the original RepliG 
version. No formal mutational signature extraction was performed. 
 
Statistical Analysis 
All statistical analysis was performed in R version 3.5.0 using core distribution 





The main aim of this project was to extend the applicability of G&T-seq to SNV calling 
in single cells. While the final method should consist of a multiomics RNA-and-DNA 
calling approach, it was essential to provide evidence that SNV calls solely based on 
G&T-seq’s genomics layer were comparable to conventional single-omics 
approaches. Since MDA-based methods are the current gold-standard for SNV calling 
in single cells, the WGA comparison was restricted to commercially available MDA 
chemistry kits 105,106,176. The chemistries selected were GenomiPhi, RepliG and 
Trueprime as explained in the methods section above. Both GenomiPhi and RepliG 
use the traditional Φ29 DNA polymerase with random hexamer priming and mainly 
differ in their undisclosed buffer composition. Trueprime uses the same DNA 
polymerase but contains a DNA primase instead of random oligonucleotide primers in 
order to improve evenness of amplification 228.  
 
Within the scope of selecting the most suitable MDA chemistry for G&T-seq, there 
were several additional requirements. As PCR-based methods are more error-prone 
than MDA, the product yield had to be sufficient for amplification-free sequencing 
library preparation 176,219. To perform these reactions within the Sanger Pipelines, a 
minimum of 500 ng was necessary. Since MDA products can be of variable quality 
and SNV analyses require moderately high sequencing depth, only high-quality 
amplifications should be subjected to whole-genome sequencing (WGS) for financial 
reasons. A previous publication demonstrated that a qPCR panel targeting a single 
locus per autosome could be used as quality control criterium for MDA based on the 
detection of all twenty-two qPCR products 229. To extend on this idea, a highly 
multiplexed PCR assay targeting several loci across all human chromosomes was 
going to be tested for its ability to predict WGS data quality. This assay can be followed 
up by shallow sequencing to check for the faithful amplification of a known reference 
genotype at a low cost for hundreds of cells at a time to select a subset of high-quality 
MDA products. Such an assay was in concurrent development in the Sanger Pipelines 
when the MDA chemistry comparison within G&T-seq was initiated and thus, was 
included in this workflow. The so-called GbS assay is described in the methods section 
in more detail. Briefly, it allows to assess the genotypes at 126 polymorphic loci sites 
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and is performed in a multi-well format on liquid handling robots which allows for high-
scale throughput if desired. Finally, the impact of the cell cycle status was considered 
for any comparison as a previous publication indicated that a more even amplification 
is possible for cells in G2/M compared to G1/0 due to the inherently higher amount of 
genetic starting material 229. 
 
The cell line HCC38-BL was selected for all amplification experiments as it had been 
used for the original G&T-seq publications 177,178. Single cells and 50-cell controls were 
flow-sorted into two 96-well plates per MDA chemistry kit and classified for their G1/0 
(only referred to as G1 hereafter) or late M and G2 (only referred to as G2 hereafter) 
cell cycle state using DNA content thresholds as indicated by Hoechst staining. Half 
of the plate was sorted into the lysis buffer from the MDA kit, while the other half was 
sorted into the G&T-seq appropriate lysis buffer and the bead-based separation of 
polyadenylated mRNA and gDNA for G&T-seq was performed only on this half of 
every plate. The DNA-fraction was transferred into a new multi-well plate and MDA 
was performed together with the original half of every plate according to the 
corresponding manufacturer’s instructions. Flow-sorting, G&T-seq separation and 
MDA amplifications were done solely by or in cooperation with Iraad Bronner in the 
Sanger Pipelines and the Cytometry Core Facilities at the Wellcome Sanger Institute 




Figure 10: Plate Layout for MDA Chemistry Comparison. To minimise batch 
effects, half of the 96-well plate was FACS-sorted into buffer appropriate for either 
GenomiPhi, RepliG or Trueprime, while the other half of the plate was FACS-sorted 
into the G&T-seq appropriate lysis buffer. Additional G&T-seq processing steps were 
only performed on the appropriate half of the plate and the final MDA reaction was 
performed in parallel per originally sorted plate according to the respective 
manufacturer instructions. To investigate the difference of the cell cycle stage on MDA 
performance, half of the cells were selected to be in the G1 stage, while the other half 
was selected from the G2 stage based on the DNA content as indicated by Hoechst 
staining during FACS-sorting. For each of the four possible combinations, one 50-cell 
control was created and one well was per reaction type was left empty to serve as 
negative control. Single cells were sorted into the remaining wells. 
 
GenomiPhi Yields Insufficient Amounts of DNA 
Subsequent to the MDA amplification according to the manufacturer’s instruction, the 
product yield was evaluated using the PicoGreen spectroscopic method 216. This work 
was done in cooperation with Iraad Bronner from the Sanger Pipelines. The product 
yield was consistent within every condition and nearly identical between the G1 and 
G2 cell cycle state but showed great differences between MDA chemistry kits and the 
original or G&T-seq version (Figure 11). 
 
For the original GenomiPhi version, an average product yield of 1.9 µg (SD = 1 µg) 
was obtained while the corresponding amplifications for G&T-seq only averaged 
0.2 µg (SD = 0.2 µg). As the minimum yield for amplification-free sequencing library 
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creation was 500 ng within the Sanger pipelines, GenomiPhi did not reach this 
threshold within G&T-seq and was excluded from further comparisons (Figure 11). 
 
For RepliG, the yield obtained from the G&T-seq version was comparable to the 
original one. They averaged 17.9 µg (SD = 3.7 µg) and 17.8 µg (SD = 5.6 µg), 
respectively and thus, significantly exceeded the minimum requirement of 500 ng 
(Figure 11). While the overall yield was lower, the G&T-seq and the original version 
were also comparable for Trueprime. The yield of 1.4 µg (SD = 0.6 µg) for the 
G&T-seq version as well as an average of 1.4 µg (SD = 1.1 µg) for the original version 




Figure 11: MDA Product Yield. The MDA product yield was determined using the 
spectroscopic PicoGreen method. A minimum of 500 ng was necessary for 
amplification-free sequencing library preparation within the Sanger Pipelines and is 
indicated with the dashed line. In general, the GenomiPhi reactions within G&T-seq 
fall short of this requirement while the original GenomiPhi as well as both the G&T-
seq and the original versions for RepliG and Trueprime displayed sufficient yield. No 
difference could be observed between cells sorted for G1 or G2 cell cycle stage within 
the same reaction conditions. 
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Pre-sequencing Quality Control Suggests Poor Amplification for Trueprime 
All RepliG and Trueprime amplification products were subjected to GbS and MDA-
derived genotypes were called as described in the methods section. Reference 
genotypes were obtained from corresponding HCC38-BL bulk sequencing data that 
was available within the Wellcome Sanger Institute. The MDA-derived genotypes were 
compared to the reference genotypes and classified as concordant, dropout, false 
positive or ADO as explained in the methods section. In general, most cells displayed 
no false positive calls across the 126 tested SNP loci and only a minor number of ADO 
calls (Mean = 10, SD = 10). As cells with fewer ADO calls usually displayed a much 
greater amount of complete dropout, this did not indicate a more faithful but rather an 
overall less successful MDA. Therefore, dropout, false positive and ADO calls were 
pooled and directly contrasted with the number of concordant calls (Figure 12). 
 
For RepliG, an average of 41% (SD = 17%) of the tested 126 SNP loci was called as 
concordant to the reference for the G&T-seq version and 30% (SD = 29%) for the 
original version (Figure 12). The lower average and greater deviation of concordant 
calls for the original version was explained by 39 of the 95 tested cells displaying a 
dropout rate of greater than 90%, indicating a complete failure of the MDA reaction for 
these cells. The cells amplified in the G&T-seq version displayed a much more uniform 
distribution around their average with only a single completely failed cell. As G&T-seq 
uses a harsher lysis buffer than any of the original versions of the MDA chemistry kits, 
the higher overall success rate for the G&T-seq version can potentially be attributed 
to a greater cell lysis efficiency. For successfully amplified cells, the distribution of GbS 
quality values was comparable between the original and the G&T-seq version and 
between the G1 and G2 cell cycle state. 
 
MDA success as indicated by GbS was significantly worse for Trueprime products 
compared to RepliG (Figure 12). Only 5% and 2% of probed genotypes were called 
as concordant for the Trueprime G&T-seq and the corresponding original version, 
respectively. Even the most successful amplifications only reached 33% and 41% for 
the G&T-seq and the original version, respectively. 
 
Based on the GbS assay, MDA products were selected for WGS. Since Trueprime 
amplifications were suggested to be of inferior quality compared to RepliG, only RepliG 
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products were chosen. A total of 20 MDA products were selected, evenly split between 
the original and the G&T-seq version as well as their cell cycle state. For all four 
conditions, the 50-cell control was chosen and the remaining four single cells were 
chosen across the range of observed concordance to the reference genotypes. The 
20 selected MDA products were subjected to amplification-free sequencing library 




Figure 12: GbS Results for RepliG and Trueprime MDA Products. Genotypes 
called in the MDA products were compared to reference genotypes called in bulk 
sequencing data of the parental cell line. MDA genotypes were classified as reference-
concordant or as displaying a mismatched or insufficiently covered locus for the 126 
polymorphic sites probed by GbS. An average of 41% of the probed loci were called 
as reference concordant for the G&T-seq RepliG version, while the average for the 
corresponding original version was 30%, mainly due to substantially more cells with 
nearly no concordant calls. For Trueprime, most MDA products displayed less than 
10% reference-concordance and even the most successful amplifications only 33% 
and 41% for the G&T-seq and the original version, respectively. 
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Coverage Statistics are Comparable for G&T-seq and Original RepliG Products 
WGS data from the 20 selected MDA products was aligned to the human genome 
build GRCh37 using bwa mem as described in the methods section. When comparing 
mapping statistics, no difference between the G&T-seq and the original RepliG version 
or between the cell cycle states could be observed (Figure 13). For the G&T-seq 
version, an average of 92.4% (SD = 0.6%) of reads were successfully mapped, 7.3% 
(SD = 0.6%) were marked as duplicates and 0.3% (SD = 0.1%) were not aligned. 
Similar values were obtained for the original version with 92.3% (SD = 0.6%) mapped, 
7.3% (SD = 0.6%) duplicated and 0.4% (SD = 0.1%) unmapped reads. Consequently, 
the obtained depth was also comparable with an average coverage of 13x (SD = 0.8) 
and 12.8x (SD = 0.6) for the G&T-seq and the original version, respectively. The even 
coverage obtained from the pooled sequencing indicated a comparable library 
complexity across all selected conditions. 
 
One of the main advantages of MDA is the greater breadth of genome coverage 
compared to other WGA approaches 105,176. The cumulative fraction of the genome 
covered at depths between 0 – 50x coverage is displayed in Figure 14. All four 50-cell 
controls achieved a total genome coverage of 88% with 32% and 33% having a 
coverage of at least 15x for the G&T-seq version and 31% and 37% for the original 
version for the G1 and G2 cell cycle state, respectively. For single cells, no significant 
difference in the average breadth of coverage could be detected between the cell cycle 
states for single cells at any of the coverage thresholds considered. When comparing 
the MDA products for single cells from the original RepliG version, it was found that 
they achieved a slightly higher breadth of coverage of 69% (SD = 13%) compared to 
the G&T-seq RepliG products with 59% (SD = 14%). Notably, this difference is only 
maintained at low depth and for a coverage of at least 15x, both the original and the 
G&T-seq version cover 23% (SD = 4%) of the genome. As SNV calling is only reliable 
at greater sequencing depths, no meaningful difference could be detected between 
the original and the G&T-seq version.  
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Figure 13: Mapping Statistics for WGS Data from RepliG MDA products. WGS 
data from twenty selected RepliG MDA products was aligned to GRCh37. The 
products were evenly selected for the G&T-seq and the original RepliG version as well 
as for the G1 and G2 cell cycle stage and comprise all four 50-cell controls. A similar 
fraction of 92% of the reads were successfully mapped with a similar percentage of 
duplicated and unmapped reads, when the original and G&T-seq version were 
compared. Furthermore, no difference could be observed between 50-cell controls 
and single cells or between the cell cycle states.    
 
Besides breadth of coverage, the uniformity of coverage is an essential quality control 
parameter for single cell WGS data to control for the evenness of amplification. The 
inequality of the coverage distribution was computed and corresponding Lorenz 
Curves are shown in Figure 15. In addition to the greater breadth of coverage, the 
50-cell controls also display a more uniform coverage distribution compared to single 
cells but are similar between the original and the G&T-seq version as well as between 
cell cycle states. For single cells, the Gini coefficients indicate slightly greater 
inequality for the G&T-seq version with an average Gini coefficient of 0.78 (SD = 0.08) 
compared to 0.74 (SD = 0.08) for the original version. However, this difference is not 
found to be statistically significant (Wilcoxon rank sum test, p = 0.32). Moreover, no 
difference between the G1 and G2 cell cycle states could be observed.  
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Figure 14: Cumulative Fraction of Genome Covered for WGS Data from RepliG 
MDA Products. The cumulative fraction of the genome covered at a minimum of 
depths between 0 – 50x was computed and illustrated above. The 50-cell controls 
show greater breadth of coverage than the corresponding single cells. While the 
average for the total breadth of coverage is slightly higher for the original RepliG 
version with 69% compared to 59% for the G&T-seq version, this difference was not 
maintained at coverages greater than 15x. No difference in the breadth of coverage 
could be detected between cell cycle states.  
 
In summary, the WGS from G&T-seq and original RepliG amplification displayed no 
significant differences regarding the average depth, breadth of coverage at depths 
relevant for SNV analyses or uniformity of coverage. Collectively, this indicates 
sequencing libraries of similar quality can be derived within G&T-seq compared to the 
original RepliG version and the precipitation, transfer and MDA in presence of partially 




Figure 15: Uniformity of Genome Coverage for WGS Data from RepliG MDA 
Products. Inequality of coverage distribution was computed and illustrated as Lorenz 
Curves. The straight black line indicates perfectly even coverage. Single cells 
displayed greater inequality of coverage than the 50-cell controls. The Gini coefficients 
from the Lorenz curves of single cells did no differ significantly between the original 
and the G&T-seq version, suggesting similar uniformity of coverage. Furthermore, no 
difference between the G1 and G2 cell cycle state could be observed. 
 
Mutational Burden and Spectra are not Altered in G&T-seq RepliG 
After establishing that sequencing libraries of similar quality could be derived for G&T-
seq compared to the original RepliG version, the impact on the false positive rate, 
mutational burden and spectrum was considered. While it is known that MDA 
introduces a substantial level of technical artefacts, it was important to verify that no 
additional level of noise is introduced within the G&T-seq workflow. Given the limited 
sequencing depth of the WGS from MDA products of about 13x on average, a 
genotyping approach on loci with known reference genotypes was performed as 
described in the methods section to estimate the false positive and ADO rate. A total 
of 1,363,033 homozygous and 515,780 heterozygous reference loci was considered 
and genotyped in the MDA-derived WGS. 
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From the total of 1,878,813 known reference sites, an average of 911,652 
(SD = 325,034) and 835,111 (SD = 330,671) sites could be called in the MDA-derived 
WGS for the original and the G&T-seq version, respectively. To avoid any differences 
in the rates of false positives that are based on differences in the ability to call 
genotypes, any further calculations were based on the sum of successfully genotyped 
loci per cell. Only considering successfully genotyped sites, the fraction of false 
positive calls was 2.6% (SD = 0.9%) and 3% (SD = 1.2%) for the original and the G&T-
seq version, respectively (Figure 16). The average ADO rates at reference 
heterozygous sites were 34% (SD = 20.2%) for the original RepliG version and 44% 
(SD = 26.8%) for the G&T-seq version. Neither the difference in FP nor in ADO rates 
was statistically significant (Wilcoxon rank sum test, p = 0.25 for FP and p = 0.13 for 
ADO). Notably, the MDA products were picked across a quality spectrum as assessed 
by the amplicon-based GbS assay. The 50-cell controls displayed nearly identical FP 
and ADO rates between the G&T-seq and the original RepliG version. The most 
favourable single cells displayed ADO rates of 33% and 35% for the original and the 
G&T-seq version, respectively. This indicated that a thorough QC before WGS is 
necessary and potentially able to mitigate any minor differences that could be 




Figure 16: WGS-based Genotyping Results for RepliG MDA Products. A total of 
1,878,813 loci with known reference genotypes derived from bulk sequencing of the 
parental cell line were genotyped within the WGS data of RepliG MDA products. The 
fraction presented is based on the total number of successful genotyping calls per 
MDA product to avoid any impact of differential coverage between MDA products. In 
total, similar average fractions of 2.6% and 3% were classified as false positive 
genotype calls for MDA products from the original and the G&T-seq version, 
respectively. For heterozygous sites, an average ADO rate of 34% and 44% was 
observed for MDA products from the original and the G&T-seq version, respectively. 
Notably, the most favourable single cells achieved a more comparable ADO rate 
between the two versions with 33% for the original compared to 35% for the G&T-seq 
version. 
 
To derive mutational spectra, SNVs were called on a whole-genome level using the 
single cell-specific algorithm SCCaller, that is trying to avoid MDA artefacts through 
estimation of local amplification bias and adaptive filtering based on this bias. A more 
detailed explanation is given in the methods section. After artefact filtering and removal 
of common database SNPs, an average of 47,396 (SD = 15,418) mutations per MDA 
product were called for the original version and 47,592 (SD = 12,107) mutations per 
MDA product for the G&T-seq version. The mutational spectrum was derived as 
described in the methods section and is shown in Figure 17. The mutational spectra 
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were highly correlated between the G&T-seq and the original version 
(Pearson’s rho = 0.99, p < 2.2e-16), indicating that no additional artefacts are 
introduced through any of the additional G&T-seq processing steps. 
 
In conclusion, the observed FP and ADO rates were comparable between G&T-seq 
and the original RepliG version and nearly identical for the most favourable single cell 
and 50-cell controls. Furthermore, the genome-wide burden as well as the mutational 
spectra were practically indistinguishable, strongly suggesting that genomic data 
derived from G&T-seq is comparable to traditional single-layer methods. 
 
 
Figure 17: Base Substitution Mutational Spectra for Genome-wide SNV Calls. 
Genome-wide SNVs were called using the single cell-specific algorithm SCCaller. 
Base substitutions were classified according to the pyrimidine base change of the 
affected Watson-Crick base pair and further distinguished by their 5’- and 3’- flanking 
base context. The mutational spectra for the G&T-seq and the original RepliG version 





















































































































































































































































































































































































































































GbS Represents an Effective Tool for MDA Quality Control Before WGS 
The amplicon-based assay GbS was chosen as tool for MDA quality control before 
WGS as previous work demonstrated that one qPCR per chromosome could be used 
to distinguish between failed and successful MDA reactions 229. The GbS assay is 
performed using multi-well plate formats and liquid handling robots, which 
substantially reduces the manual labour per tested MDA product, while providing 
genotype-level information in 126 loci across all human chromosomes compared to 
only a binary classification of successful amplification for all autosomes in the 
previously published approach 229. As explained in the section above describing the 
GbS results, MDA products were chosen for WGS across a range of GbS-indicated 
quality for all considered conditions. While the original and the G&T-seq version of 
RepliG were shown to be comparable for all the considered metrics, there was always 
substantial deviation within every condition. To consider how well the WGS quality 
compared to the quality indicated by GbS, the percentage of reference-concordant 
genotypes per MDA product was chosen as numeric metric for GbS quality and 
compared to several WGS-derived quality criteria. 
 
For all WGS-derived quality criteria considered, the GbS-indicated quality score 
displayed a strong correlation and the general pattern was independent of the cell 
cycle state and application of the G&T-seq or original RepliG version. Consequently, 
ordinary least squares regression (OLS) was performed for the complete data set to 
evaluate the statistical significance of GbS and the respective WGS quality scores 
(Figure 18). As SNV calling is only reliable at moderate to high sequencing depth, the 
fraction of the genome covered at a depth of at least 15x was chosen to represent the 
meaningful breadth of coverage, which displayed a positive correlation with the 
fraction of reference-concordant genotypes per MDA product (adjusted R2 = 0.84, p = 
1.03e-8; Figure 18A). To assess the how well uniformity of coverage is predicted by 
GbS, the Gini coefficients from WGS of MDA products were used. High Gini 
coefficients indicate greater inequality and a significant negative correlation with the 
GbS-indicated quality could be observed (adjusted R2 = 0.9, p = 1.06e-10; Figure 18B). 
ADO as assessed during the genotyping analysis of WGS from MDA products was 
compared to the fraction of reference-concordant genotype calls from the GbS results 
as another critical parameter of WGS quality. A greater reference-concordance during 
GbS strongly correlated with low ADO values in WGS data, suggesting a less biased 
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amplification in MDA products with higher GbS quality scores (adjusted R2 = 0.84, 
p = 9.69e-9; Figure 18C). Finally, the genome-wide burden of mutations also 
displayed a significantly negative correlation with the GbS quality score (adjusted R2 
= 0.35, p = 3.53e-3; Figure 18D). As MDA is known to produce a high level of artefacts, 
a reduced overall burden of mutations across cells with similar genetic background, 
suggested a lower level of technical noise in cells with greater GbS quality scores. 
 
 
Figure 18: Correlation of GbS-indicated Quality with WGS-derived Quality 
Metrics. Linear regression was performed between the four displayed WGS-derived 
quality metrics and the fraction of reference-concordant genotype calls as assessed 
by the GbS assay before sequencing. Strong correlations were observed for all 
considered metrics, which suggested that GbS represents an effective tool to screen 
for high-quality MDA products. (A) Breadth of coverage displayed as fraction of the 
genome with a depth of at least 15x. (B) Uniformity of coverage as measured by the 
Gini coefficient. (C) ADO rates derived from genotyping in the WGS data. (D) The 





Whole-genome amplification is a crucial processing step for single cell sequencing 
and several comparisons have been published to identify the most suitable 
chemistries for their particular experimental setting and downstream analyses 
105,106,194-200. While a general consensus appears that hybrid methods are superior for 
CNV analyses and MDA-based approaches are more suitable for SNV analyses, the 
final results vary given the experimental settings, metrics used and chemistry kits 
considered. As G&T-seq includes several unique processing steps, a comparison of 
three MDA chemistry kits was performed to assess their suitability within this workflow 
and to ensure that the additional processing steps do not impair the WGS quality. 
Moreover, the semi-automated amplicon-based assay GbS was evaluated as cost-
effective and scalable means to assess the MDA amplification quality before 
expensive WGS.  
 
For each of the three selected chemistries - GenomiPhi, Trueprime and RepliG – a 
total of 188 MDA reactions was performed, evenly split between cells that had 
undergone the additional processing steps necessary for G&T-seq as well as cells that 
were directly subjected to the MDA reactions according to the respective 
manufacturer’s instructions. The MDA reactions were assessed according to their 
yield (Figure 11) as well as their concordance with reference genotypes derived from 
bulk sequencing data from the same parental cell line using GbS (Figure 12).  
 
GenomiPhi amplifications failed to reach the required minimum of 500 ng to perform 
amplification-free sequencing library generation within the Sanger Pipelines for cells 
that had undergone the additional G&T-seq processing steps. Notably, standard 
GenomiPhi amplifications performed directly on single cells exceeded this threshold 
four-fold on average. The additional processing steps within G&T-seq require the MDA 
reaction to be performed in the presence of potentially partially bead-bound DNA and 
trace residues of ethanol. Additionally, cells have to be lysed within a different lysis 
buffer for G&T-seq compared to the manufacturer’s recommendations for GenomiPhi. 
These differences are potentially accountable for the lower efficiency of G&T-seq 
GenomiPhi reactions compared to the original version. Notably, the difference in yield 
between the G&T-seq and the original version was only observed for GenomiPhi but 
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neither for Trueprime nor for RepliG (Figure 11). Thus, the specific and non-disclosed 
reaction conditions of the GenomiPhi kit were decided not to be suitable for G&T-seq. 
While Trueprime reactions yielded 1.4 µg on average and thus, were deemed to be in 
a suitable range for amplification-free sequencing library preparations, nearly all 
RepliG reactions generated at least 10 µg up to over 30 µg of DNA. According to the 
manufacturer’s instructions, the MDA for Trueprime should be performed for only 3 h 
in contrast to the 8 h recommended for RepliG. As the product yield scales with the 
duration of amplification and time-limited MDA has been demonstrated to generate 
less technical artefacts, the long amplification time recommended for RepliG could 
potentially be reduced for future experiments to restrict technical noise while still 
creating enough product for amplification-free sequencing library preparation 205,229. 
 
The MDA reactions from Trueprime and RepliG were subjected to GbS to assess their 
genotype concordance with bulk sequencing data from the same parental cell line. As 
a previous publication demonstrated that qPCR-based methods could be used to 
verify the successful amplification per chromosome, I wanted to extend on this idea 
229. Indeed, great variability within MDA product quality was indicated for RepliG 
reactions with an average genotype concordance of 33% for the original and 41% for 
the G&T-seq version while Trueprime reactions only showed minimal concordance 
with the bulk sequencing data (Figure 12). Motivated by the GbS results, twenty 
RepliG products were selected for WGS across a range of GbS quality scores, evenly 
split between the original and G&T-seq RepliG version and the G1 and G2 cell cycle 
state of the originally sorted cells. As GbS was shown to be an effective predictor of 
WGS quality later on (Figure 18), it can be assumed that WGS derived from Trueprime 
MDA products would have been of inferior quality compared to the RepliG products. 
Another MDA comparison that included Trueprime and RepliG evaluated their WGA 
quality based on amplicon-based sequencing of over 3400 loci. Similar to the results 
presented in this thesis, most Trueprime products were considered failed reactions 
due to their poor amplicon recovery rate, while RepliG was considered to be the most 
suitable for SNV analyses of the seven WGA chemistries considered 197. Another MDA 
comparison considering Trueprime also concluded that Trueprime products are not 
suitable for CNV analyses due to high locus dropout rates and substantially biased 
amplification 199. The main difference between Trueprime and RepliG is the usage of 
a DNA primase within Trueprime compared to random oligonucleotide priming within 
 65 
RepliG. While the DNA primase was postulated to result in more evenly amplified 
genomes compared to the random priming in traditional MDA approaches, only the 
original publication on Trueprime amplification supports this claim so far 228. 
 
The RepliG products selected for WGS were assessed for general genome 
sequencing quality criteria including their read mapping statistics, breadth and 
uniformity of coverage (Figure 13-15). These criteria were compared between 50-cell 
controls and single cells, the G1 and G2 cell cycle states and most importantly, 
between the G&T-seq and the original RepliG version. In general, the 50-cell controls 
displayed a greater breadth and a more even genome coverage compared to single 
cells as expected. However, no substantial or significant differences could be found 
between the G&T-seq and the original RepliG version for any of these metrics 
(Figure 13-15). Moreover, the results were also comparable between cell cycle states, 
not supporting a claim from previously published work that MDA amplifications are 
more successful when starting from material of cells in G2 phase 229. 
 
Furthermore, quality criteria more specific to SNV analyses were assessed. The ADO 
and false positive rates were assessed through comparison to reference genotypes 
from bulk sequencing data from the same parental cell line (Figure 16). While the false 
positive rates were very similar between the G&T-seq and the original version with 
2.6% and 3%, respectively, the average ADO rates were about 10% higher for 
products generated from G&T-seq samples compared to the original version. 
However, the most favourable single cell products achieved similar ADO values of 
33% and 35% for the original and the G&T-seq version, respectively. As the MDA 
products were selected across a range of GbS quality values and these were 
demonstrated to be able to predict ADO rates of WGS data (Figure 18C), this indicated 
that the difference in ADO rates is not necessarily systematic and can be mitigated by 
careful quality control before WGS. Moreover, the genome-wide burden of base 
substitutions was assessed using SNV calls from a dedicated single cell algorithm and 
the resulting mutational spectra were compared between the original and the G&T-seq 
version. Despite the additional processing steps necessary for G&T-seq, MDA 
products had comparable burdens of 47,396 mutations for the original and 47,592 
mutations for the G&T-seq version. As their corresponding mutational spectra were 
also nearly identical (Figure 17), this indicates that the processing steps necessary for 
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G&T-seq do not create substantial additional technical noise and the obtained genome 
sequencing data is of similar quality compared to conventional approaches. Notably, 
the cell cycle state did not have any impact on the SNV analyses-specific quality 
criteria. This is an important finding in the context of post-mitotic tissues that have no 
or only very few cells in the G2 cell cycle state as these can be analysed using a 
G&T-seq RepliG approach without any considerations beyond the general challenges 
of calling SNVs in MDA-amplified sequencing data 51,104,176,205,229. 
 
In summary, G&T-seq was successfully shown not to interfere with RepliG MDA 
reactions and the corresponding genomics data is suitable for SNV analyses 
independent of the cell cycle state of the tissue of interest. The insufficient yield of 
GenomiPhi reactions within G&T-seq and the general lack of high-quality Trueprime 
products, highlight the need for thorough WGA consideration within new experimental 
settings. Moreover, GbS could be identified as powerful predictor of WGS quality, 
enabling scalable and cost-efficient screening of MDA products before WGS. 
Collectively, these findings support the extension of G&T-seq to SNV analyses and 









A Multiomics Approach to Define Mutational Spectra 
in Single Neurons 
 
Introduction 
This chapter describes the application of G&T-seq to cortical neurons to identify 
somatic base substitutions. Previous studies published just prior to and during the time 
of this analysis have used MDA amplified data to explore the mutational burden and 
signatures in human neurons. However, they did not have access to transcriptomic 
data of the same single cell 102,103. While the more recent study acknowledged a high 
burden of MDA artefacts in the data from the first publication and addressed this with 
computational filtering methods, an integrated DNA-and-RNA approach enables the 
confirmation of somatic variants in a molecular layer that is independent from MDA 
amplification and the corresponding artefacts. 
 
Human cortical development as well as the relevance and burden of somatic mutations 
in normal brain and neurodegeneration are briefly summarised as background for this 
chapter. 
 
Human Cortical Development and Neurogenesis 
Human brain development starts with the formation of the neural tube around three 
weeks after conception. Roughly one week later, the three vesicles called 
prosencephalon, mesencephalon and rhombencephalon have budded of the neural 
tube, which form the forebrain, the midbrain and the hindbrain, respectively. During 
the course of another week, the prosencephalon divides into the diencephalon, which 
amongst other structures will develop into the thalamus and hypothalamus, and the 
telencephalon, which becomes the cerebral cortex (reviewed in 230). The cortex 
accounts for over 80% of the human brain mass and is involved in several higher 
functions including processing of language and most sensory stimuli as well as the 
regulation of voluntary movement 231. 
 
Following the initial compartmentalisation, cortical development proceeds with a 
phase of rapid neuronal proliferation and migration, followed and partially overlapped 
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by series of apoptosis, the generation of synapses and axon myelination 230. 
Generation and migration of neurons is different for the two main neuronal subtypes 
of the cortex. The excitatory, glutamatergic projections neurons are generated in the 
dorsal telencephalon and migrate mostly radially over short distances, while the 
inhibitory, GABAergic interneurons primarily derive from the ventral telencephalon and 
have to migrate tangentially over longer distances (Figure 19A) 232. 
 
At the onset of neurogenesis in the dorsal telencephalon, the founder population of 
neuroepithelial cells (NECs) turn into radial glial cells that are associated with the 
apical membrane of the ventricular zone (VZ) and span the entire thickness of the 
developing cortex. Radial glial cells are stem cells that give rise to excitatory neurons 
and eventually differentiate into astrocytes. Besides symmetric division for self-
renewal, radial glial cells can asymmetrically divide to directly give rise to neurons or 
to intermediate progenitor cells (IPCs). These IPCs migrate into the subventricular 
zone (SVZ), which is directly above the VZ, where they significantly contribute to 
neurogenesis in humans. The excitatory neurons generated in these regions attach to 
the radial glial cells and migrate alongside their processes to populate the eventually 
six-layered cortex. The six layers of the fully developed neocortex differ with respect 
to the relative fraction and subtype of excitatory neurons and are involved in different 
neurocircuits (reviewed in 232-234). Cortical GABAergic interneurons can be found in all 
of the six layers as well with a similarly variable fraction of inhibitory subtypes in 
different layers. While there is some evidence for GABAergic neurogenesis directly 
within the developing human neocortex, the vast majority of interneurons derives from 
the ganglionic eminence, which is a transient embryonic structure of the ventral 
telencephalon. Therefore, new GABAergic neurons first have to migrate tangentially 
into the neocortex before they are integrated into the cortical layers after their 
attachment to radial glial cells (Figure 19B). Although the tangential migration across 
a large distance compared to the short radial migration, lacks the physical guidance 
of radial glial or similar cells, it is highly specific as clonally related interneurons were 
demonstrated to cluster spatially in the fully developed neocortex (reviewed in 232-234).  
 
Notably, the fully developed human cerebral cortex comprises around 16 billion 
neurons with the majority being generated over a short time span of four to six weeks 
of embryonic development 230,231,235. While adult human stem cells can give rise to 
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neurons in the olfactory bulb and the hippocampus, cerebral neurons are post-mitotic 
cells that persist for a whole human lifespan after embryonic proliferation eventually 
subsides around 26 weeks after conception 235,236. 
 
 
Figure 19: Neurogenesis and Neuronal Migration. SVZ: Subventricular Zone. VZ: 
Ventricular Zone. GE: Ganglionic Eminence. IZ: Intermediate Zone. CP: Cortical Plate. 
(A) Cortical excitatory and inhibitory neurons originate from morphologically distinct 
regions of the developing brain. Excitatory neurons are generated in the ventricular 
and subventricular zone while the majority of inhibitory neurons derives from the 
ganglionic eminence. (B) Excitatory and inhibitory neurons are the main neuronal cell 
types in the human cortex. Excitatory neurons migrate primarily radially along radial 
glial cells. Inhibitory neurons first migrate tangentially without physical guidance before 
attaching to radial glial cells. Both types of neurons are interconnected in neural 
circuits throughout all cortical layers. 
 
Somatic Mutation in Normal Brain and in Neurodegeneration 
The concept of somatic mosaicism is discussed in the general introduction to this 
thesis 45,46. Similar to other tissues, nearly all cells in the brain will carry clonal and 
private mutations that were caused by various endogenous and exogenous factors 
including replication, transcription or mutagen exposure, resulting in a high degree of 
intra-tissue heterogeneity 13-15,237. In recent years, especially single cell sequencing 
methods provided the opportunity for detailed exploration of the somatic mosaicism in 
the human brain. Substantial differences have been observed between the fetal and 
the adult brain with much higher rates of mutation during earlier stages of 
development 87,95-97,102,238. Furthermore, an age-related effect on SNVs and CNVs was 
demonstrated even within post-mitotic neurons of the adult brain 102,239.  
 
 72 
In more detail, whole-chromosome aneuploidy rates between 30-40% have been 
indicated by single cell sequencing and fluorescence in-situ approaches in the fetal 
brain, while a prevalence of only 2% was found in the adult brain 95-97,238. L1 
retrotransposition is another process that is highly active during embryonic 
development of the brain 240,241. Several studies have analysed the corresponding 
prevalence in the adult brain with variable estimates between less than one or more 
than ten retrotransposition events per neuron on average 98,101,242. Notably, a re-
analysis of the study claiming ubiquitous L1 retrotransposition in the human 
hippocampus, challenged the original author’s high estimate of more than ten events 
per neuron and aligned their data with the consensus of less than one 
retrotransposition per neuron. The re-analysis identified several sources of artefacts 
and highlights the importance of careful examination of single cell sequencing-derived 
data 100. In contrast to low levels of aneuploidy and retrotransposition, a substantial 
fraction of 5% to 30% of all neurons in neurotypical individuals carried at least one 
mega-base scaled CNV with an average of 63 genes being affected per alteration 
94,96,97,239,243. Interestingly, the relative percentage of neocortical neurons with CNVs 
declines with age. As neocortical neurons enter a post-mitotic state upon 
differentiation during embryonic development, the decline in CNV prevalence 
suggests an increased vulnerability to age-associated atrophy for neurons with 
particular mutations 239. 
 
The most abundant type of somatic mutations in the human brain are SNVs 87,102,103. 
Several hundred base substitutions could be already detected in single cell-derived 
colonies from neural progenitor cells that were sampled from post-mortem human 
foetuses 15 to 21 weeks after conception. Remarkably, SNVs accumulated at variable 
rates during different developmental phases with around one mutation per cell division 
for early cleavage stages and over five manifested base substitutions per day during 
the highly proliferative stage of neurogenesis. The observed mutation rates would 
result in around 1,000 somatic SNVs per neuron at the time of birth 87. Two additional 
studies have investigated somatic SNVs in individual human neurons using single cell 
genome sequencing of MDA products 102,103. The first study found an average of 
around 1,500 SNVs per neuron across three different individuals with relative 
enrichment in actively transcribed regions in neurons. The second study from the 
same authors acknowledged the potential existence of MDA artefacts in their first 
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publication and implemented a computational approach to distinguish true variants 
from technical artefacts using phasing of candidate sites with germline SNPs 102,206. 
Fifteen neurotypical individuals spanning an age range of over 80 years were 
investigated with less than 1,000 SNVs for young individuals and between 3,000 – 
6,000 base substitutions for donors at around 80 years of age. Hence, an age-
dependent pattern of SNV accumulation could be detected with an average of 23 and 
40 mutations per genome and year in post-mitotic neurons from the prefrontal cortex 
and the dentate gyrus, respectively 102. 
 
The relevance of somatic mutations in the context of neurodegenerative diseases has 
initially been proposed based on the comparison of familial and sporadic cases of 
these diseases and simulations estimating the degree and impact of somatic 
mosaicism 244,245. As mutations known from familial cases of diseases such as 
Alzheimer’s and Parkinson’s, could not be detected in the blood-derived DNA of 
sporadic cases, the mutations were suggested to be restricted to the central nervous 
system. Indeed, several somatic mutations including SNVs and CNVs in disease-
relevant genes were demonstrated in human brain samples from affected donors by 
now (reviewed in 246). Additionally, post-mortem brain samples of patients with 
neurodegenerative disorders display an increased burden of somatic SNVs and 
distinct enrichment of L1 retrotransposition in intronic regions compared to non-
pathological cases 102,247. 
 
Collectively, these findings demonstrate the substantial degree of somatic mosaicism 
in brains of neurotypical individuals and highlight the impact of particular somatic 
mutations in the context of neurodegeneration. Single cell sequencing is ideally suited 
to explore the mutational landscape in neurons due to their lack of proliferative 
capacity or a distinct clonal architecture, which would be needed for organoid or 
targeted microdissection approaches discussed in the general introduction of this 
thesis. Although previous studies have published important findings about the SNV 
burden and corresponding mutational signatures in post-mitotic neurons, they solely 
rely on MDA amplified data, which is known to comprise high levels of technical noise 
176. The substantial variability and partial disagreement in the estimated burden of 
CNVs and retrotransposition derived from single cell sequencing data, highlights the 
importance of complementary approaches in this still emerging field to accurately 
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determine mutational processes within single cells. Multiomics data from methods 
such as G&T-seq provides the unique opportunity to analyse information from different 
molecular layers from the same single cells. This does not only allow for a more 
detailed characterization based on analyses on the individual layers but also for an 
integrated approach. Since genomic information from G&T-seq was shown to be 
comparable to conventional MDA approaches and the RNA layer is independent of 
this WGA method, cortical neurons from five neurotypical individuals were subjected 
to G&T-seq and the corresponding first-time multiomics SNV calling approach is 




Brain Sample Collection 
Frozen post-mortem human brain tissues were obtained by the Voet research group 
at KU Leuven with appropriate ethical approval. Tissues were obtained in collaboration 
with Professor Bart Dermaut from the University of Ghent and the University of Lille 
and Professor Vincent Deramecourt from the Lille NeuroBank. The brain donors were 
not diagnosed with any neurodegenerative diseases and the brain tissues were 
assessed as histologically normal. Data from five donors was generated in this chapter 
and are referred to according to their naming convention at KU Leuven as Brain19, 
Brain20, Brain21, Brain22 and Brain23. The data set covered an age range of around 
three decades, ranging between 40 and just over 70 years of age. 
 
Isolation of Single Neuronal Nuclei 
Isolation of neuronal nuclei was performed by Sarah Geurs at the KU Leuven. Briefly, 
frozen tissue blocks of around 0.25 cm3 from the prefrontal cortex were manually 
homogenised using a pre-cooled cell lysis buffer and a tissue grinder. The 
homogenate was layered on top of a sucrose density gradient and nuclei were 
separated from cellular debris via ultracentrifugation at 4 °C. The nuclear pellet was 
resuspended and stained using DAPI and the neuron-specific antibody NeuN 248. 
Individual neuronal nuclei were isolated via FACS. Doublet discrimination was 
performed using a Forward-Scatter height versus Forward-Scatter area approach and 
neuronal nuclei were discriminated by positive NeuN staining. Neuronal nuclei were 
sorted into 96-well plates containing 2.5 µL Buffer RLT Plus from Qiagen 
supplemented with 1:16M dilution of External RNA Controls Consortium (ERCC) 
spike-in controls 249. A full 96-well plate was sorted for Brain23 and half a plate each 
for the remaining four donors. Therefore, Brain19 and Brain20 as well as Brain21 and 
Brain22 were processed in common batches. The 96-well plates were briefly spun 
down and stored at -80 °C before further processing. 
 
G&T-seq for Neuronal Nuclei. 
All processing steps for G&T-seq were done by Sarah Geurs at the KU Leuven. 
Separation of mRNA and gDNA as well as mRNA processing were performed 
according to the original G&T-seq publications with MDA amplifications of the gDNA 
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layer as described in a previous chapter 177,178. Briefly, polyA-tailed RNA was 
separated from gDNA using magnetic beads with oligo-dT primers. The gDNA was 
transferred into a new 96-well plate, while the mRNA was converted to cDNA using 
the Smart-seq2 method to derive full-length transcripts 250,251. The gDNA was 
amplified using the RepliG protocol with restricted MDA duration of 3 h. The obtained 
cDNA and amplified gDNA was sent to the Wellcome Sanger Institute for GbS, library 
preparation and sequencing. 
 
DNA Extraction for Bulk Sequencing Controls 
In addition to isolation of individual neuronal nuclei from the frontal cortex for G&T-seq, 
DNA extractions from frozen brain tissue samples of the occipital lobe or the 
cerebellum of the same brain donors were performed. The obtained DNA was 
subjected to bulk genome sequencing and served as matched control during the 
analysis of the corresponding G&T-seq data. DNA extractions were performed by 
Sarah Geurs at the KU Leuven and sent to the Wellcome Sanger Institute for library 
preparation and sequencing. 
 
Genotyping-by-Sequencing for MDA Product Quality Control 
The lab work required for GbS was performed by Scott Goodwin and Naomi Park 
within the Sanger Pipelines. The amplicon-based assay as well as the subsequent 
genotype calling and comparison to the bulk reference genotypes were performed as 
described in the previous MDA implementation chapter. 
 
Sequencing Library Preparation, Genome and Transcriptome Sequencing 
Two different sequencing libraries were generated for the cDNA. The first round of 
cDNA libraries was created to obtain an overview of all cells that had been subjected 
to G&T-seq to determine the available neuronal subtypes in the data set. These 
libraries were generated in the Sanger Pipelines using the Nextera XT technology for 
RNA-seq from Illumina 252. The pools of libraries per 96-well plate generated by the 
Nextera XT workflow were multiplexed in equimolar ratios and submitted for 125 bp 
paired-end sequencing on two lanes of the Illumina HiSeq 2000 using the v4 chemistry 
within the Sanger Pipelines. 
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After the selection of 50 successful MDA amplification products based on the GbS 
results from appropriate neuronal subtypes as indicated by the initial round of RNA 
sequencing, the corresponding original cDNA of these selected cells was submitted to 
the Sanger Pipelines for conventional Illumina sequencing library preparation and 
sequencing as an equimolar pool on two lanes of the Illumina HiSeq 2000 with v4 
chemistry to yield 125 bp paired-end reads. 
 
The 50 selected MDA products were submitted to the Sanger Pipelines for 
amplification-free sequencing library preparation using standard Illumina protocols 219. 
The libraries for six to eight samples were multiplexed in equimolar ratios and 
sequenced on one lane of the Illumina HiSeq X platform per sample to generate 
150 bp paired-end reads. 
 
DNA extracted from corresponding bulk brain tissue was submitted to the Sanger 
Pipelines for conventional Illumina sequencing library preparation. These libraries 
were pooled in equimolar ratios and sequenced on one lane of the Illumina HiSeq X 
platform per sample to generate 150 bp paired-end reads. 
 
Genome alignments for WGS and RNA-seq Data 
RNA- and DNA-seq data was obtained as individual cram files per lane and per cell. 
The cram files were converted back into FAST format using biobambam 220. RNA- and 
DNA-seq data was concatenated separately per cell. The Nextera or conventional 
Illumina sequencing adapter, bases with phred-scaled quality scores less than 10 and 
unknown nucleotides were removed using TrimGalore and Cutadapt 221. For RNA-seq 
data, trimmed reads with a length of less than 20 bp were discarded. RNA-seq data 
was aligned using STAR v2.5.2 with default parameters to a GRCh37 build 
supplemented with the ERCC sequences as additional chromosomes 253. Genome 
alignments of the WGS data to GRCh37 was performed with bwa mem and default 
parameters 222. The genome alignments were sorted and indexed with samtools, 
STAR alignments only had to be indexed 223. Duplicates were removed for DNA-seq 
and flagged for RNA-seq data using Picard v1.6 224. 
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Count Matrix Generation and Quality Control for RNA-seq Data 
A count matrix from the STAR alignments was created with featureCounts against the 
Ensembl version 73 gene annotation 254. Only reads with a phred-scaled alignment 
score of greater than 30 were considered and fragment-based counts were 
summarised across Ensembl gene IDs. The count matrix was processed in R using 
the scater package 255. Features with less than five counts in less than two cells were 
removed to avoid spurious mapping to unexpressed genes. Mitochondrial genes as 
well as ERCCs were defined as control features and were used to filter for libraries 
that contained only limited biological information. Cells with less than 100,000 total 
counts or relative count fractions of at least 25% accounting for either mitochondrial 
genes or ERCCs were removed. Finally, a minimum of 1000 expressed endogenous 
features was required to consider an RNA-seq library for the subsequent cell type 
identification. The filtered count matrix was transformed into counts per million 
mapped reads (CPM) for size-normalisation and potential batch effects were 
considered using the Principal Component Analysis (PCA) from the scater 
package 255. 
 
Computation of FPKM Values 
FPKM values as measure for gene expression annotation were computed from STAR 
alignments against the Ensembl version 73 annotation using RSeQC 256. 
 
Neuronal Subtype Identification 
The filtered and size-normalised count matrix was loaded into SC3 for unsupervised 
consensus clustering to determine the cell types in the RNA-seq data set from NeuN-
positive nuclei 257. SC3 performs parallel clustering using three different distance 
measures and two transformations and derives a consensus clustering from these 
individual clustering results. The clustering is k-means-based and a range of two to 
ten possible clusters was evaluated. The optimal number of clusters was evaluated by 
maximising the silhouette value of the consensus clustering. Unbiased marker gene 
identification was performed using SC3 257. To determine marker genes, SC3 
constructs a binary classifier for each gene based on the mean expression value for 
every cluster. Subsequently, SC3 computes the area under the receiver operating 
characteristic curve (AUROC) and a p-value for the robustness of the assignment 
using the Wilcoxon signed rank test. Here, marker genes were required to display an 
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AUROC > 0.8 and a Wilcoxon-derived p-value < 0.01. The obtained marker genes 
were compared to published marker genes from the literature to classify the neuronal 
subtypes that were present in the data set. 
 
SNV Calling in RNA-seq Data 
SNVs from RNA-seq data were called in the 50 neurons selected for the integrated 
analysis using GATK-v3.4 and the corresponding GATK Best Practices workflow for 
RNA-seq data 258. Briefly, the novel splice junctions as discovered by STAR during the 
first alignment were added to the STAR index and the reads were re-aligned to the 
GRCh37 genome using the extended splice junction index. Subsequently, read group 
information was added, duplicates were flagged and the alignments were indexed. 
Short intronic overhangs were hard clipped using the SplitNCigarReads function and 
base quality score re-calibration was performed. Variants were called using the 
Haplotype Caller while ignoring soft-clipped bases and requiring a minimum phred-
scaled confidence threshold of 20 as recommended in the Best Practices workflow. 
Clusters of at least three SNV calls in a 35 bp window were filtered. Furthermore, 
variants with Fisher Strand values greater than 30, which indicates significant strand 
bias, and Qual By Depth Values less than 2, which is a re-scaled quality score given 
the read depth, were filtered as well. 
 
Germline variants called in the donor-matched bulk sequencing file and common 
polymorphisms present in dbSNP build 138 or the 1000 Genome Phase 1 panel were 
flagged and not considered during analyses relating to somatic mutations and 
processes. However, these variants were used to compute the relative fraction of 
RNA-confirmed germline SNPs to obtain a sensitivity estimate for RNA-confirmation 
of known genomic variants. 
 
Mutation calls for the ERCC controls was performed in all available RNA-seq with a 
minimum of 10,000 reads aligned to the ERCC sequences. The workflow was identical 
to the SNV calling for endogenous RNA-seq data with the exception of germline and 
polymorphic variant flagging, which was not possible for the artificial ERCC control 
sequences 249. SNV calls on ERCC sequences that passed GATK variant filtering were 
used to visualise the mutational spectrum of technical artefacts in RNA-seq data. 
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Germline SNP Calling in Bulk WGS Data 
Germline SNPs from bulk WGS data were called using the GATK-v3.4. Haplotype 
Caller in single sample mode following the corresponding Best Practices Workflow. 
Read groups were added to the bwa genomic alignments with removed duplicates. 
After recalibration of base quality scores, gvcf files were produced using Haplotype 
Caller and genotype likelihoods computed in individual runs per donor. For the variant 
score calibration, dbSNP build 138 was specified as true known variants and the 
polymorphic sites from the 1000 Genome Phase 1 panel, HapMap 3 and Omni2.5 
SNP array were used as training set. The flags considered for variant calibration were 
as recommended in the Best Practices and included QualByDepth, FisherStrand, 
StrandOddsRatio, MQRankSum and ReadPosRankSum. To maximise detection of 
germline SNPs, the desired sensitivity was set to 99.5% as defined by the GATK 
tranches. All variants with calibrated scores that passed the sensitivity-tranche filtering 
were used as donor-specific germline SNPs in further analyses. 
 
Somatic SNV Calling in Single Cell WGS Data 
Four SNV calling algorithms with different statistical framework and corresponding 
filtering routines were used for analysis of the WGS data. The four tools considered 
were Caveman, joint-sample Haplotype Caller from GATK, SCCaller and 
LiRA 104,206,258,259. All algorithms were run according to the corresponding guidelines 
and recommended thresholds for statistical significance were applied if appropriate. 
Following significance and any additional recommended filtering, all germline SNPs 
from the donor-matched bulk sequencing data and variants within the segmental 
duplication or simple repeat track from the UCSC Genome Browser database were 
removed as well 260. For some of the subsequent analyses, a consensus set of base 
substitutions per cell was defined by all SNV calls that passed the appropriate filters 
of at least two different algorithms. The main principles and applied filters for the four 
different algorithms are briefly summarised in the following paragraphs. 
 
Caveman is an expectation maximisation-based algorithm that uses a Bayesian 
classifier to decide for the most likely genotype at any given locus 259. Caveman 
considers the ploidy and purity of the sample and to account for the non-uniformity of 
MDA-based amplification, the ploidy was set to five and purity to 90%. Caveman was 
run within the CASM Core Informatics Processing Pipeline at the Wellcome Sanger 
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Institute against the donor-matched bulk sequencing sample. Several post-processing 
filters are applied within this pipeline addressing quality metrics such as depth, base 
quality, read position and orientation (as described in 18). Germline variants are 
removed from Caveman calls during the pipeline processing through comparison to 
the matched bulk sequencing data and an unrelated normal panel to account for 
common polymorphisms. Further post-hoc filters were applied to remove variants if 
the supporting reads had median alignments scores (ASMD) less than 140 or more 
than half of them were clipped during alignment. 
 
SNV calling using GATK was performed similar to the procedure described for bulk 
sequencing data. The main difference was the common genotyping of all ten single 
cell samples per donor to leverage any potential support of clonal variants across 
multiple cells. After variant score calibration, the 95% sensitivity tranche was selected 
to reduce the potential for false positives compared to the 99.5% tranche selected for 
germline variant calls 258. 
 
SCCaller is a single cell-specific variant caller that was designed to detect locus-
specific ADO and non-uniformity of amplification introduced by MDA 104. SCCaller was 
used for variant calling in the MDA implementation chapter and is described in more 
detail in the corresponding method section. 
 
LiRA is another single cell-specific variant caller that applies read-backed-phasing of 
potential somatic variants with germline heterozygous SNPs (gHet) from a donor-
matched bulk reference. LiRA requires both observed alleles of somatic variants to be 
in perfect phasing agreement with the two alleles of the nearby gHet. The perfect 
phasing of both alleles is required to ensure that the somatic variant was present on 
the Watson as well as on the Crick strand of the original DNA molecule. Since strand 
information is lost during library preparation and sequencing, LiRA estimates a 
sample-specific composite coverage threshold that corresponds to the minimum read 
depth in bulk and single cell sequencing data at which somatic SNVs can be called. 
The main reasoning for this minimum read depth in single cells is that with increasing 
coverage the sole presence of phasing-concordant reads is not only due to 
undersampling of the MDA-amplified sequencing data. Despite the great non-
uniformity of MDA amplification, LiRA assumes even binomial sampling from the 
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original Watson and Crick strand. Since LiRA can only call the fraction of somatic 
variants with a nearby gHet, the genome-wide burden is extrapolated on the basis of 
fraction of the genome with sufficient power and the corresponding amount of passed 
variant calls  206. LiRA was run according to the author’s recommendations 206. Briefly, 
potential variants in single cell and gHets in bulk-sequencing data were called using 
the GATK Haplotype Caller 258. The raw variants before variant score calibration were 
used as input for LiRA. LiRA was run with references to the dbSNP build 151, the 1000 
Genome Phase 1 panel and SHAPEIT v2.r837 as phasing software 169. As 
recommended, 100 bootstrap iterations were specified during somatic rate estimation 
and the composite coverage threshold corresponding to a 10% FDR was estimated 
by LiRA. The actual variant calls from LiRA were considered for mutational spectrum 
analysis and the extrapolated genome-wide burden was compared to the total burden 
called by the three other variant callers. 
 
Analysis of Shared Mutations from WGS Data and Phylogenies 
Shared mutations were defined within the consensus SNV calls per cell. The amount 
of mutations shared between at least two or at least three cells per donor was 
considered. Additionally, the mutations shared across three cells were further 
restricted to sites with coverage of at least 10 reads and a maximum VAF of 0.25 in 
the donor-matched bulk sequencing data.  
 
Mutations shared across at least two cells and the restricted set shared across at least 
three cells were subjected to phylogenetic reconstruction using the single cell-specific 
tree inference algorithm SCITE 261. The average ADO rates per brain were used as 
false negative rates and the false positive rate was fixed at 10%. The maximum 
likelihood implementation to construct cell-centric trees was run in five independent 
Markov chains per donor and set of shared mutations with one million iterations each. 
All trees per run that achieved a similar maximum likelihood were emitted by SCITE 
and combined into consensus trees using the R package ape v5.3 262.    
 
Integration of SNV Calls in RNA-seq and DNA-seq Data 
SNV calls from RNA-seq data were integrated with the corresponding consensus SNV 
call set from WGS of the same single cell. Identical locus and alternative allele were 
required to be included in the putative set of integrated DNA-and-RNA calls. All 
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mutations within this putative set were visually checked in JBrowse to identify 
mutations supported by noisy reads, alignments errors or loci in close proximity to 
oligonucleotide repeats 263. Only mutations that could pass visual inspection were 
considered in the final set of integrated calls. 
 
Estimation of Upper Limit for Genome-wide Burden of Mutations 
An approximate estimate for the upper limit of the genome-wide burden of mutations 
was derived from the integrated DNA-and-RNA variant set. To estimate the fraction of 
the genome with sufficient power for SNV variant calls, the overlap of RNA-seq and 
WGS data from the cell was computed. The overlap was restricted to a coverage of at 
least eight reads in the WGS data since Caveman and SCCaller use read depth as 
hard filter. Given the fraction of the genome fDR with sufficient power to call SNVs in 
an integrated manner and the corresponding amount of calls nDR, an estimate for the 
genome-wide burden B was obtained. Furthermore, the RNA-confirmation rate of 
known genomic variants rR (derived from the heterozygous germline SNP confirmation 
rate in RNA-seq) as well as a false negative rate for WGS calls rD (derived from ADO 













Genome Feature Annotation 
The fraction of the genome with sufficient coverage for integrated DNA-and-RNA 
variant calls as well as the corresponding integrated SNV calls were annotated with 
respect to their genome feature distribution using the R package genomation 264. The 
considered genomic features were promoter – defined as 1 kb window around 
transcription start sites – as well as exons, introns and intergenic regions as defined 
by the Ensembl version 73 annotation. 
 
Association Between DNA-and-RNA SNV Calls and Gene Expression 
The final set of integrated DNA-and-RNA variant calls were associated with a gene if 
they were located within the gene body as defined by the Ensembl version 73 
annotation. To avoid inflated expression percentile ranks, only genes with FPKM 
values of at least one were used for the cell-specific ranking of expression values.  
 
Mutational Spectra and Signature Extraction 
The concept how mutational spectra were derived for base substitutions is described 
in the methods section of the MDA implementation chapter. Mutational signatures 
were extracted de novo from these spectra using SigProfiler v.2.1. that applies a non-
negative matrix factorisation approach. If appropriate, the de novo-extracted 
signatures were compared to the SBS signatures from the ICGC PCAWG Platinum 
release using SigProfiler v.2.1 36. During this comparison, SigProfiler attempts to 
reconstruct the de novo-observed signatures through combinations of variable 
exposures to known signatures. To avoid overfitting the de novo signatures through 
fractional exposure to many known signatures, the stability of the initial solution is 
evaluated by comparison to bootstrap samples of the input mutational spectrum. An 
inverse relationship between quality of approximation and stability is usually observed 
and was evaluated for combinations of 1 – 10 known signatures. The solution with 
maximised approximation and stability was chosen and exposure to known signatures 
was considered significant if the combination of exposures and the de novo-extracted 




Gene Ontology and Pathway Enrichments 
Gene Ontology (GO) and Pathway Enrichments were performed by GREAT v4.0.4 
within the rGREAT package 265,266. The GRCh37 annotation was used and 
backgrounds specified as appropriate and explained in the respective result sections. 
Since GREAT expects coordinate-based input, all genes considered for the GO 
analysis were converted into the transcription start site (TSS) coordinates as 
downloaded from the GREAT annotation. The coordinate-based input was mapped 
back to the corresponding gene within GREAT by choosing the association with the 
single-nearest gene within a 1 kb window while excluding curated enhancer regions. 
Considered GO categories were GO Biological Process, GO Cellular Component, GO 
Molecular Function as well as Panther, BioCyc and MSigDB Pathways. 
 
Statistical Analysis 
All statistical analysis was performed in R version 3.5.0 using core distribution 





Fifty Neurons are Selected for the Multiomics SNV Calling Approach 
Single neuronal nuclei from the prefrontal cortex of five deceased neurotypical donors 
were FACS-sorted in three 96-well plates and subjected to G&T-seq using MDA for 
WGA of the nuclear DNA. Notably, the five donors were processed in three different 
batches with Brain19 and Brain20 constituting the first, Brain21 and Brain22 the 
second and Brain23 the third batch. 
 
A previous publication focussed on SNV analyses in human neurons suggested that 
active transcription positively correlates with the mutational burden in post-mitotic 
neurons, which is contrary to SNV profiles observed in the human germline or 
cancer 103,267. Since they used conventional MDA approaches, the authors from this 
previous study had to rely on average neuronal expression values from databases 103. 
As neurons were shown to be a cell type with highly diverse expression profiles, the 
RNA layer from G&T-seq was used to select different neuronal subtypes to directly 
correlate the impact of active transcription with mutational burden 268-271. In order to 
identify the neuronal subtypes in the present G&T-seq data, a gene expression count 
matrix against the Ensembl version 73 annotation was generated from the RNA-seq 
alignments of all 288 neuronal nuclei. The count matrix was restricted to 22,520 
features with at least five counts in at least two nuclei. Furthermore, only nuclei with 
at least 100,000 total counts, a fraction of no more than 25% of these counts mapping 
to either mitochondrial genes or ERCC spike-in controls and a minimum of 1,000 
expressed endogenous features were considered for the cell type identification. The 
final count matrix with 157 neuronal nuclei from all five donors was CPM-normalised 
and subjected to an unsupervised consensus clustering approach using the SC3 R 
package 257. Best consensus clustering results were obtained with three clusters with 
a corresponding average silhouette index of 0.83. The first cluster only contained three 
neuronal nuclei from Brain19 and Brain20 each, while the second and third cluster 
were comprised of 77 and 74 cells from all five brain donors, respectively (Figure 20A). 
 
To associate known neuronal subtypes with the unbiased identification of subtypes, 
marker genes for these clusters were derived using the SC3 R package and compared 
to subtype-specific marker genes from the literature. When using the binary 
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classification approach for marker gene identification from SC3, ten genes each were 
identified as significant for the first two clusters and eight genes for the third cluster 
(AUROC > 0.8, Wilcoxon signed rank p-value < 0.1). Notably, the six neurons from 
the small first cluster also showed expression of all marker genes of the second cluster 
when restricted to the five most significant hits (Figure 20B). When these five most 
significant marker genes per cluster from the present G&T-seq data sets were 
compared to known marker genes from the literature, several overlaps were detected. 
One of the two major clusters expressed the glutamate transporter SLC17A7 and 
SV2B, which is a synaptic vesicle protein preferentially found in excitatory 
neurons 269,270,272. Marker genes for the other major cluster comprised the GAD1 and 
GAD2 genes, which are both coding for central enzymes in GABA synthesis, and the 
GABA transporter SLC6A1 269-271. Therefore, these clusters could be identified as 
glutamatergic projection neurons and GABAergic interneurons, respectively. The five 
most significant marker genes for the small cluster of six neurons were not reported 
as neuronal marker genes in the literature. However, they expressed the five most 
significant marker genes of the major excitatory cluster as identified by SC3 and were 
found to cluster evenly within the population from the major excitatory cluster in a PCA 
based on their global expression profiles (Figure 20C). Therefore, the small cluster 
was considered to consist of a subtype of excitatory neurons. In summary, the 
resolution provided by the G&T-seq data set of 157 quality-filtered cortical neurons 
was sufficient to distinguish between excitatory and inhibitory neurons as main 
neuronal subtypes in the human cortex 232,233. 
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Figure 20: Unbiased Consensus Clustering Identifies Excitatory and Inhibitory 
Neurons as Main Subtypes in Transcriptome Data from G&T-seq. (A) Consensus 
clustering for cell type identification using SC3 reveals two major clusters with 77 and 
74 neurons and an additional small cluster consisting of six neurons. (B) De-novo 
marker gene identification reveals SLC17A7 and SV2B as highly expressed in one of 
the major as well as the small consensus cluster. Moreover, the marker genes 
discovered for the second major cluster comprise GAD1, SLC6A1 and GAD2. These 
genes are ubiquitous marker genes for excitatory and inhibitory neurons. (C) The six 
neurons from the small cluster are evenly distributed within the main excitatory cluster 
on a PCA based on single nuclei RNA-seq data. Therefore, the small cluster is 
identified as a sub-cluster of excitatory neurons without previously published marker 
genes. 
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In parallel to the neuronal subtype identification, all MDA products were evaluated for 
their quality by comparing GbS-derived genotypes of MDA products to reference 
genotypes obtained from bulk sequencing of donor-matched brain samples. A total of 
126 polymorphic sites across all chromosomes was compared for every MDA product 
and considerable difference was observed between processing batches. Neuronal 
nuclei from Brain19 and Brain20 featured an average of 45% (SD = 16%) 
concordance to the donor-matched bulk reference, while the Brain21 and Brain22 
processing batch and nuclei from Brain 23 reached average concordance of 56% 
(SD = 17%) and 62% (SD = 15%), respectively. Notably, some nuclei from each batch 
also displayed drastically higher or lower concordance values (Figure 21). 
 
Since GbS was demonstrated to be a powerful predictor of WGS quality, five neurons 
with the highest GbS quality score each from the main excitatory and main inhibitory 
neuron cluster were chosen per donor. MDA products from the fifty selected cells were 
subjected to amplification-free library preparation and WGS. The corresponding cDNA 
of selected MDA products was subjected to a conventional Illumina library preparation 
and further RNA-seq was performed in an attempt to improve read depth and 





Figure 21: Quality Control of MDA Products Indicates WGA-related Batch 
Effects and Identifies the Most Suitable Amplification Products for WGS. MDA 
was performed in three separate batches as indicated in the plate layouts. Genotype 
concordance of MDA product was compared to germline references derived from 
donor-matched bulk sequencing data. While all processing batches include MDA 
products with low concordance values, the average GbS-indicated quality score is 
substantially lower for the processing batch including Brain19 and Brain20. The five 
excitatory and inhibitory neurons with the best GbS score per donor were selected for 
WGS to generate the final data set of 50 single cells considered in further analyses. 
 
Increased Read Depth Slightly Improves Feature Detection in RNA Data 
The initial RNA-seq for neuronal subtype identification had been performed on 
Nextera-based libraries on two Illumina HiSeq 2000 lanes for all 288 neuronal nuclei. 
To improve transcriptome-wide coverage for the fifty neurons selected for WGS, their 
corresponding cDNA was subjected to conventional Illumina sequencing library 
preparation and re-sequenced on another two Illumina HiSeq 2000 lanes. When the 
obtained read depths for the fifty selected neurons were compared between the two 
rounds of RNA-seq, an increase of the median depth from about 8,5 x 105 to nearly 
1,1 x 106 reads per nuclei was observed. Moreover, the median number of expressed 
endogenous features per nuclei was slightly increased with about 5,800 features 
detected for the deeper sequencing depth compared to the initial round of RNA-seq 
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with only 5500 features (Figure 22). Therefore, conventional RNA-seq library 
preparation increased read depth and improved transcriptomic coverage. The 
corresponding data was used in further analyses. 
 
 
Figure 22: Deep Sequencing of Transcriptomes Corresponding to the 50 MDA 
Products Selected for WGS Improves Endogenous Feature Detection. New 
conventional Illumina sequencing libraries were generated from the cDNAs of 50 
neurons that were selected for WGS based on the initial neuronal subtype 
identification and GbS quality scores. The deeper sequencing improved read depth by 
an average of over 250,000 reads per nuclei and resulted in an average detection of 
about 5,800 expressed features per nuclei compared to about 5,500 features for the 
shallow RNA-seq. 
 
Deep-sequenced RNA Confirms Excitatory and Inhibitory Neuronal Subtypes 
Since increased read depth for the transcriptomes of neurons selected for WGS 
improved the detection of expressed features per nucleus, the neuronal subtype 
classification was repeated using the combined data set of shallow and high 
sequencing depth RNA-seq. Similar to initial analysis, the combined data set was 
analysed using SC3 and the best intra-cluster cohesion and inter-cluster separation 
was achieved with three consensus clusters with a silhouette value of 0.83 
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(Figure 23A). The best consensus clustering identified two major clusters with 104 and 
95 nuclei as well as a small cluster with nine nuclei. While the two major clusters 
contained neurons from all brains and sequencing depths, the small cluster included 
three high-depth transcriptomes from Brain19 and Brain20, their corresponding low-
depth transcriptomes and three additional low-depth transcriptomes from Brain21 that 
had not been selected for the deep RNA-seq. Marker genes for the three consensus 
clusters were predicted by SC3 as described for the analysis of the shallow 
sequencing depth and restricted to the five most significant hits per consensus 
cluster (Figure 23B). Compared to the previous marker gene analysis, three of the 
current top five hits for the major cluster with 104 neurons overlapped with the cluster 
identified as excitatory projection neurons, including the two published marker genes 
SLC17A7 and SVB2 269,270,272. This cluster contained the 25 deep transcriptomes of 
excitatory neurons for which the corresponding MDA products were selected for WGS. 
Four marker genes from the major cluster with 95 nuclei overlapped with the five most 
significant hits from the cluster previously identified as inhibitory interneurons. This 
included GAD1 and SLC6A1 as known marker genes for GABAergic neurons 269-271. 
Marker genes for the small cluster did not overlap with the previous marker gene 
analysis from the shallow sequencing and did not contain any published neuronal 
marker genes. The three deep transcriptomes within this small cluster all featured 
expression of GAD1 and SLC6A1 (Figure 23B). Moreover, all neurons from the small 
consensus cluster were found to cluster evenly within the major inhibitory cluster when 
visualised on a PCA (Figure 23C). Since the small cluster still displayed expression 
similar to GABAergic neurons but could not be identified as a further particular 
subtype, the 25 deep transcriptomes from the small and the major inhibitory 




Figure 23: Excitatory and Inhibitory Neurons are Still Identified as Main 
Subtypes when Deep Sequenced Transcriptomes are Considered. The unbiased 
cell type detection was repeated using the combined shallow and deep RNA-seq data 
to evaluate if further known subtypes can be defined with improved feature detection 
in deep RNA-seq data. (A) Consensus clustering using SC3 identified two major 
clusters with as well as a new small cluster comprised of nine cells. (B) Marker genes 
for the two main clusters defined by SC3 overlapped with the known marker genes for 
excitatory neurons SLC17A7 and SV2B as well as with GAD1 and SLC6A1 for 
inhibitory neurons. The three deep sequenced cells from the small cluster also 
featured GAD1 and SLC6A1 expression but the unique marker genes for the small 
cluster did not overlap with any neuron-specific marker genes from the literature. 
(C) All cells from the small cluster are evenly distributed within the main excitatory 
cluster and thus, were grouped together for further analyses. 
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Germline SNP Confirmation Rate in RNA is Limited by Bimodal VAF Distribution 
SNVs in the RNA-seq data were called and filtered using GATK while following the 
corresponding Best Practices workflow as described in the methods section 258. SNV 
calls in RNA-seq can derive from germline and somatic mutations of the genome, post-
transcriptional modifications of the mRNA or represent technical artefacts. SNV calls 
from RNA-seq data were planned to be integrated with the corresponding calls from 
the genomic layer of the same cell in the presented G&T-seq SNV calling approach. 
Any calls representing post-transcriptional modifications of the mRNA or technical 
artefacts would be filtered during the integration due to their absence in the genomic 
call set. Therefore, high sensitivity for RNA-derived SNV calls was desirable to 
maximise the confirmation of genomic variants. An estimate for this sensitivity was 
calculated using the donor-matched germline SNPs known from bulk DNA sequencing 
data and common polymorphisms from dbSNP build 138 or the 1000 Genome Phase 
1 panel. The amount of germline SNP loci that demonstrated any RNA-seq coverage 
was highly variable with averages of 20135 (SD = 6681), 9364 (SD = 7722), 8397 
(SD = 5097), 13938 (SD = 6716) and 11942 (SD = 5737) for Brain19 to Brain23, 
respectively. When restricted to germline SNP loci covered by RNA-seq, a relatively 
constant fraction of 58% (SD = 6%) of these loci featured an RNA-seq SNV call with 
matching alternative allele (Figure 24A). However, an average of 91% (SD = 1%) of 
the variant calls were homozygous in the RNA-seq data with very little variation 
between cells or donors. In contrast, an average of only 40% (SD = 1%) of these 
germline SNPs were found to be homozygous in the donor-matched bulk sequencing 
data. When the VAF distribution in RNA-seq reads across all loci was visualised, a 
clearly bimodal pattern was observed with the majority of loci only displaying either 
the reference or an alternative allele (Figure 24B). Due to this intrinsic restriction of 
sensitivity, no distinction between heterozygous and homozygous SNV calls was 
made in further analyses. Furthermore, the average sensitivity of 58% to detect known 
genomic variants in RNA-seq covered loci was accepted to be the upper limit for this 




Figure 24: Germline SNP Confirmation Rate in RNA-seq Data is Limited by the 
Bimodal Pattern of Allelic Expression. (A) The detection rate of the alternative allele 
of germline SNPs derived from donor-matched DNA bulk sequencing was evaluated 
in SNV calls from single cell RNA-seq data. Notably, only SNP loci with RNA coverage 
were considered. While cell-specific variation exists, the maximum confirmation rate 
is limited to about 65%. (B) A clearly bimodal VAF distribution in single cell RNA-seq 
data was observed for all loci across all read depths, which intrinsically limited the 
germline SNP confirmation rate. 
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Substantial Level of RNA Editing Detected in Single Cell RNA-seq Data 
Following the removal of germline variants and flagging of calls on the ERCC control 
sequences, substantial levels of base substitutions were detected with considerable 
intra- and interindividual variation. On average, 10,196 (SD = 3262), 3890 
(SD = 4092), 4025 (SD = 2703), 7612 (SD = 3983) and 6363 (SD = 3271) SNV calls 
passed the filtering for Brain19 to Brain23, respectively (Figure 25A). Interindividual 
variation was found to be statistically significant (F[4,45], p < 0.001, one-way Anova) 
and corresponding post-hoc tests demonstrated that the difference between Brain19 
with Brain20 and Brain21 was below significance thresholds of 0.05 (adjusted p < 
0.003, Tukey’s HSD). Notably, the interindividual differences were still significant when 
correcting the total number of SNV calls in the RNA-seq data for sequencing depth 
and total genomic breadth of coverage. Moreover, SNV calls were found to be largely 
independent of sequencing depth, which suggested that no direct correlation exists 
between absolute expression values and the ability to call SNVs in the RNA-seq data 
(Figure 25B). 
 
A mutational spectrum was generated for SNV calls on endogenous features for the 
fifty deep-sequenced transcriptomes and compared to the corresponding spectrum of 
base substitutions called on the ERCC control sequences (Figure 26). The mutational 
spectra displayed a modest correlation of 0.47 but greatly differed in the relative 
amount of the six main substitutions classes. Nearly 47% of SNV calls on endogenous 
features were classed as T>C with only about 23% for calls on ERCC control 
sequences (Bonferroni-adjusted p < 1e-14, Binomial test). The main form of canonical 
RNA editing in humans is adenosine deamination to inosine (A-to-I) mediated by the 
ADAR family 273. Any inosine present on the original mRNA is detected as guanosine 
during Illumina sequencing and due to the classification based on the pyrimidine base 
of the Watson-Crick-base pair, any A>G mutation caused is classified as T>C mutation 
in the mutational spectrum. Due to the significant enrichment of SNV calls on 
endogenous features over the artefact background that correspond to the main 
canonical form of RNA editing in humans, a substantial level of RNA editing in the 




Figure 25: Substantial Amounts of Base Substitutions are Observed in 
Germline-cleaned SNV Calls from RNA-seq Data Across all Read Depths. (A) 
SNVs in single nucleus RNA-seq data were called following the GATK Best Practices 
and germline variants derived from donor-matched DNA bulk sequencing were 
removed. Substantial amounts of base substitution calls were observed, which 
account for the expression of somatic genomic variants, post-transcriptional 
modification of mRNA and technical noise. (B) SNV calls in RNA-seq data display a 
relatively even distribution across all read depths, which suggested that transcriptomic 
coverage did not limit SNV calling in single nucleus RNA-seq data. 
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Figure 26: The Mutational Spectrum of Base Substitutions in Endogenous RNA 
is Significantly Enriched in T>C Substitutions Compared to Artefactual Calls on 
ERCC Control Sequences. Base substitutions were classified according to the 
pyrimidine base change of the Watson-Crick base pair and further distinguished by 
their immediate 3’- and 5’-context. The profile derived from SNV calls on endogenous 
RNA substantially differs from the profile generated by technical noise as estimated 
on artificial ERCC spike-ins. The most prominent difference is the enrichment of T>C 
substitutions in endogenous RNA calls (adj. p < 1e-14, Binomial test). 
 
RNA Editing is More Prevalent in Excitatory than in Inhibitory Neurons 
Since a substantial amount of RNA editing was indicated in the deep transcriptome 
data from cortical neurons, potential differences between the two main subtypes were 
considered. As the main enrichment over the artefact background was observed for 
T>C substitutions, the following analyses were restricted to SNV calls that were 
compliant with canonical A-to-I editing. SNV calls corresponding to A-to-I editing were 
significantly higher in excitatory neurons compared to inhibitory neurons with average 
counts of 3767 and 2242, respectively (p = 4e-3, Student’s t-test, Figure 27A). 
Notably, the significant difference was maintained when controlling for read depth and 
breadth of genome coverage. Furthermore, a significantly higher fraction of genes 
expressed in excitatory neurons contained at least one T>C substitution within their 
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gene body compared to genes expressed in inhibitory neurons (odds ratio = 1.13, 
p = 2.2e-6, Fisher’s Exact test). To explore the functional impact of RNA editing in the 
neuronal subtypes, potential editing events were restricted to recurrent T>C 
substitutions that were called in at least two cells per subtype. This resulted in 3593 
recurrent sites for excitatory and 1374 recurrent sites for inhibitory neurons. These 
recurrent sites were found within the gene bodies of 1834 genes for excitatory neurons 
and 737 genes for inhibitory neurons according to the Ensembl version 73 annotation. 
The genes associated with recurrent potential A-to-I editing sites were analysed for 
GO term and pathway enrichment compared to the background of all expressed genes 
in the corresponding neuronal subtype. No pathway enrichments could be detected 
but several GO Molecular Function terms were associated with the potentially edited 
genes for both neuronal subtypes (Figure 27B). When restricting to the five most 
significant hits according to the hypergeometric p-values, the GO terms for inhibitory 
neurons could all be related to calcium ion channel and transporter activity. While 
similar GO terms were also within the five most significant hits for excitatory neurons, 
two GO terms related to glutamate receptor activity, which is the main neurotransmitter 
of excitatory neurons. Therefore, A-to-I editing was indicated to affect common 
functions in both neuronal subtypes with additional subtype-specific molecular 
functions in excitatory neurons. 
 
Canonical A-to-I editing is thought to be mainly mediated by enzymes of the ADAR 
family, which comprises the catalytically active ADAR and ADARB1 genes as well as 
the potentially inactive ADARB2 gene 273. Differences in expression of ADAR family 
members were considered for the observed differences in A-to-I editing between 
neuronal subtypes. However, when A-to-I editing compliant SNV calls per cell were 
compared to ADAR and ADARB1 expression, no significant effect could be detected 
in an ordinary linear regression (Adj. R2 = -0.03, p = 0.7 for ADAR, see Figure 28; 




Figure 27: RNA Editing is More Prevalent in Excitatory Neurons and is Enriched 
in Genes Regulating Glutamate Receptor and Ion Channel Activity. (A) 
Substitution calls that were in accordance with canonical A-to-I RNA editing are 
significantly enriched in excitatory compared to inhibitory neurons (p = 4e-3, Student’s 
t-test) (B) Genes containing loci with recurrent SNV calls in accordance with A-to-I 
editing were subjected to GO enrichment analysis. These genes were enriched in 
several Molecular Function annotations regarding ion channel activity for both 
subtypes as well as glutamate receptor activity for excitatory neurons.  
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Figure 28: Differences in ADAR Expression Levels do not Account for Observed 
Variation in SNV Calls in Accordance with A-to-I Editing. An ordinary linear 
regression was performed to correlate differences in ADAR expression to suggested 
variation in A-to-I editing. However, no significant effect could be observed 




Batch Effects and Extreme Mutational Burden are Discovered in WGS Data 
The WGS libraries from the fifty selected MDA products were sequenced to an 
average depth of 33X (SD = 3X). While the mean coverage was similar across brains, 
the fraction displaying moderate to high read depth more suitable for SNV calling, 
varied significantly among brains (Genome Fraction covered at >=15X; F[4,45], 
p < 1e-9, one-way Anova). On average, only 40% (SD = 5%) and 44% (SD = 5%) of 
the genome displayed read depths greater than 15X for Brain19 and Brain20, while a 
significantly higher proportion of 51% (SD = 3%), 54% (SD = 2%) and 52% (SD = 3%) 
of the genome featured similar coverage values for Brain21 to Brain23 (Figure 29A; 
adjusted p < 0.002 for all comparisons between Brain19 and Brain20 with Brain21, 
Brain22 and Brain23, Tukey’s HSD). Moreover, MDA products from Brain19 and 
Brain20 displayed greater variance in ADO rates - as determined through comparison 
to germline SNPs derived from donor-matched bulk sequencing data - compared to 
Brain21 to Brain23 (Figure 29B). However, the nominally elevated average of 54% 
ADO (SD = 4%) for Brain19 and Brain20 was not significantly different to the average 
of 53% ADO (SD = 2%) for Brain21 to Brain23 (F[4,45], p = 0.7, one-way Anova). 
Notably, MDA amplifications for Brain19 and Brain20 were performed in one 
processing batch and lower WGS quality was indicated by the lower GbS quality 




Figure 29: WGS from Brain19 and Brain20 Display Limited Breadth of Coverage 
and Substantial ADO Rates are Observed for all Selected MDA Products. (A) All 
MDA products were sequenced to the same average depth of 33X. However, Brain19 
and Brain20 displayed significantly lower breadth of coverage at modest read depth 
compared to the remaining three donors. (B) ADO rates were evaluated on WGS 
covered loci of heterozygous SNPs known from donor-matched bulk sequencing. 
Substantial ADO rates above 50% for most cells were observed with greater variation 
for Brain19 and Brain20 compared to cells from the other three donors. 
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Despite the indicated differences in WGS quality, base substitutions were determined 
in WGS data of all MDA products using the four algorithms Caveman, GATK 
Haplotype Caller, SCCaller and LiRA as described in the methods section 104,206,258,259. 
Subsequent to germline variant removal and further algorithm-specific filtering as 
described in the methods section, differences across an order of magnitude with 
respect to the total mutational burden were observed between different calling 
algorithms and between donors (Figure 30). Independent of the algorithm used, 
Brain19 and Brain20 featured substantially higher mutational burdens than neurons 
from the remaining three donors. For Caveman, the average mutational burden for 
cells from Brain19 to Brain23 were 361,898 (SD = 55,510), 277,521 (SD = 38,186), 
73,950 (SD = 5,547), 65,978 (SD = 6,839) and 76,843 (SD = 8,562). Similar 
mutational burdens were estimated for Brain19 to Brain23 by GATK with 
449,432 (SD = 60,679), 316,887 (SD = 37,325), 61,797 (SD = 3,652), 65,477 
(SD = 5,909) and 75,998 (SD = 8,428) average mutations per cell of the 
corresponding donor. The single cell-specific algorithm SCCaller yielded overall 
drastically reduced numbers of mutations, while the general pattern between different 
donors was maintained. The average mutational burdens of 122,441 (SD = 41,053), 
104,181 (SD = 21,705), 20,222 (SD = 1,705), 17,995 (SD = 1,413) and 20,381 (SD = 
2,110) were the most conservative estimates obtained from all considered algorithms. 
The read-backed-phasing algorithm LiRA that was used to explore base substitution 
variation in MDA-amplified WGS data from cortical neurons in a previous study 102, 
indicated even higher mutational burdens for Brain19 and Brain20 than the other three 
callers, while estimates for Brain21 to Brain23 were lower than the burden called by 
Caveman or GATK but higher than for SCCaller. On average, LiRA estimated an 
average mutational burden of 610,448 (SD = 89,916), 443,599 (SD = 63,293), 49,790 
(SD = 6,091), 42,448 (SD = 5,029) and 47,946 (SD = 10,407) for Brain19 to Brain23, 
respectively (Figure 30). Notably, the mutational burden reported in other normal 
human tissues including muscle, liver, colon, intestine, blood, dermal fibroblasts, 
endometrium as well as neurons, range between a few hundred up to several 
thousand base substitutions per cell 77,84,86,87,91,92,102-104,274. The most extreme 
estimates for genome-wide mutational burden by LiRA for neurotypical cells from 
Brain19 with an average of over 600,000 base substitutions are even high compared 




Figure 30: Extreme Mutational Burdens were Implied in Single Cell WGS Data. 
SNVs from WGS data were called using the four different algorithms Caveman, GATK, 
SCCaller and LiRA. While the results differed substantially between different 
algorithms, the mutational burden in Brain19 and Brain20 was implied to be nearly an 
order of magnitude greater than for the other three donors. Notably, Brain19 and 
Brain20 were processed in the same WGA batch. 
 
Mutational spectra were generated for the genome-wide calls from the four different 
algorithms (Figure 31). The relative contribution of the 96 considered context-specific 
substitution classes displayed great similarity between the different algorithms and 
strong dominance of C>T substitutions. A total of 83%, 84%, 90% and 95% of the 
mutations called by Caveman, GATK, SCCaller and LiRA, respectively, were 
classified as C>T substitutions. Notably, the majority of cells from Brain19 and Brain20 
displayed even greater proportions of C>T substitutions than the average across all 
brains. The majority of technical artefacts introduced during MDA-based WGA is 




Figure 31: Mutational Spectra for SNVs Called from All Considered Algorithms 
are Strongly Enriched in C>T Substitutions. Base substitutions were classified 
according to the pyrimidine base change of the Watson-Crick base pair and further 
distinguished by their immediate 3’- and 5’-context. The profiles generated by the four 
different algorithms are highly correlated and all display overwhelming dominance of 
C>T substitutions. 
 
The extreme mutational burden with strong enrichment in substitutions corresponding 
to the most prevalent WGA-associated artefact, implied technical artefacts as the 
primary source of SNV calls independent of the algorithm used. Additionally, it was 
reasonable to assume a WGA batch effect resulting in elevated levels of technical 
noise in Brain19 and Brain20 compared to the remaining three donors due to their 




Deconvolution of Mutational Spectra and Restriction to Shared Mutations 
Cannot Resolve the High Artefact Background in WGS Data 
The mutational spectra from the four different algorithms were deconvoluted to extract 
underlying mutational signatures in an attempt to distinguish true biological processes 
from signature contributions driven by technical artefacts. Deconvolution of the 
mutational spectra into individual mutational signatures suggested the existence of 
SBS19, SBS30, SBS32 and SBS44 as defined in the ICGC PCAWG Platinum release 
for the mutational spectra from Caveman, GATK and SCCaller and only SBS19 and 
SBS30 for the corresponding LiRA spectrum 36. SBS19 and SBS30 also accounted 
for the majority of the mutations when the additional existence of SBS32 and SBS44 
was suggested, with an average of 79% (SD = 14%) for Brain19 and Brain20 and 65% 
(SD = 3%). All suggested SBS displayed great C>T dominance and SBS19 and 
SBS30 nearly exclusively account for this class of base substitutions. SBS19 is of 
unknown aetiology, SBS30 is related to base excision deficiency caused by 
inactivating mutations in NTHL1, SBS32 is caused by the immunosuppressive agent 
azathioprine and SBS44 is a signature for defective mismatch repair. The mutational 
spectra of germline mutations derived from donor-matched bulk sequencing data 
displayed none of the signatures suggested by SNV calling results from single cell 
sequencing data. Since treatment of all five neurotypical donors with azathioprine and 
causative mutations within all five donors necessary for SBS30 and SBS44 that were 
not present in the donor-matched brain bulk sequencing data were extremely unlikely, 
the deconvolution of mutational spectra was considered inefficient to distinguish true 
somatic variants from WGA-related artefacts in the present data set with substantial 
levels of technical noise. 
 
Since the mutation calls from all algorithms were implied to primarily include WGA-
related artefacts, a consensus set of WGS SNV calls per neuron was defined for 
further analyses by all base substitutions that passed the appropriate filters of at least 
two different algorithms. This consensus set was explored for the presence of shared 
mutations across multiple cells from the same donor. When restricting to variants 
present in at least two cells, a greatly increased burden of 5,513 and 3,048 shared 
mutations for Brain19 and Brain20 was observed compared to 264, 281 and 291 
shared mutations in the remaining three donors. Base substitutions shared across at 
least two donors were strongly enriched in C>T mutations with an average of 97% for 
 108 
Brain19 and Brain20 and 58% for Brain21 to Brain23. While this represented a 
substantial relative depletion of C>T mutations for Brain21 to Brain23, the relative 
fraction of C>T mutations for Brain19 and Brain20 was largely unchanged and the 
potential WGA batch effect in the mutational burden was still prominent. Phylogenies 
were reconstructed using the single cell-specific tree inference algorithm SCITE 261. 
Given the high ADO rate and pattern of mutation calls that were in conflict with proper 
phylogenies, the consensus trees derived from SCITE output included no resolved 
lineage relationships and corresponded to one polytomy of all ten cells. 
 
Restricting to SNV calls in only two neurons can still retain WGA-related artefacts that 
appear in the same locus as a true biological variant in another neuron from the same 
donor. Since this appeared to retain substantial amounts of technical artefacts in 
Brain19 and Brain20, a more stringent set of shared mutations was defined by 
requiring detection in at least three neurons from the same donor. While no germline 
variants that were called in donor-matched bulk sequencing data were included in the 
consensus WGS SNV set, variants present in at least three of ten post-mitotic neurons 
from the same donor were restricted to loci with coverage of at least 10 reads and VAF 
less than 10% in the corresponding bulk sequencing data. Given these restrictions 
only 8, 4, 5, 2 and 4 shared mutations could be identified for Brain19 to Brain23, 
respectively. Similar to the lineage reconstruction for mutations shared between at 
least two cells, SCITE could not resolve any phylogenetic relationships between the 
cells and the consensus tree corresponded to one polytomy of all ten cells per donor. 
 
In summary, high levels of WGA-related artefacts were indicated during the SNV 
analyses of the genomic layer of single cortical neurons. While this was observed for 
all cells from all five donors, a WGA batch effect further amplified the level of technical 
noise for Brain19 and Brain20. Notably, the level of WGA-related artefacts did not 
seem to be reduced in the results from single cell-specific compared to conventional 
SNV calling algorithms. Since deconvolution of mutational spectra and restriction to 
base substitutions shared between multiple cells from the same donor also suffered 
from substantial levels of technical noise or could only identify very few mutations, 
SNV calling solely based on the genomic layers was considered to be ineffective in 
the present data set. 
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Integrated DNA-and-RNA SNV Calls Uncover a Unique Mutational Spectrum 
Compared to Individual Molecular Layers 
For the integrated DNA-and-RNA calling approach, SNV calls from RNA-seq and the 
consensus WGS SNV set were overlapped and identical base substitution calls from 
both molecular layers were accepted into the provisional set of integrated variants. 
Using this approach, a total of 56 variant calls could be detected across all 50 cells. 
Notably, no integrated variant was detected in 24 cells and the maximum of seven 
integrated SNV calls was observed in a single cell from Brain19. Due to the low 
number of variants, it was feasible to visually confirm the robustness of variant calls. 
Alignment tracks from the genome and transcriptome data were visualised in JBrowse 
and SNV calls that were supported by noisy reads, terminal variants and in direct 
proximity to oligonucleotide repeats were excluded to derive the final integrated set of 
SNV calls (see Figure 32 for examples). After manual confirmation, 47 of the 56 initial 




Figure 32: Quality of Integrated DNA-and-RNA SNV Calls can be Assessed by 
Visual Inspection of Corresponding Alignments. WGS and RNA-seq alignments 
were inspected on all loci with a putative DNA-and-RNA SNV call. (A) High quality 
calls are supported by variants across varying read positions and few to none 
additional variants on the supporting reads. (B) Low quality examples are found in 
regions with high variant density and are often supported by a terminal variant with 
fixed read position in RNA-seq, which implies mapping artefacts. 
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Figure 33: A Total of 47 Integrated DNA-and-RNA SNV Calls was Observed in 
the G&T-seq Data Set. Individual SNV calls from WGS and RNA-seq were combined 
and after visual inspection, 47 variants in 24 of the 50 considered neurons could be 
confirmed. 
 
Since integrated variants have to be called both in RNA-seq as well as at least in two 
variant callers in WGS data, the fraction of the genome in which integrated SNV calls 
are possible, is limited to loci with genome coverage in alignments from both molecular 
layers. Moreover, Caveman and SCCaller apply thresholds to the minimum coverage 
during variant filtering, so that a minimum of eight DNA reads was necessary to include 
a locus into the fraction of the genome with sufficient power for DNA-and-RNA SNV 
calls. For the present G&T-seq data set, only 0.3% (SD = 0.1%) of the genome was 
sufficiently powered to call SNVs using the multiomics approach. However, the 
powered genome fraction significantly correlated with the number of SNVs called per 
cell, providing an explanation for the variable amount of zero to six integrated SNV 
calls per neuron (Kendall's tau = 0.4, p < 1-e4). Further factors with impact on the 
ability to generate DNA-and-RNA calls are the ADO rate in WGS, which is equivalent 
to a false negative rate to detect true genomic variants (Figure 29B), and the cell-
specific confirmation rate of true genomic variants in the RNA-seq data (Figure 24B). 
Considering these factors, a somatic mutation rate was computed and extrapolated to 
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a genome-wide burden. While this was a very approximate extrapolation based on a 
limited fraction of the genome, the obtained estimates ranged between 221 and 2560 
genome-wide base substitutions for all cells with integrated SNV calls (Figure 34). 
Notably, the substantial difference in mutational burden for Brain19 and Brain20 
compared to the remaining three donors in SNV calls from WGS data was no longer 
present and the highest mutational burden was predicted in a cell from Brain23 




Figure 34: A Genome-wide Burden in the Hundreds to a Few Thousand Base 
Substitutions per Post-mitotic Neuron is Estimated Using the Integrated DNA-
and-RNA SNV Calls. The genome-wide burden of base substitutions was 
extrapolated in cells with at least one integrated DNA-and-RNA variant based on the 
amount of integrated variant calls and the fraction of the genome with sufficient power 
to apply the integrated approach in. These results were corrected using the WGS ADO 




While a more reasonable mutational burden was predicted by the integrated SNV 
calling approach, the low amount of variant calls made it necessary to restrict the 
mutational spectrum to the six main substitution classes. The mutational spectrum 
from the integrated SNVs featured a unique distribution across the six main 
substitution classes while reducing the main source of non-genomic SNV calls in the 
WGS and RNA-seq data (Figure 35). C>T substitutions as main WGA-related artefact 
was reduced to 49% in the DNA-and-RNA compared to over 80% for WGS-based 
SNV calls. Compared to SNV calls from RNA-seq, the substantial amount of 46% of 
T>C mutations that was implied to include to A-to-I editing was reduced to 27% in the 
integrated SNV calls. Notably, the relative fraction of different substitution classes for 
the DNA-and-RNA calls was not only the average between variant calls from the 
individual molecular layers but was depleted compared to both layers for C>G and 
T>A mutations and substantially elevated for T>G substitutions. 
 
 
Figure 35: Integrated DNA-and-RNA SNV Calls Display a Unique Mutational 
Spectrum Compared to Base Substitutions in the Individual Molecular Layers. 
Base substitutions were classified according to the pyrimidine base change of the 
Watson-Crick base pair. SNV calls from RNA-seq and WGS of the same single cells 
display complementary spectra, caused by different sources of biological variation and 
technical noise for both data types. The spectrum for integrated SNV calls mitigates 
the dominance C>T and T>C calls from WGS and RNA-seq, respectively. Moreover, 
unique enrichment or depletion can be observed for T>G, C>G and T>A mutations. 
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Integrated DNA-and-RNA SNV Calls are Enriched in Highly Expressed Genes 
The powered fraction of the genome for the multiomics SNV calls as defined in the 
previous result section was annotated with respect to their genomic features as 
defined in the Ensembl version 73 annotation. Within the powered genome 
background, 13% (SD = 2%) accounted for promoter, 24% (SD = 3%) for exons, 45% 
(SD = 3%) for introns and 18% (SD = 3%) for intergenic regions. It is important to 
stress that the genomic overlap and the corresponding feature annotation only 
indicates the breadth of genome coverage for the transcriptome layer since no hard 
depth filters were applied to SNV calls in RNA-seq data. Considering the total amount 
of RNA-seq reads, only 7% (SD = 2%) map to intergenic regions and no substantial 
DNA contamination was observed in RNA-seq data. 
 
Subsequently, the loci of the 47 DNA-and-RNA SNV calls were correspondingly 
annotated and revealed a significant enrichment in genic regions (p < 2e-3, binomial 
test), while the distribution between promoter, exon and intron did not significantly 
deviate from the background distribution (Bonferroni-adjusted p > 0.4; see Figure 36). 
The genic enrichment was expected due to the integration with SNV calls in RNA-seq. 
Only one of 47 variants was annotated as intergenic and the substantial read support 
in RNA-seq for this variant either represented expression from an unannotated 
element or could derive from gDNA contamination during cDNA synthesis. Notably, 
three other neurons displayed substantial coverage in RNA-seq data at the same 
locus, suggesting genuine expression rather than gDNA contamination.  
 
Cell-specific percentile ranks of expression were computed for all cells with at least 
one DNA-and-RNA SNV call to explore the relationship between transcriptional activity 
and the occurrence of base substitutions. Genes without noticeable expression were 
excluded to avoid inflating percentile ranks by unexpressed genes and to prevent 
erroneous association with zero dropouts that are common in single cell and single 
nucleus RNA-seq data 190. Given this limitation, a total of 36 genes could be 
associated with the 46 DNA-and-RNA SNV calls within genic regions. Genes 
associated with integrated SNV calls were highly expressed with an average cell-
specific percentile rank of 63% (SD = 30%) and specifically enriched in the highest 
3-quantile with 21 of the 36 genes ranking amongst the 33% of the most highly 
expressed genes per cell (p = 2e-3, binomial test; see Figure 37).  
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Figure 36: Integrated DNA-and-RNA SNV Calls are Evenly Distributed Across 
Genic Features Compared to the Genome Background with Sufficient Coverage 
for the Multiomics Approach. The genome background with sufficient coverage in 
WGS and RNA-seq as well as the loci of 46 integrated variant calls were annotated 
with respect to their genomic features according to the Ensembl version 73. Only one 
integrated variant was found within intergenic regions, which was expected due to the 
necessary overlap with RNA-seq. Within genic regions, the integrated calls were 




Figure 37: Integrated DNA-and-RNA Variant Calls are Enriched in Highly 
Expressed Genes. The cell-specific percentile ranks of gene expression were 
computed with restriction to genes with FPKM values of at least one. Given this 
restriction, 36 genes could be associated with the 46 DNA-and-RNA variant calls 
within genic regions. Genes that could be associated with an integrated variant call, 
were significantly higher expressed than expected by chance (p = 2e-3, binomial test 




The analysis of G&T-seq data focussed on 50 cortical neurons from five neurotypical 
donors was presented in this chapter. First, the transcriptome and genome of single 
neurons was analysed individually and similar to conventional approaches. 
Subsequently, information from the multiomics data was combined to derive an 
integrated set of DNA-and-RNA SNV calls and put into context with cell-specific 
transcription levels. 
 
From the RNA-seq analysis, glutamatergic excitatory and GABAergic inhibitory 
neurons could be identified as the main neuronal subtypes and no robust sub-
classification based on known marker genes was possible in the present data set 
(Figure 20 and 23). While one small cluster in addition to the two main clusters was 
implied by the unbiased cell type identification both in the initial shallow and the 
combined shallow and deep RNA-seq data set, the small clusters displayed 
expression of the most significant marker genes from a corresponding main cluster 
(Figure 20B and 23B). Notably, the small cluster identified in the initial shallow 
RNA-seq data set was grouped with excitatory neurons and the small cluster in the 
combined shallow and deep RNA-seq data set was closely related to the main 
inhibitory cluster (Figure 20 and 23). The most significant marker genes identified for 
the small clusters did not overlap with previously published marker genes to facilitate 
a further subtype identification within excitatory or inhibitory neurons. Previous studies 
could identify several of these subtypes but considered at least twice as many cells at 
higher read depth compared to the presented data set with 157 neurons 269,270. Even 
more comprehensive efforts profiled the transcriptome of nearly 20,000 human 
neuronal nuclei and thus, had much greater power to cluster single cell-derived 
transcriptomes at higher granularity 271. Since neuronal subtype identification was not 
the primary aim of this project, the cells within the small consensus clusters were 
grouped with their corresponding main cluster for further analyses. Notably, this 
affected none of the 25 excitatory neurons that were selected for WGS and only three 
of the 25 corresponding inhibitory neurons. 
 
SNV calls from RNA-seq data were generated with a focus on sensitivity to maximise 
the probability to confirm true genomic variants with complementary RNA-seq calls 
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during the eventual integration. Germline SNPs from donor-matched bulk sequencing 
data were used as ground truth to derive the confirmation rate of genomic variants 
with RNA-seq coverage to be 58% on average across all cells (Figure 24A). This cell-
specific confirmation rate was limited by the strongly bimodal VAF distribution across 
all loci in the RNA-seq data (Figure 24B). Nearly all loci displayed VAFs below 25% or 
above 75%, indicating high levels of allele-specific expression, stochastic bursting of 
gene expression or technical dropouts. These factors are known to generate strongly 
skewed monoallelic expression patterns in single cell RNA-seq data with mono-allelic 
expression being detected in up to over 76% of heterozygous germline SNPs 276-279. 
While global transcriptional profiles were shown to be similar between single cell and 
single nucleus RNA-seq data, the effect of transcriptional bursts might be even more 
pronounced in data from single nuclei 280,281. This stochastic pattern of allele-detection 
caused an average of 91% of SNV calls from RNA-seq data to be homozygous. Since 
this mainly reflects biological and technical limitations of the data, RNA-seq variant 
calls were restricted to locus and alternative allele while information about homo- or 
heterozygosity was not considered in further analyses. Furthermore, the germline 
confirmation rate of 58% suggested a highly sensitive variant calling approach in the 
RNA-seq data given the stochastic detection of mono-allelic expression (Figure 24). 
 
Germline-filtered RNA-seq variant calls were substantially enriched in T>C 
substitutions compared to variant calls on ERCC control sequences (Figure 26). While 
base substitution calls on ERCCs only represent technical artefacts, somatic SNV 
calls from RNA-seq data can also derive from genomic variation as well as post-
transcriptional modifications such as RNA-editing. As explained in the corresponding 
result section, the detection of T>C substitutions is indicative of to A-to-I editing, which 
is the main form of canonical editing in humans 273. The amount of base substitutions 
corresponding to canonical A-to-I editing was significantly higher in excitatory 
compared to inhibitory neurons and affected a higher proportion of the expressed 
genes in the corresponding subtypes (Figure 27A). Genes associated with recurrent 
editing events were enriched in GO terms regarding calcium channel activity in both 
subtypes and the glutamate receptor activity in excitatory neurons (Figure 27B). 
 
RNA editing is widespread in humans with potentially over a hundred million sites in 
most human genes being affected in a cell type and state-specific manner 273,282,283. 
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Notably, RNA editing is especially prevalent in the human brain and was shown to play 
a crucial role in regulating mRNA trafficking and direct post-translational modification 
of ion channels and neurotransmitter receptors 273,282,283. One of the earliest and best 
characterised examples of RNA editing in human brain is the modification of the 
calcium ion channels of the AMPA glutamate receptor 284. Only one published study 
specifically addresses RNA editing in single cell RNA-seq data thus far 285. The 
authors investigate the levels of A-to-I editing in 268 human brain cells. These cells 
are divided into seven subgroups including various glial cells and identify neurons as 
the cell type with highest prevalence of A-to-I editing. Similar to the results in this study, 
the authors also cannot detect a correlation between A-to-I editing with ADAR 
expression (Figure 28). Moreover, they observe a clear bimodal pattern of editing 
across all read depths, similar to the observations in the presented G&T-seq data 
(Figure 24B and 26B). They also observe that the vast majority of editing events is 
only present in a single cell and conclude that the true extent of RNA editing events is 
nearly impossible to detect in comparable bulk sequencing 283,285. Collectively, all 
these findings support that substantial levels of RNA editing were detected in the SNV 
calls from G&T-seq transcriptome data. While considerable differences in various 
tissues and cell types are known for RNA editing, this is the first time that differences 
in the transcriptome-wide levels of A-to-I editing were observed for the main human 
neuronal subtypes. 
 
The analysis of SNVs from single cell WGS data with four different variant callers 
implied extreme mutational burden for all selected MDA products (Figure 30).  The 
two SNV calling algorithms Caveman and GATK established for bulk sequencing 
suggested a mutational burden of around 70,000 base substitutions for Brain21, 
Brain22 and Brain23 and around 300,000 – 400,000 mutations for Brain19 and 
Brain20. For comparison, all studies focussed on SNVs in normal tissues identified a 
burden between several hundred up to several thousand base substitutions. These 
studies have been performed in various tissues and used different methodological 
approaches including bulk sequencing of clonal cell cultures or microdissections as 
well as MDA-amplified single cell sequencing 77,84,86,87,91,92,102-104,274. Furthermore, the 
corresponding mutational spectra displayed an overwhelming dominance of C>T 
mutations (Figure 31). Notably, C>T substitutions have been identified previously as 
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primary technical artefact introduced through cell lysis and amplification in 
conventional MDA protocols 104,229,275. 
 
These findings suggested WGA-related artefacts as the primary source for SNV calls 
from the single neuronal sequencing data with an additional WGA batch effect. A 
general trend of even further increased burden in neurons from Brain19 and Brain20 
and a comparable burden between the remaining three donors was observed for all 
SNV callers (Figure 30). Cells from Brain19 and Brain20 already displayed lower GbS 
quality scores, which were shown to predict WGS quality in the previous MDA 
implementation chapter (Figure 18 and 21). Since the cells from Brain19 and Brain20 
were processed in the same WGA batch, this increased burden is most likely to 
attribute to a further elevated level of technical noise introduced in this batch given the 
general dominance of WGA-related artefacts in the present WGS data. 
 
Notably, it had been established that G&T-seq does not introduce elevated levels of 
artefacts compared to conventional processing in the previous MDA implementation 
chapter and the data quality for Brain21, Brain22 and Brain23 is comparable to several 
published data sets. Using conventional MDA approaches on single cells and nuclei 
was reported to result in ADO rates of over 43% compared to an average of 53% in 
the presented neuronal data 229,286. Moreover, SNV calls from conventional algorithms 
were shown to result in around 32 errors per megabase 229. Given that SNVs could be 
called in around two thirds of the genome after excluding insufficiently covered and 
highly repetitive regions, this corresponds roughly to the 70,000 mutations called for 
Brain21 to Brain23 from Caveman and GATK.  
 
In addition to the two conventional SNV calling algorithms, two single cell-specific 
callers were used that were designed to mitigate WGA-related artefacts. SCCaller 
estimates local non-uniformity of amplification from gHets and considers this for final 
variant calls and LiRA uses read-backed-phasing of gHets with potential somatic 
variants 104,206. The genome-wide burden from SCCaller were the most conservative 
ones from all four algorithms with about 20,000 mutations for Brain21 to Brain23 and 
over 100,000 for Brain19 and Brain20 (Figure 30). In the original SCCaller publication, 
nearly 23,000 mutations with around 90% C>T substitutions are detected in WGS data 
from conventionally MDA-amplified cells. Remarkably, less than 1,000 SNVs are 
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called with a drastically reduced fraction of C>T substitutions in cells that undergo a 
modified MDA approach where cell lysis and DNA denaturation are performed on 
ice 104. These results are in line with the observations for cortical neurons from Brain21 
to Brain23 in this data set and confirm that technical artefacts are the primary source 
of SNV calls in conventionally MDA-processed cells even when single cell-specific 
variant callers are used (Figure 30 and 31).   
 
The genome-wide burden estimated by LiRA was around 45,000 for Brain21 to 
Brain23 and over 400,000 - 600,000 mutations for Brain20 and Brain19, respectively. 
While the suggested genome-wide burden for Brain21 to Brain23 was lower compared 
to the estimates of around 70,000 from conventional SNV callers, the estimates in 
Brain19 and Brain20 with higher levels of technical noise even surpassed the 
300,00 - 400,000 mutations called with the conventional algorithms. This suggests 
that WGA-related errors are not completely accounted for in LiRA, especially in high 
artefact backgrounds. One of the main problems inside LiRA is the assumed binomial 
sampling from both strands of the original DNA molecule. This even sampling is 
considered when deciding for sufficiently powered loci to call phasing-backed 
SNVs 206. However, any DNA molecule with artefacts introduced during cell lysis or 
early in the MDA amplification process that is affected by a sufficient level of uneven 
amplification will give rise to sequencing data that can be in perfect phasing 
agreement. The ADO rates of over 50% observed in the presented data set provide a 
direct estimate of the extent of non-uniform amplification between homologous loci 
(Figure 29B). While the degree of non-uniformity between the Watson and Crick strand 
from the same original molecule has not directly been assessed so far, it is not 
unreasonable to assume a similar level to the one observed between homologous loci. 
Consequently, current computational methods are likely to retain a fraction of WGA-
related artefacts, even in modified MDA approaches with reduced technical noise. 
 
Subsequent to the analysis of the individual molecular layers from G&T-seq, SNV calls 
from RNA-seq and WGS of the same neurons was integrated to derive a set of 
DNA-and-RNA SNV calls. After manual inspection, a total of 47 integrated variants 
was confirmed in 24 of the 50 neurons (Figure 32 and 33). Due to the requirement for 
sufficient coverage in RNA-seq and WGS data and exclusion of repetitive regions, 
only a small fraction of less than 1% of the genome was sufficiently powered to derive 
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integrated calls. Notably, the amount of DNA-and-RNA SNV calls per cell significantly 
correlated with the corresponding fraction of sufficiently powered genome. Therefore, 
a very rough extrapolation under consideration of false positive rates in WGS and 
RNA-seq data was performed (Figure 34). This extrapolation has several limitations, 
most notably that no mutations could be confirmed in about half of the cells and the 
extrapolation is based on expressed somatic variants that are functionally different 
from the majority of the genome. Despite these limitations, the corresponding 
estimated burden of several hundred up to about 2,500 mutations agree with the 
burden observed in other normal tissues as well with previous publications 
investigating somatic SNVs in human neurons 77,84,86,87,91,92,102-104,274.  
 
In addition to the more reasonable estimated burden from integrated DNA-and-RNA 
SNV calls, they also displayed a unique mutational burden compared to the individual 
molecular layers (Figure 35). As mentioned earlier, the predominant sources of 
variation were over 80% C>T substitutions as likely WGA-related artefacts in the WGS 
data and about 46% T>C substitutions in RNA-seq that included a high proportion of 
A-to-I RNA editing 104,229,273,275. The integrated SNV calls displayed drastically reduced 
relative contributions of these classes with 49% accounting for C>T substitutions and 
27% for T>C substitutions. While these substitution classes still account for most of 
the integrated SNV calls, this is in line with observations from WGS of other normal 
human tissues that have not undergone single cell sequencing 84,86,91,92. 
 
The burden and mutational spectra for human cortical neurons have been analysed in 
two previous single cell studies from the same research lab using WGS from MDA-
amplified products 102,103. In both studies, the authors apply a modified MDA approach 
similar to the one introduced in the SCCaller publication 102-104. In their first analysis, 
the authors use the consensus calls from three conventional callers and error 
corrections based on mutation calls of the hemizygous X chromosome in men. They 
conclude that around 1,500 base substitutions were present in neurons from two 
teenagers and a 42-year-old individual. Notably, the mutational spectrum displayed a 
similar fraction of around 80% C>T substitutions as observed for SNV calls from 
conventional callers in the present data set (Figure 31) 103. In their follow-up study, the 
authors acknowledged the possibility of MDA artefacts and applied LiRA to establish 
the burden and base substitution spectrum in human post-mitotic neurons 102. Their 
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main findings in neurons from healthy donors was an age-dependent mutational 
burden of less than 1,000 SNVs for new-borns and teenagers that increases to around 
3,000 – 4,000 substitutions for individuals over 80 years of age. Furthermore, they 
identify two signatures that primarily contribute to the mutational burden in healthy 
donors. One signature is similar to the clock-like signature 5, while the second 
signature is overwhelmingly C>T dominant and virtually identical to the signature 
derived from LiRA in the presented G&T-seq data with the exception of a small 
contribution of T>A substitutions (Figure 31) 66,102. Notably, the C>T dominant 
signature accounted for nearly 100% of the 300 – 900 mutations detected in infants. 
The authors argue that this is in great alignment with the 200 – 400 somatic base 
substitutions reported for neural progenitor cells up to 20 weeks of gestation 87,102. 
However, the mutations detected in sequencing data from clonal cultures of neural 
progenitors were predominantly C>A mutations with less than 30% accounting for C>T 
substitutions 87. Notably, cell culture has been demonstrated to introduce high levels 
of C>A mutations and the significant enrichment of C>A mutations in private compared 
to mosaic mutations, suggests a complementary source of artefacts in the results for 
the neural progenitor cells 79,87,287. 
 
While estimates for the mutational burden from the integrated DNA-and-RNA 
approach are too approximate to allow a detailed comparison, the average estimated 
burden of less than 1000 SNVs in cells with at least one integrated call is nominally 
less than the burden of usually around 1000 – 2000 base substitutions assigned by 
LiRA in the most recent study exploring the SNV landscape in adult human neurons 
(Figure 34) 102. Moreover, the average spectrum derived by LiRA in modified MDA 
approaches with less technical noise are still enriched in C>T substitutions with around 
55% compared to the relative fraction of 49% for the integrated DNA-and-RNA 
approach (Figure 35) 102,206. Collectively, the critical analysis of published data 
together with the results presented in this chapter, suggest that a remaining fraction 
of MDA artefacts obscure some of the previously published insights into the mutational 
landscape in post-mitotic human neurons. However, the present data set with 50 
cortical neurons and high levels of technical noise is too limited to finally resolve all 
discrepancies with sufficient granularity. 
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To improve the proposed method, the G&T-seq workflow should be adjusted to 
conform with the modified MDA approaches that have been demonstrated to 
significantly reduce the level of technical noise instead of following the conventional 
MDA guidelines 102-104. Furthermore, application to a greater number of neurons from 
several donors across a wide age range would allow for greater power for mutation 
detection and the analysis of age-related effects. More importantly, improving the 
fraction of genome coverage with sufficient power for the integrated DNA-and-RNA 
approach would facilitate the detection of a greater number of variants and thus, allow 
for a more detailed mutation spectrum analysis and a more robust genome-wide 
extrapolation. While the modified MDA approach potentially improves genome 
coverage and uniformity for WGS data, the RNA-seq data represents the more limiting 
factor. Currently, G&T-seq is restricted to analysis of polyadenylated mRNA and the 
Smart-seq2 protocol used in the present data set allows for the greatest detection of 
full-length transcripts of currently available protocols for single cell RNA-seq 250,288,289. 
Therefore, improving genome coverage for the transcriptome layer of G&T-seq is 
unlikely given the current methodological limitations. 
 
While the presented multiomics approach still has limitations and cannot fully resolve 
outstanding inaccuracies from previously published studies, the parallel acquisition of 
genome and transcriptome of the same cell could directly address the suggested role 
of active transcription for mutagenesis in post-mitotic neurons. The confident set of 
DNA-and-RNA variant calls were significantly enriched in highly expressed genes 
(Figure 37). Notably, this association was directly derived from cell-specific expression 
values and confirmed a previous suggestion based on correlation to expression values 
from databases 103. Remarkably, high transcription is correlated with low mutational 
frequencies in cancer genomes 267. The positive correlation with active transcription 
previously indicated and now confirmed in the presented multiomics data, points out 




In summary, the presented G&T-seq approach provides a method with unique benefits 
to SNV calling in single cells. Despite limitations in genome coverage and a low 
number of high-confidence variants, a refined mutational spectrum for base 
substitutions and a direct role of high transcriptional activity for mutagenesis could be 





Mutational Processes and Clonal Dynamics 
in Prostatic Epithelium 
 
Introduction 
This chapter discusses mutational processes and burden in histologically normal 
prostatic glandular epithelium and characterises clonal dynamics within ductal 
networks of the human prostate. Targeted microdissections were subjected to WGS 
to infer the mutational status and signatures in histologically normal prostatic 
epithelium. Additionally, long-ranging ductal networks were reconstructed for one 
donor to overlay WGS samples with spatial information and their corresponding 
morphological relationship. 
 
A brief summary of prostate anatomy and development, relevant aspects of benign 
prostate hyperplasia (BPH) and prostate cancer as well as previous work addressing 
stem cells and clonal dynamics within the normal human prostate are presented as 
background for this chapter. 
 
Anatomy and Development of the Human Prostate 
The human prostate is an accessory gland of the male reproductive system, which is 
situated directly underneath the bladder and surrounds the prostatic urethra as well 
as the ejaculatory ducts 290. The human prostate is classically divided into four different 
zones. Glandular epithelial tissue is distributed throughout the central, the transitional 
as well as the peripheral zone while the anterior fibromuscular stroma (AFMS), 
representing the fourth zone, contains no ductal tissue 291. The central zone surrounds 
the ejaculatory ducts while the transitional zone surrounds the proximal urethra 
approximately until the verumontanum, where the ejaculatory ducts enter the prostatic 
urethra. The peripheral zone covers the posterior and lateral prostate and largely 
surrounds the central and transitional zones 291. Within the normal prostate in younger 
men, the central zone forms around 25% of the glandular tissue, the transitional zone 




Figure 38: Anatomical Zones of Human Prostate. The human prostate can be 
divided into four anatomical zones. Only the central, transitional and peripheral zone 
contain glandular epithelium (This figure is a derivative of “Creative Commons Zones 
of the prostate” by Mikael Häggström licensed under CC0 1.0). 
The glandular function of the prostate is performed by a network of epithelial 
compound tubular-alveolar glands that are embedded in the prostatic stroma 293. 
Approximately 25 – 30 independent glandular subunits extend from the urethra in a 
complex branching pattern before terminating in multiple acini 294,295. The glandular 
tissue mainly consists of a two-layered stratified columnar epithelium of luminal and 
basal cells. In the human prostate, luminal and basal cells contribute evenly to the 
glandular epithelium 296. Traditionally, only luminal and basal as well as very rare 
neuroendocrine (NE) cells were described in prostatic epithelium based on cellular 
locations as well as a selected subset of surface antigens and marker gene expression 
297. More recently, an unbiased approach applying single cell RNA-seq to histologically 
normal prostatic epithelium, could confirm luminal, basal and NE cells but also 
identified two further epithelial cell types that were enriched in the urethra and peri-
urethral ducts 298.   
 
The complex branching pattern of the epithelial glandular subunits is established 
during embryonic and extended during pubertal development 290,299,300. Development 
of the human prostate can be divided into four stages 290. The first stage is the 
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androgen-induced fate determination that results in prostate development in males 
from the pelvic part of the urogenital sinus (UGS) at around 8 – 9 weeks of gestation. 
Shortly thereafter, prostatic buds arise from the UGS epithelium that elongate into the 
surrounding UGS mesenchyme. During this stage, a primitive ductal network 
composed of solid epithelial cords is established. Starting at around 11 weeks of 
gestation, more pronounced bud elongation and complex branching morphogenesis 
can be observed within the glandular network 290,301. While some anatomical 
trajectories are conserved and paracrine signalling between the UGS epithelium and 
mesenchyme is essential for budding and branching morphogenesis, it is thought that 
branching follows a stochastic process, where budding tips explore the surrounding 
mesenchyme according to a model described by branching and annihilating random 
walks 290,301,302. Repeated cycles of branching and ductal elongation driven by budding 
tips terminate independently when a budding tip comes into proximity of a previously 
established duct. This explains the complex organisation and irregular length of ducts 
within the same glandular subunit 302. Budding tips are most prevalent during 
embryonic development, are still present during adolescence but are not present in 
adult human prostates 300. The final stage of development within prostatic glandular 
subunits comprises the canalization of the solid epithelial cords and differentiation into 
the mature stratified columnar epithelium. Similar to the branching morphogenesis, 
this process follows a proximal to distal direction within each glandular subunit 290,301. 
 
While a period of functional maturity of the prostatic glandular epithelium is observed 
at latest at 20 weeks of gestation, the prostate gland enters a quiescent phase in the 
last trimester. With the strongly increased androgen production during puberty, 
another substantial period of human prostate development is observed resulting in the 
final complex glandular architecture and full maturity 299,300,303,304. The extent of 
glandular morphogenesis and additional branching is substantial during puberty with 
the epithelial to stromal ratio increasing by a factor of four in a study analysing fifty 
normal prostates between 0 – 30 years of age with a distinct step up in the ratio 
observed at around 15 years of age 305.  
 
Following embryonic and pubertal development, neoformation of glandular tissue is 
only observed in context of the two prostate diseases BPH and prostate cancer 301. 
Relevant aspects of these diseases are briefly summarised in the next section. 
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Benign Prostate Hyperplasia and Prostate Cancer 
BPH and prostate cancer are both common diseases in older men 306,307. Since the 
age profile, several symptoms and risk factors as well as features like neoformation of 
glandular tissue are shared between these diseases, there has been controversy 
about whether the diseases share pathogenic mechanisms 308-310. While the most 
recent meta-analysis of previous studies addressing this question concludes that BPH 
is associated with increased risk of prostate cancer, it is not considered a direct 
precursor lesion 293,309. 
 
BPH is the benign growth of nodules of glandular and stromal tissue nearly exclusively 
in the transitional zone. Commonly, the transitional zone accounts for over 50% of 
prostatic volume in men over 70 years of age compared to 5% during early 
adulthood 306. While the aetiology of BPH is not well understood, comorbidities such 
as type 2 diabetes and obesity are risk factors, perhaps acting through hormone 
activity alteration and pro-inflammatory pathways 293,306. Moreover, the declining ratio 
of testosterone to oestradiol as well as the accumulation of dihydrotestosterone (DHT) 
may play a role in the disease progression of BPH. Notably, symptomatic BPH can be 
treated by inhibition of the enzyme 5a-reductase, which converts testosterone into 
DHT 293,306.  
 
Prostate cancer is the most common solid malignancy in men 307. With respect to the 
different anatomical zones, only very few prostate cancers originate in the central 
zone, while the transitional and peripheral zone account for around 25% and 70%, 
respectively 292. Around 90% – 95% of prostate cancers are acinar adenocarcinoma, 
which originate in the acini of glandular subunits. The most common histological 
variant are ductal adenocarcinoma that account for around 3% of prostate cancer 
cases and often present as mixed ductal-acinar carcinomas 311. Therefore, nearly all 
prostate cancers derive from glandular tissue, preferentially in the periphery of the 
complex ductal networks. Remarkably, prostate cancer is frequently multifocal and 
several studies support an independent clonal origin for these foci 312-315. However, 
some somatic mutations found within the cancer foci were also observed in spatially 
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distinct, histologically normal prostate tissue and one report proposes a common 
clonal origin for multifocal prostate cancer 315,316. 
 
The prostate cancer genome is characterised by a modest mutational burden of 
around one mutation per megabase and usually only contains few focal CNVs 307. The 
most frequently mutated genes comprise TP53, SPOP, KMT2C, KMT2D and FOXA1. 
A recent study of over 1,000 prostate cancers identified a total of 97 genes to be 
significantly mutated. Notably, great inter-individual heterogeneity exists and most of 
these genes are only mutated in fewer than 3% of patients 317. In contrast to the low 
mutational burden, prostate cancer often presents with a high amount of chromosomal 
rearrangements 307. These rearrangements frequently include gene fusion with the 
ETS transcription factor family, which are present in over 50% of all cases of prostatic 
adenocarcinoma 318,319. In comparison to the primary disease, metastatic prostate 
cancer presents with significantly increased mutational burden as well as substantially 
reduced genomic heterogeneity, highlighting the importance of continuing evolutionary 
processes 307,320,321. 
 
The high frequency of prostatic diseases with neoformation of glandular tissue, a 
highly diverse but comparably quiescent mutational landscape as well as the 
multifocality of prostate cancer prompt questions about somatic evolution and clonal 
dynamics within the normal prostatic epithelium. An overview about previous insights 
into these clonal dynamics and corresponding stem cell biology in the human prostate 
is given below.  
 
Stem Cell Biology in the Normal Human Prostate 
Most insights into stem cell biology of the prostate have been gained from rodent 
models. However, different anatomic organisation, shortened postnatal development 
as well as the absence of naturally occurring prostate cancer in these rodent models 
point out that stem cell organisation and clonal dynamics are likely to be substantially 
different between the rodent and the human prostate 293,295. 
 
During embryonic development, it is well established that ducts and acini form in 
proximal to distal direction through elongation and branching of budding tips. Epithelial 
cells within these budding tips therefore contain the embryonic stem cell population 
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that is responsible for directed morphogenesis 290,301. Similar budding tips are 
observed before and during adolescence but are absent in the adult prostate 300.  
 
Following these two phases of development, the prostate enters the state of adult 
tissue maintenance. Tissue turnover and regeneration that is maintained over 
decades is commonly attributed to adult stem cells, which are long-lived, possess self-
renewal and high proliferative capacity as well as multipotent lineage potential 322. Due 
to these features, adult stem cells (ASCs) that escaped tissue-typical regulation are 
hypothesised to give rise to cancer and the presence of these so-called cancer stem 
cells has been identified in prostate cancer 323. Therefore, an improved understanding 
of normal clonal dynamics will contribute to the understanding of prostate diseases. 
 
Some ASC compartments are large and highly proliferative. For example, the 
hematopoietic system has to replace up to billions of highly specialised cells and 
50,000 – 200,000 stem cells are estimated to contribute to leukocyte generation 
alone 86. In contrast, the normal prostate is relatively quiescent with an estimated 
turnover of epithelial cells in the range of 200 days 324. The existence of ASCs 
throughout the human prostate has primarily relied on the identification of cell 
populations with stem cell markers and their proliferative capacity in-vitro and in 
xenograft models 324-329. Collectively, these studies propose a small population of cells 
with stem cell-like properties scattered throughout the glandular epithelium. This stem 
cell-like population is primarily located in the basal cell compartment and hypothesised 
to account for about 1% – 2% of the cellular mass 324-329. Moreover, bulk RNA-seq of 
the basal and luminal cells confirmed stem cell-like features in the basal 
compartment 330. 
 
Additionally, three studies have performed in-situ lineage tracking in glandular 
epithelium from serial sections of the normal human prostate. All of these studies relied 
on visual tracking of a mitochondrial DNA mutation in the cytochrome c oxidase (COX) 
enzyme, that can be stained using immunohistochemistry approaches 295,331,332.  The 
two earlier studies established the common clonal origin for basal, luminal and NE 
cells throughout the ductal system. While most terminal acini were found to be 
polyclonal, demonstrated by co-existence of normal and COX-deficient tissue, rare 
monoclonal conversion was observed indicating that single stem cells can generate 
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whole terminal branches 331,332. The more recent study performed long-ranging 
reconstruction of individual glandular subunits and was able to demonstrate that some 
COX-deficient clones spanned the whole length from urethra-proximal ducts to distal 
acini. Additional functional assays established that proliferative activity was mainly 
restricted to the basal cell layer and decreased in proximal to distal direction. Since a 
higher proportion of long-ranging COX-deficient clones was detected in glandular 
tissue from older patients, continuous migration of COX-deficient clones was 
postulated and integrated into a stem cell model. According to this model, the stem 
cell niche is confined to the urethra-proximal ducts, where basal stem cells extend in 
directed streams with decreasing proliferative potential and give rise to luminal cells 
295. In support of a specific stem cell population in the peri-urethral ducts, recent single 
cell RNA-seq discovered two new epithelial cell types enriched in this area that display 
expression similarities with immature cell types in other human tissues and prostate 
cancer. While their cellular function is not validated, the authors hypothesise that these 
cell types could be enriched for prostate ASCs 298. 
 
While the in-situ lineage tracking studies significantly contributed to the understanding 
of clonal dynamics within the prostate, a unique stem cell niche in the peri-urethral 
ducts with distinct proximal to distal gradient of stemness contradicts the earlier 
findings of scattered and isolated stem cell populations throughout the basal 
compartment of glandular subunits 324-328. Moreover, COX-deficient lineage tracking 
relies on the existence of a single mutation that cannot be temporally dated to different 
phases of development or tissue homeostasis. Similarly, no subclonal relationships 
can be distinguished within COX-deficient clones. Here, glandular reconstruction is 
combined with WGS to explore the more complex mutational processes on the whole-






A snap-frozen whole prostate sample from a 59-year-old donor suitable for the 3D 
reconstruction and phylogenetic analysis of long-ranging glandular subunits was 
provided by Rakesh Heer from Newcastle University. Additional prostate samples 
were obtained to explore the mutational landscape and to infer the relationship 
between mutation accumulation and aging in normal prostate epithelium. Another 
snap-frozen prostate biopsy from a 70-year-old donor was provided by Rakesh Heer. 
Four snap-frozen post-mortem prostate biopsies from 22-, 30-, 47- and 71-year-old 
donors were obtained from AMS Biotechnology. Furthermore, WGS data of 
microdissections from normal prostate epithelium from a 59- and 78-year-old donor 
were made available by Luiza Moore. All samples were obtained, stored and 
processed with appropriate ethical approval. 
 
Sample Preparation for Laser-Capture Microscopy 
The frozen prostate samples were equilibrated to 0 °C before fixation in PAXgene 
Tissue Fix and the corresponding PAXgene Tissue Stabilizer (PreAnalytiX). 
Subsequently, the whole prostate sample was cut longitudinally into two 10 mm 
blocks. The prostate biopsies were of variable thickness between 2 – 5 mm and could 
directly be subjected to paraffin embedding. Paraffin embedding was performed by 
Yvette Hooks using a Sakura Tissue Tek VIP 6 Processor with standard histological 
tissue processing protocols. The paraffin-embedded prostate blocks were sectioned 
by Yvette Hooks to derive 10µm thick cross-sections of the whole prostate or biopsy 
region and mounted onto PEN-membrane slides (Leica). Individual sections were 
stained with haematoxylin and eosin (H&E) by sequential immersion into: the 
xylene-substitute Neo-Clear (two minutes, twice), ethanol (70%, 1 minute, twice), 
ethanol (100%, 1 minute, twice), deionised water (1 minute, once), Gill’s haematoxylin 
(15 seconds), tap water (20 seconds, twice), eosin (6 seconds, once), tap water 
(15 seconds, once), ethanol (70%, 15 seconds, twice), ethanol (100%, 30 seconds, 
twice), and Neo-Clear (15 seconds, twice). The stained sections were scanned using 
a NanoZoomer S60 (Hamamatsu) up to a 20- or 40-fold magnification. No cancerous 
lesions were detected in the regions of interest that were subjected to Laser-Capture 
Microscopy (LCM) and WGS. 
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Reconstruction of Prostatic Glandular Subunits 
Prostatic glandular subunits were only reconstructed for the 59-year-old donor of the 
whole prostate. Low-resolution images at 10x magnification were extracted in jpg 
format from the high-resolution digital slide scans to be able to perform image 
registration on 671 sequential whole prostate images. Intensity-based automatic rigid 
image registration was performed within Matlab. The aligned images were screened 
for long-ranging prostatic glandular subunits and series of several hundred image files 
containing the ductal trees of interest were imported into the serial section microscopy 
editor Reconstruct 333. Branching of prostatic ductal trees was followed in proximal to 
distal fashion and regions of interest were annotated for subsequent LCM 
microdissection. Three-dimensional structures of LCM microdissections and their 
histological connection through the ductal network were visualised in R using the plotly 
package 334. Two-dimensional projections were generated using metric 
multidimensional scaling (MDS) in R.  
 
Laser-Capture Microscopy and Whole-Genome Sequencing 
Prostatic ducts and acini of interest were dissected using a LMD7 laser-capture 
microscope (Leica) and collected into separate wells of a 96-well plate. Regions of 
interest were cut from up to three adjacent sections to yield an approximate total of 
200 – 2000 cells epithelial cells per well. For the 59-year-old-donor of the whole 
prostate, most LCM microdissections were derived from the reconstructed glandular 
subunits. Ductal and acinar regions of interest from the remaining donors were 
selected only based on benign histological appearance and appropriate cell number 
for microdissection without detailed knowledge about their morphological relationship. 
 
The DNA was extracted using the Arcturus PicoPure DNA Extraction Kit (Thermo 
Fisher Scientific) according to the manufacturer’s instructions. The 96-well plates with 
extracted DNA were submitted to the Sanger Pipelines for bespoke sequencing library 
preparation from low DNA input samples and subsequent WGS. Typically, six to eight 
samples were multiplexed and sequenced on the same total number of Illumina HiSeq 
X lanes to generate 150 bp paired-end reads. 
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Genome Alignment and Variant Calling 
The WGS data was aligned against the GRCh37 genome by the CASM Core 
Informatics Processing Pipeline at the Wellcome Sanger Institute. Base substitutions 
were called using Caveman against a donor-matched stromal prostate sample with 
corresponding filtering as described in the chapter presenting the G&T-seq analysis 
of human cortical neurons. Structural variations were called using BRASS 335. 
 
Inference of the Relationship Between Mutation Accumulation and Aging 
To infer the relationship between mutation accumulation and aging, all WGS samples 
derived from LCM of normal prostate epithelium that were already available within the 
Wellcome Sanger Institute or generated for this study were considered.  
 
To obtain more accurate estimates for the amount of base substitutions present in 
every section considered, clonality and sequencing depth of the corresponding WGS 
data had to be considered since polyclonality or low sequencing depth will result in 
low estimates of the mutational burden. Sequencing depth was computed using 
samtools 223. The degree of polyclonality was estimated by the median VAF of all 
passed base substitution calls in a sample. Since a minimum of four variant reads was 
required during filtering, robust estimation of polyclonality c was only possible in 





For example, perfectly clonal diploid samples would display a median VAF and 
corresponding estimate of c = 0.5 and thus, only required a minimum depth d = 8, 
while highly polyclonal samples with c = 0.1 required a sequencing depth of at least 
d = 40. Only samples that displayed sufficient sequencing depth for their 
corresponding clonality estimates in at least 75% of the genome, were considered in 
the final regression analysis. 
 
For these samples, the sensitivity for SNV calls based on clonality and sequencing 
depth was computed using a generalised linear model (GLM) provided by Simon 
Brunner. The GLM parameters were calculated based on LCM-derived WGS data of 
human liver tissue. Directly adjacent tissue sections were assumed to comprise the 
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same variants and thus, any diverging SNV calls in directly adjacent sections were 
attributed to polyclonality and insufficient sequencing depth. Subsequent to sensitivity 
estimation s, the mutational burden as estimated from Caveman and corresponding 
filtering br was corrected to yield the mutational burden bc: 
𝑏1 = 	
𝑏2 𝑠4  
 
To account for dependent multiple samples from the same donor as well as the 
observed distribution of mutation count data, a generalised linear mixed-effect model 
with negative binomial response distribution and log-link function was fitted using the 
Laplace approximation to infer the effect of age a on the mutational burden bc using 
the R package lmerTest with following formula 336:  
𝑏1	~	log	(𝑎) + (1	|	𝐷𝑜𝑛𝑜𝑟) 
 
A linear relationship between donor age a and corrected mutational burden bc:is 
considered using this approach. Since a log-link function is used, the logarithm of age 
a is used to account for the exponentiation during computation. A random intercept 
per donor is considered to account for the interdependency of samples from the same 
donor and is indicated by (1 | Donor) according to the R syntax. The age effect was 
derived from this model using the R package effects 337. 
 
Mutational Spectra and Signature Extraction 
Mutational spectra for base substitutions, corresponding signature extraction and 
comparison to SBS signatures from the ICGC PCAWG Platinum release was 
performed using SigProfiler v.2.1 as described in more detail in the chapter presenting 
the G&T-seq analysis of human cortical neurons 36. 
 
Detection of Positive Selection and Driver Mutations 
Positive selection of mutations was evaluated using a dN/dS approach within the R 
package dndscv 338. This method compares the amount of non-synonymous to 
synonymous mutations within coding regions and accounts for local mutation rates as 
well as for the globally observed trinucleotide context of mutations. An excess of non-
synonymous compared to synonymous mutations relative to what is expected by 
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chance indicates positive selection, while a corresponding depletion would suggest 
negative selection 117.  
 
In addition to the unbiased detection by the dN/dS approach, genic base substitutions 
resulting in missense, nonsense or essential splice site mutations were intersected 
with the most comprehensive catalogue of base substitution driver mutations in 
prostate cancer comprising 97 significantly mutated genes (SMGs) as published by 
Armenia and colleagues in 2018 317. The observed change was annotated as a known 
driver mutation if it was present within the discovery set of Armenia and colleagues or 
within hotspots as annotated by the COSMIC Cancer Gene Census or the IntOGen 
database 127,317,339.   
 
Telomere Length Estimation 
Telomere lengths were estimated from genomic alignments using the Telomerecat 
bam2length command with 100 iterations for estimating the impact of insert size 
distribution and default parameters otherwise 340. 
 
Lineage Tree Inference 
Base substitution profiles from LCM microdissections of reconstructed ductal subunits 
were used to infer their phylogenetic relationships. Adhering to the principle of the 
infinite site model of molecular evolution, it was assumed that only one independent 
mutation occurred per locus and was subsequently maintained in all cellular 
progeny 40. For perfectly clonal samples, binary mutation calls can directly be used to 
infer the corresponding lineage tree. However, most microdissection samples were 
found to be oligo- or polyclonal. Therefore, not all mutations called in one 
microdissection derive from the same most recent common ancestor (MRCA). 
 
The VAF distribution of base substitutions within one sample provides information 
about the clonal origin of these mutations. Discrete clusters of mutations observed at 
similar VAFs suggest a common clonal ancestor for all of these mutations. To use VAF 
instead of binary mutation calls for the lineage tree inference, the total read depth and 
the alternative allele count were obtained for all loci that were called by Caveman in 
at least one sample from the same prostatic ductal subunit. Formal inference of 
discrete clusters of mutations based on their VAFs was performed with an 
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n-dimensional hierarchical Dirichlet process (n-HDP). The stick-breaking process of 
the n-HDP results in highly concentrated clusters of mutations that display similar VAF 
across samples. The algorithm was implemented by Peter Campbell as previously 
described 18. Every cluster derived by the n-HDP represents an ancestral cell that was 
the MRCA of all cells carrying these mutations. Under the assumption that most 
normal epithelial cells are diploid, the median VAF m from all mutations associated 
with one n-HDP-derived cluster hdp directly translates into the cellular contribution cc 
per microdissection i: 
𝑐𝑐ABC,E = 	𝑚ABC,E ∗ 2 
 
For example, if the median VAF for one n-HDP-derived cluster corresponds to 0.5 in 
one microdissection, 100% of the cells in this microdissection share the corresponding 
ancestral cell as their MRCA.  
 
For the phylogenetic inference, only clusters with at least 10 mutations were 
considered. Furthermore, up to 20 mutations from each cluster were manually 
inspected to identify clusters that comprised common sequencing and alignment 
artefacts. Using the relationship between median VAF and cellular contribution per 
microdissection, lineage relationships can be inferred based on the pigeonhole 
principle. Since the sum of cellular contributions cannot exceed 100% per 
microdissection, clones providing smaller cellular contributions must be subclones to 
n-HDP-derived clusters with greater cellular contributions. Absolute certainty for 
lineage nesting was assumed if two n-HDP-derived clusters exceeded 95% cellular 
contribution in at least one microdissection. Furthermore, lineage nesting was strongly 
suggested if two n-HDP-derived clusters displayed the same pattern of relative cellular 
contribution in all microdissections and their sum of cellular contribution was at least 
75% in at least one microdissection.  
 
Statistical Analysis 
All statistical analysis was performed in R version 3.5.0 using core distribution 




Data Set Description 
The work presented in this chapter was focussed on two complementary aspects of 
mutational processes in normal prostate epithelium. Firstly, mutational burden, 
corresponding mutational signatures and the presence of driver mutations was 
ascertained within histologically normal prostate tissues from a total of eight donors 
as listed in Table 1. Secondly, the clonal dynamics within individual glandular subunits 
could be explored for one of the eight donors as a whole prostate sample from this 
donor allowed detailed morphological reconstruction of these ductal structures. 
 
To address both of these overarching topics, targeted microdissections of 
histologically normal prostate epithelium were obtained via LCM for all of these donors 
and subjected to WGS (Figure 39). For two donors, the WGS data was kindly provided 
by Luiza Moore. For the remaining six donors, tissue sections and corresponding WGS 
data was generated for this study. In total, 409 WGS samples were considered for the 
presented work. The majority of these samples were collected from the whole prostate 
sample of a 59-year-old donor and annotated according to their position within 
individual glandular subunits. These samples account for 319 WGS samples. For the 
remaining donors, two to thirty-two WGS samples were obtained and an overview is 
given in Table 1.  
 
 
Figure 39: Example of Three Targeted Microdissections. Microdissections from 
histologically normal prostate epithelium were sampled using Laser-Capture-
Microscopy. Microscopy images of the same area are displayed before (A) and 
(B) after collection of three distinct microdissections. 
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Table 1: Overview of Available Prostate and WGS Samples. WGS from 
microdissections of histologically normal prostatic epithelium was obtained from eight 
different donors. For six donors, WGS data was generated for the presented work and 
additional WGS data from two further donors was kindly provided by Luiza Moore. 
Donor ID Donor Age [Years] Sample Type WGS Samples 
PD43390 22 Post-mortem biopsy 32 
PD43391 31 Post-mortem biopsy 9 
PD43392 47 Post-mortem biopsy 2 
PD37885 59 WGS data 5 
PD40870 59 Whole prostate 319 
PD42298 70 Biopsy 21 
PD43393 71 Post-mortem biopsy 9 
PD28690 78 WGS data 12 
 
 
Mutations Accumulate with Age in Normal Prostatic Epithelium 
To consider a potential relationship between age and the accumulation of mutations 
in normal prostatic epithelium, base substitutions were called in the 409 WGS samples 
from LCM microdissections. While targeted microdissections aim to reduce cellular 
heterogeneity compared to traditional bulk sequencing and allow for calling of somatic 
variants in normal tissue, the sensitivity is still limited by the remaining degree of 
polyclonality and the obtained sequencing depth. The impact of polyclonality and 
sequencing depth on variant calling sensitivity in WGS data from LCM 
microdissections was estimated previously in our group by Simon Brunner. Since a 
robust estimate of polyclonality is essential for a correction of the observed mutational 
burden per microdissection, this correction could only be applied to 282 WGS 
samples. Notably, neither of the two WGS samples from the 47-year-old donor 
PD43392 could be considered in the final set of 282 WGS samples. Intuition and 
criteria for the sample selection and sensitivity correction are described in the methods 
section in more detail. 
 
The sensitivity correction resulted in an average increase of 288 (SD = 241) mutations 
per microdissection. The average mutational burden observed per microdissection 
varied between donors with substantial intra-individual differences as listed in Table 2. 
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A negative-binomial GLM as described in the methods section was fitted to infer a 
potential age effect on the mutational burden within normal prostatic epithelium. 
Despite the considerable intra-individual variation, a significant age-effect across 
donors could be ascertained (Model Log-likelihood = -2125, fixed effect of 
log(age) = 0.83, corresponding standard error = 0.13, p < 3e-10). After reversing the 
log-transformation that was necessary for the negative-binomial GLM and 
marginalisation over the random effect accounting for dependence of microdissections 
from the same donor, the best estimates from the model corresponded to an increase 
of 16 (SD = 0.3) mutations per year with a predicted offset of 150 (SD = 15) mutations 
(Figure 40). 
 
Table 2: Corrected Mutational Burden in WGS Data from Microdissections of 
Normal Prostatic Epithelium. The mutational burden per microdissection was 
corrected for clonality and sequencing depth in appropriate WGS samples. While the 
average burden varies between donors, substantial intra-individual variation is also 
observed. 
Donor ID Donor Age [Years] WGS Samples 
Considered 
Mutational Burden 
(Mean ± SD) 
PD43390 22 25 439 ± 175 
PD43391 31 5 1096 ± 329 
PD43392 47 0 N/A 
PD37885 59 3 1019 ± 567 
PD40870 59 208 991 ± 589 
PD42298 70 21 1371 ± 498 
PD43393 71 8 1255 ± 849 





Figure 40: The Mutational Burden in Microdissections from Normal Prostatic 
Epithelium Increases with the Age of the Tissue Donor. Mutational burdens were 
ascertained in WGS samples and corrected for clonality and sequencing depth. A 
negative-binomial GLM revealed a significant age effect on the mutational burden per 
donor despite substantial intra-individual variation (p < 3e-10). The model suggests 
accumulation of 16 (SD = 0.3) mutations per year with an intercept at 150 (SD = 15) 




Clock-like Mutational Signatures Dominate the Mutational Landscape in Normal 
Prostatic Epithelium 
Following the analysis of the total mutational burden in normal prostatic epithelium and 
its relationship with age, mutational signatures were extracted for all 409 WGS 
samples to reveal the underlying mutational processes. Across the eight donors, a 
total of five different mutational signatures could be observed. The main contribution 
to all microdissections from all eight donors were the clock-like mutational signatures 
SBS1 and SBS5, that were previously associated with cell division and the age of the 
individual 36,66. For the three younger donors between 22 and 47 years of age as well 
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as the 59-year-old donor PD37885 and the 70-year-old donor PD42298, these 
signatures accounted for 100% of the observed mutations with an average 
contribution of SBS1 of 17% (SD = 4%) and 83% (SD = 4%) of SBS5.  
 
Similar average contributions of SBS1 and SBS5 could be observed in the 
microdissections in the 59-year-old donor PD40870 as well as in samples from the 
two oldest donors. However, in some of the microdissections from these donors, 
substantial presence of additional mutational signatures was detected. When 
additional mutational signatures could be detected, the relative contribution of SBS1 
remained largely unchanged, while the contribution of SBS5 was decreased. The 
smoking signature SBS4 was detected in 3 of the 9 samples from 71-year-old donor 
PD43393, where they contributed to 25% (SD = 6%) of the mutational burden. 
Notably, the smoking status was unknown for all of the prostate donors and 
contribution of this smoking signature was only observed in a single patient. In seven 
microdissections from PD40870, SBS8 contributed to 22% (SD = 1%) of the observed 
mutational burden and SBS40 in 49 microdissections to 56% (SD = 12%). SBS40 was 
also observed in six of the 12 microdissections for the oldest donor PD28690, where 
they contributed to 52% (SD = 4%) of the mutational burden. While SBS8 and SBS40 
do not have an associated aetiology, SBS40 has been shown to be correlated with 
patient’s ages in some types of human cancer and thus, can display some clock-like 
features like SBS1 and SBS5 36. 
 
In summary, the mutational landscape in normal prostatic epithelium was shown to be 
dominated by clock-like mutational signatures. While SBS1 and SBS5 accounted for 
100% of the observed mutations in younger patients, additional signatures could be 
observed in microdissections from older patients with SBS40 being the only one 




Figure 41: The Mutational Landscape in Normal Prostatic Epithelium is Primarily 
Shaped by Clock-like Mutational Signatures. For five of the donors, SBS1 and 
SBS5 contribute to 100% of the observed mutations. SBS4 and SBS8 are observed 
in a single patient with minor overall contributions while SBS40 is observed in 
increasing percentages in two older patients. SBS1, SBS5 and SBS40 all display 
clock-like features in several cancer types. 
 
No Signs of Positive Selection and Low Frequency of Driver Mutations in Normal 
Prostatic Epithelium 
Genes under positive selection feature an excess of non-synonymous mutations 117. 
To identify corresponding genes in normal prostatic epithelium, a dN/dS approach was 
applied to SNV calls from all 409 WGS samples that were available for this study as 
described in the methods section. After correction for multiple testing, no gene 
displayed significant signs of positive selection (q > 0.1 for all tested genes). 
 
From the total amount of 153,706 unique mutations called in the 409 available WGS 
samples, 16 non-synonymous mutations were observed in 14 genes that were 
recently published as SMGs in prostate cancer (Table 3) 317. From these sixteen 
mutations, one missense mutation in RAG1 as well as one nonsense mutation in 
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SMARCA1 were identical to the ones observed in the discovery cohort that was used 
to define the catalogue of SMGs 317. Furthermore, the established R219S driver 
mutation in FOXA1 was observed in the 59-year-old donor PD40870 341-343. The 
remaining mutations did not overlap with previously annotated mutations or hotspots 
of mutations for prostate cancer as defined in the COSMIC Cancer Gene Census or 
the IntOGen database 127,339. Thirteen of the non-synonymous mutations in SMGs 
were only detected in a single microdissection. The missense mutations in COL15A1 
and PTPRC were observed in two spatially adjacent microdissections each. 
Remarkably, R219S in FOXA1 as the only established driver mutation detected in the 
presented data set, was detected in five spatially related microdissections. 
 
Gene fusions involving the ETS transcription factor family are present in over half of 
all prostate cancers and are clinically used as marker for molecular 
subclassification 307,319. Due to their high abundance in prostate cancer, the presence 
of relevant gene fusions was ascertained in microdissections in normal glandular 
epithelium. A total of 16 SV events as called by BRASS involved any of the ETS 
transcription factors or their most relevant fusion partners TMPRSS2, SLC45A3 or 
HNRP2AB1 across all 409 microdissections. Most of these events represented 
sequencing artefacts and no prostate cancer-relevant gene fusion could be detected. 
 
Collectively, these results demonstrate that limited selection for base substitutions and 
a low amount of driver mutations existed in normal prostatic epithelium. However, the 
rare occurrence of driver mutations was implied to be associated with spatial 




Table 3: Overview of Non-synonymous Mutations in Significantly Mutated 
Genes in Prostate Cancer. Sixteen mutations called in microdissections from normal 
prostatic epithelium were found in previously published SMGs in prostate cancer. Most 
mutations were only detected in a single microdissection. Notably, the known driver 
mutation R219S in FOXA1 was observed in five microdissections from the donor 
PD40870. 
Donor ID Gene Change Impact Affected Samples 
PD42298 KMT2A C1479W Missense 1 
PD42298 ZNF292 Y2193C Missense 1 
PD40870 RPRD2 D327G Missense 1 
PD40870 RAG1 R34W Missense 1 
PD40870 RAG1 V529M Missense 1 
PD40870 MRE11A I647L Missense 1 
PD40870 BRCA2 F1336L Missense 1 
PD40870 FOXA1 R219S Missense 5 
PD40870 NCOR1 P1665T Missense 1 
PD40870 NOX3 V72I Missense 1 
PD40870 CHD7 R1155C Missense 1 
PD40870 COL15A1 A542D Missense 2 
PD40870 AR . Essential Splice 1 
PD40870 AR R832Q Missense 1 
PD40870 SMARCA1 W426* Nonsense 1 
PD28690 PTPRC E362K Missense 2 
 
Long-Ranging Glandular Subunits are Reconstructed from Serial Sections of a 
Whole Prostate Sample 
A frozen whole prostate sample for the morphological reconstruction of individual 
glandular subunits was kindly provided by Rakesh Heer from Newcastle University. 
The prostate sample was received with a longitudinal cut through the AFMS, which 
exposed the prostatic urethra. After tissue fixation, a block of approximately 10 mm 
from the lower to mid prostate, which was centred around the verumontanum, was 
selected for the morphological reconstruction (Figure 42). Serial cross-sections 
alongside the prostatic urethra of 10 µm thickness were prepared by Yvette Hooks. 
Slide scans of the serial prostate whole-mount sections were manually screened and 
followed to reconstruct the complex branching pattern of individual glandular subunits. 
During the reconstruction process, samples were selected for subsequent 
microdissection to be able to overlay genomic with morphological information. The two 
glandular subunits that were reconstructed to the greatest detail comprised 91 and 88 
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WGS samples and could be traced across most of the distance from proximal to far 
peripheral parts of the prostate (Figure 43). These glandular subunits were selected 
from the left- and the right-hand side of the prostate and covered a cubic area of 
33.4 mm3 and 32.7 mm3, respectively (Figure 44). 
 
 
Figure 42: Overview of Unprocessed Whole Prostate Sample. A whole prostate 
sample from a 59-year-old-donor was used to explore the clonal dynamics within 
individual glandular subunits. The prostatic urethra was exposed through a 
longitudinal cut alongside the AFMS. A block of approximately 10 mm (indicated by a 
black box) around the verumontanum (indicated by the straight-line black arrow) was 
selected for serial cross-sectioning alongside the prostatic urethra. Glandular subunits 
originate in the proximal prostate (indicated in grey shading) where they drain into the 
urethra and extend into the periphery in a complex branching pattern. (A) Overview of 




Figure 43: Exemplary Cross-section and Part of Glandular Subunit. Serial cross-
sections were obtained from a whole prostate sample and manually screened for long-
ranging glandular subunits that extend from the urethra-proximal to peripheral areas 
of the prostate. (A) H&E-stained cross-section of the whole prostate sample. Large 
amounts of ductal and acinar tissue can be seen enclosing cell-free brighter areas 
within the uniformly stained stromal tissue. The area indicated by the black box 
contains a long-ranging glandular subunit and is shown in more detail in (B). (B) Part 
of a long-ranging glandular subunit is outlined in black. Following the epithelial 
structures in the adjacent serial sections, connections between the highlighted 
glandular tissue could be observed and were used to reconstruct the branching pattern 
and extent of individual glandular subunits.  
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Figure 44: Overview of 3D-Reconstruction of Glandular Subunits. Individual 
glandular subunits were manually traced and reconstructed from serial cross-sections 
of a whole prostate sample. Grey globes indicate a microdissection sample with WGS 
data and the connecting black lines indicate the branching pattern of the ductal 
network. The microdissection sample at the origin is the most proximal sample of the 
respective glandular subunit. (A) Glandular subunit from the left-hand side of the 
prostate with 91 microdissection samples. (B) Glandular subunit from the right-hand 
side of the prostate with 88 microdissection samples. 
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Increased Rates of Mutation Accumulation and Cell Division are Observed in the 
Peripheral Parts of Individual Glandular Subunits 
Substantial intra-individual variation in the mutational burden of microdissections could 
be observed during the analysis of age-dependent accumulation of mutations 
(Figure 40). Notably, a clock-like pattern of mutation acquisition was also supported 
by the mutational signatures that are active in normal prostatic epithelium (Figure 45). 
Due to the morphological reconstruction of glandular subunits that was possible for 
donor PD40870, a spatial effect on the mutational burden within one donor could be 
considered. Such an effect could be confirmed as the mutational burden was 
significantly increasing in a proximal to distal fashion within individual glandular 
subunits (0.06 mutations per µm, p < 8e-6, OLS; Figure 45A). Moreover, the mean 
telomere length per microdissection decreased in the same direction (-0.08 bp per µm, 
p = 1e-5, OLS) and telomere length was shown to be inversely correlated with the 
mutational burden in microdissections from normal prostatic epithelium (-0.32 bp per 
mutation, p < 1e-10, OLS; Figure 45B). Notably, the observed clonality per 
microdissection was not correlated with the ductal distance of the sample, suggesting 
the change in mutational burden and telomere length did not depend on the clonal 
structure but rather were independent and local effects (p = 0.7, OLS; Figure 45C). 
Collectively, these results demonstrate that mutation accumulation and cell division 
are tightly interlinked in normal prostatic epithelium. Furthermore, rates of cell division 
and corresponding accumulation of mutations are variable within the ductal networks 




Figure 45: Mutational Burden and Cell Division Increase in Proximal to Distal 
Fashion within Glandular Subunits. Data points are coloured to distinguish between 
the two main glandular subunits discussed in this chapter and additional ones not 
extensively discussed here.  (A) The mutational burden per microdissection increases 
with the ductal distance to the most proximal sample per glandular subunit. (B) 
Telomere length and mutational burden are highly correlated in prostatic ductal 
epithelium, pointing out cell division and parallel processes as main drivers for 
mutation accumulation. (C) The median VAF per microdissection as a measure for 
clonality does not change with ductal distance to origin. The increased mutational 
burden and decreased telomere length along the proximal to distal axis is not an effect 
of the clonal structure of the microdissection. 
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Complex Lineage Relationships are Observed Within Glandular Subunits 
Information about somatic variants can be used to retrospectively infer the lineage 
relationship of somatic cells. Under the assumption of the infinite site model of 
evolution, shared mutations between currently existing cells imply the existence of a 
MRCA for all cells carrying this mutation 39. In case of single cell or single cell-derived 
organoid data, the lineage tree can in theory directly be inferred from a matrix of 
mutation identity across all considered samples 82,86,344. However, microdissections 
from prostatic epithelium comprised several hundred to a few thousand somatic cells, 
which made consideration of the clonal structure within one microdissection necessary 
before generation of a lineage tree. Microdissections from the left- and right-hand side 
of the prostate reconstructed to most detail displayed median VAFs of 27% 
(SD = 14%) and 26% (SD = 13%), respectively. These moderate median VAFs 
suggested that cells within one microdissection did not share a very recent MRCA. 
While glandular epithelium was targeted in the microdissections, residual 
contamination with surrounding stromal cells would explain a distant MRCA. Notably, 
detachment of the epithelial structures from the surrounding stroma was frequently 
observed as common artefact from tissue processing. These structures could be 
sampled with minimised risk for stromal contamination and displayed a similar degree 
of polyclonality. Therefore, the observed median VAFs were more likely to be linked 
to the existence of several epithelial clones within one microdissection and the degree 
of polyclonality rendered lineage tree inference strictly based on mutational identity 
inappropriate. 
 
While lineage relationships between microdissections could not directly be inferred 
from a mutation identity matrix, corresponding lineage trees could be derived by 
identifying ancestral clones based on discrete clusters of mutations at similar VAF and 
the relative contribution of the ancestral clones to individual microdissections. This is 
explained in the methods section in more detail. For the left- and right-hand side 
structure with 91 and 88 WGS samples, a total of 25,163 and 62,759 mutations were 
grouped into 64 and 79 clusters, respectively. While most clusters only contributed to 
a limited number of microdissections, for both glandular subunits three clusters could 
be identified that contributed evenly to a low percentage in all microdissections. Upon 
manual inspection, these clusters were shown to nearly exclusively include mutations 
in adjacency to short mononucleotide stretches or from repetitive genomic regions 
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(Figure 46). These artefactual clusters as well as all clusters with less than ten 
mutations were excluded before manual inference of the lineage tree based on the 
pigeonhole-principle. From the remaining 39 and 49 clusters for the left- and right-
hand structure, 37 and 43 clusters could be placed on the respective lineage trees for 
the two glandular subunits accounting for 19,624 and 31,046 mutations. The clusters 
that could not be placed during this step represent a resolution limitation of the 
clustering algorithm used. Especially mutations at low VAFs in one or few samples 
cannot correctly be placed. Therefore, the presented phylogenies are an 
approximation with greater inaccuracy in terminal branches. 
 
 
Figure 46: Discrete Clusters of Mutations Identify Ancestral Clones that 
Contribute to Current Prostatic Epithelium. Clusters of mutations are identified 
based on VAF using an n-HDP clustering algorithm and constitute the rows of the 
heatmap. These clusters of mutations represent ancestral clones which contribute to 
current cells sampled in individual microdissections, which are shown in the columns 
of the heatmap. The median VAF of cells associated with an ancestral cluster is used 
to estimate the cellular contribution to each microdissection and is visualised using 
colour intensities. The co-occurrence of multiple ancestral clones within the same 
microdissection sample and their corresponding cellular contribution was used to 
construct the lineage tree for individual glandular subunits. The shown example 
corresponds to the glandular subunit on the left-hand side of the prostate. Cluster 70, 
9 and 7 include nearly exclusively artefactual mutations and were excluded from the 
lineage tree. Furthermore, cluster 1 and 41 are insufficiently split by the clustering 
algorithm used and could not be placed unambiguously. 
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The two inferred phylogenetic trees revealed complex lineage relationships within 
individual glandular subunits and shared common patterns between both structures. 
The 37 clusters from the left-hand side glandular structure were divided into nine 
distinct clades (Figure 47). Four of these clades included 28 of the 37 clusters and 
featured several parallel as well as nested branches. These four clades were all 
defined by an initial cluster of only 13 – 16 mutations, named Cluster 67, 72, 76 and 
77 respectively, according to the random naming convention of the n-HDP clustering 
algorithm. Notably, the most terminal branches in these clades extended to 
approximately 1,000 - 1,500 mutations. Data presented earlier showed that somatic 
mutations accumulate linearly with age (Figure 40), and unpublished work from our 
laboratory has indicated that fetal tissues at around 18 weeks of gestation have 
accumulated 20 – 40 mutations per cell (MS Chapman, Personal Communication). 
Therefore, these four clusters with 13 – 16 mutations each must represent ancestral 
clones that existed very early in life, likely during embryonic development. Directly 
underneath Cluster 76 and Cluster 77, three short branches of 18-21 mutations are 
observed defined by Cluster 20 as well as Cluster 19 and 85. After these early 
coalescences that also potentially occurred during embryonic development, a second 
group of seven coalescence events was observed in the clades defined by Cluster 67 
and 76 as well as two further clades defined by Cluster 13 and 38. Considering the 
total branch length of these coalescence events, they occurred after the accumulation 
of 414 (SD = 117, range 248 - 602) mutations on average. According to the age 
regression, the average mutational burden of 414 is reached after 16 to 17 years. 
Remarkably, the observed mutational burden for these clones is similar to, but slightly 
lower than the mutational burden observed in microdissections from the 22-year-old 
donor PD43390 with average corrected burden of 439 (SD = 175, range 129 - 745) 
mutations. Therefore, this second wave of coalescences is likely to have occurred 
during adolescence. While coalescence events were observed during embryonic and 
pubertal development in six of the nine clades, three additional polytomous clades 
without further sub-nesting and respective burden of 527, 795 and 1,218 mutations 
were observed (Figure 47).  
 
For the right-hand side glandular subunit, a lineage tree with 16 clades comprising 43 
ancestral clones could be inferred (Figure 48). Again, four clades were defined by 
initial coalescences after 10 – 27 mutations and included 25 ancestral clones in 
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parallel and sub-nested branches. The ancestral clones corresponding to Cluster 8, 
61, 71 and 98 were again likely to represent embryonic development. A second group 
of coalescence events was observed in three of these clades as well as in four further 
clades defined by Cluster 11, 16, 31 and 119. Similar to the second group of 
coalescence events observed in the lineage tree for the previously described glandular 
subunit, these coalescence events were associated with an average mutational 
burden of 338 (SD = 66, range = 193 - 415) mutations. Therefore, these events were 
likely to have happened during pubertal development. In addition to the eight clades 
with embryonic or pubertal coalescence events, a total of eight additional clades 
without any internal coalescence events was observed (Figure 48). 
 
While no further coalescence event was observed in the lineage tree for the glandular 
subunit on the left-hand side of the prostate after the events associated with pubertal 
development, further sub-nesting in the lineage tree of right-hand side structure could 
be observed in the clade defined by Cluster 98 (Figure 48). Here, Cluster 118 was 
identified as an ancestral clone that existed with a total mutational burden of 981 
mutations. Moreover, Cluster 36 was identified within the progeny of Cluster 118 with 
an additional 267 mutations. These coalescence events were unique and could not be 
dated back to embryonic or pubertal development. Thus, they potentially happened 
during adult tissue homeostasis. Remarkably, the R219S driver mutation in the 
FOXA1 gene identified in a previous analysis was associated with Cluster 118 
(Table 3). 
 
In summary, the analysis of lineage trees from two glandular subunits of the same 
donor revealed complex lineage relationships in the long-ranging ductal network. 
Coalescence events were likely to be associated with the time periods of embryonic 
and pubertal development. Moreover, the only observed coalescence events that 
could reliably be associated with the time period of adult tissue homeostasis were 




Figure 47: Phylogenetic Tree of Prostatic Epithelium From a Glandular Subunit 
of the Left-Hand Side of the Prostate. Mutations called in microdissections from 
prostatic epithelium were clustered to reveal the presence of ancestral clones that 
gave rise to the sampled cells. These ancestral clones were arranged in a lineage tree 
based on their co-occurrence pattern and cellular contribution to individual 
microdissections. Solid lines indicate nesting with absolute confidence, while 
relationships marked by dashed lines are highly supported but not strictly necessary 
(see methods section). Four main clades defined by ancestral clones 67, 72 76 and 
77 comprised 28 of the 37 identified clones in this lineage trees. These ancestral 
clones as well as Cluster 19, 20 and 85 were dated to embryonic development. A 
second group of coalescence events was observed at average mutational burden of 






Figure 48: Phylogenetic Tree of Prostatic Epithelium From a Glandular Subunit 
of the Right-Hand Side of the Prostate. Mutations called in microdissections from 
prostatic epithelium were clustered to reveal the presence of ancestral clones that 
gave rise to the sampled cells. These ancestral clones were arranged in a lineage tree 
based on their co-occurrence pattern and cellular contribution to individual 
microdissections. Solid lines indicate nesting with absolute confidence, while 
relationships marked by dashed lines are highly supported but not strictly necessary 
(see methods section). The four clades defined by Cluster 8, 61, 71 and 98 revealed 
ancestral clones that were likely to have existed during embryonic development. The 
majority of further coalescence events was observed at total mutational burdens of 
193 – 415 mutations, which point to ancestral clones that have existed during 
adolescence. Notably, Cluster 118 and 36 were identified as unique ancestral clones 
that must have existed during adult tissue homeostasis. Cluster 118 included an 
established prostate cancer driver mutation in FOXA1. 
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Directed Morphogenesis is Observed During Embryonic and Pubertal 
Development of Glandular Subunits 
The relative cellular contribution of ancestral clones to microdissections from two 
reconstructed glandular subunits was explored in their corresponding 3D-models to 
consider the interdependence of phylogenetic and morphological relationships (see 
Figure 44 for an overview of the 3D models). In general, similar observations could be 
made in both glandular subunits.  
 
Clusters that were dated back to embryonic development displayed a very wide and 
mostly contiguous distribution across several different main and side ducts. For the 
left-hand glandular structure, where a higher percentage of all clones was found to be 
nested within one of the four main clades defined by such an embryonic development 
clone, most microdissections displayed a contribution of greater than 70% of one of 
these four clones. In several examples, the relative cellular contribution of each of 
these clones to individual microdissections increased in a proximal to distal direction. 
Remarkably, while their general spatial distribution largely overlapped, the contribution 
to individual microdissections was largely mutually exclusive (Figure 49). 
 
More recent clones still displayed a contiguous but more spatially confined distribution. 
Clones that were nested in the phylogenetic tree also showed a matching nesting in 
the anatomical ductal tree - that is, the subclone of an ancestral clone was confined to 
a subsection of the duct encompassed by the ancestral clone. Parallel branches within 
the same clade usually displayed a mutually exclusive distribution. While clones that 
existed during embryonic development were found to be widely distributed across 
several main and side-branches of the ductal network, the clones associated with 
pubertal development were mainly found in one or few directly adjacent side-branches 
(Figure 50). Cellular contribution of pubertal clones usually increased in proximal to 
distal direction and commonly reached over 50%. Since even proportions of luminal 
and basal cells constitute normal prostatic glandular epithelium, MRCAs with cellular 





Collectively, the spatial distribution of ancestral clones that were associated with 
embryonic and pubertal phases supported a model of directed morphogenesis during 
prostate development. Remarkably, only few clones were implied to initially give rise 
to the ductal network during embryonic development and another more spatially 
confined expansion in proximal to distal direction was suggested during adolescence. 
 
 
Figure 49: Few Ancestral Clones Contribute to a Whole Glandular Subunit 
During Embryonic Development. The cellular contribution of four main ancestral 
clones that were dated back to embryonic development during lineage tree 
reconstruction of the glandular subunit from the left-hand side of the prostate is 
displayed. Light grey colours indicate absence of clones while more intense colours 
show higher contributions to the cell mass comprising the corresponding 
microdissection. These four clones display a wide and mainly contiguous spatial 
distribution. While their general distribution overlaps, the contribution to individual 
microdissections is largely mutually exclusive. (A) Cluster 77. (B) Cluster 76. (C) 




Figure 50: Phylogenetic Relationships are Recapitulated by the Spatial 
Distribution of Clones. Clones that were nested underneath more ancestral clones 
in the lineage tree displayed a contiguous but more spatially confined distribution. 
Parallel branches usually displayed a mutually exclusive spatial distribution. 
(A) Cluster 76 represented a clone that was dated back to embryonic development 
within the glandular subunit on the left-hand side of the prostate. (B) Cluster 20 was 
nested underneath Cluster 76 in the lineage tree and showed a more spatially confined 
distribution within the area covered by Cluster 76. (C) Cluster 25 was further nested 
underneath Cluster 20 on the lineage tree, which was also reflected by an even more 
restricted spatial distribution. Cluster 25 was dated to have existed during 
adolescence. (D) Cluster 34 represented another ancestral clone during adolescence 
and was nested underneath Cluster 76. Notably, it represents a parallel branch to 
Cluster 20 and 25. Cluster 34 covered a contiguous area within Cluster 76 but did not 
display a spatial overlap with the clones defined by Cluster 20 and 25. 
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Local Proliferation of Progenitor Cells is Suggested During Adult Tissue 
Maintenance 
Similar to the trend that pubertal clones were observed with more confined spatial 
distribution compared to embryonic clones, the more recent terminal nodes generally 
displayed an even more confined but still contiguous distribution. Terminal nodes of 
clusters with hundreds of mutations were commonly only observed in few 
microdissections. Similar to the observation for ancestral and pubertal clones, the 
cellular contribution to microdissections often increased in proximal to distal fashion.  
 
However, few examples with the highest contribution to more proximal 
microdissections could be observed. For example, Cluster 36 that was nested 
underneath the embryonic clone Cluster 76 and 25 as well as the pubertal clone 
Cluster 20 was observed in three contiguous microdissections from a peripheral side 
duct (Figure 47 and 51A). Within these microdissections, Cluster 36 contributed to 
29% of the most proximal sample, 5% of the middle one and 10% of the most distal 
sample. Cluster 36 was associated with 753 mutations and only 176 and 230 of these 
mutations were detected in the two more peripheral samples. The sequencing depth 
at the remaining 523 – 577 loci ranged between 21 – 28 in the peripheral samples, 
setting the VAF detection limit at about 4%. Notably, the median VAF of the detected 
mutations was substantially higher with 9% and 13% and potentially suggested an 
incomplete split of Cluster 36 during the n-HDP-based identification of ancestral 
clones.  
 
Notably, the most proximal sample with the highest contribution of Cluster 36 featured 
the lowest clonality of the three microdissections with a global median VAF of 24%. In 
contrast, the two more peripheral microdissections featured median VAFs of 37% and 
33%, respectively. The higher clonality in the more distal samples suggested that 
absence of the remaining 523 – 577 mutations associated with Cluster 36 in the more 
peripheral microdissections was not due to a technical limitation of the WGS approach. 
Remarkably, the distance between the most proximal and middle microdissection of 
the presently described side duct were only 140 µm (Figure 51A).  
 
Several other examples for substantial local accumulation of mutations could be 
observed like Cluster 21 for the glandular subunit on the left-hand side that marked 
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the acquisition of at least 300 mutations across a distance of just 250 µm. Notably, 
Cluster 21 contributed to 58% of the cells in one microdissection (Figure 51B). 
Contributions to over 50% of the cellular mass of microdissections from glandular 
epithelium were observed for several terminal branches that marked MRCAs, which 
have existed during the time period of adult tissue maintenance. As explained for the 
pubertal clones, these MRCAs must have had at least bipotent lineage potential as 
they had to give rise to luminal as well as to basal cells. 
 
In summary, most terminal nodes that marked the period of adult tissue homeostasis 
were strongly spatially confined, commonly displayed at least bipotent lineage 
potential and acquired hundreds of private mutations across a distance of a few 
hundred micrometres. Hence, the presented data suggested extensive local 
proliferation of progenitor cells for adult tissue maintenance. 
 
 
Figure 51: MRCAs That Existed During Adult Tissue Homeostasis Are Strongly 
Spatially Confined and Display High Amounts of Private Mutations. (A) 
Cluster 36 from the left-hand side glandular subunit is associated with 753 mutations. 
Substantial evidence for the presence of Cluster 36 is only observed in the most 
proximal microdissection from a peripheral side duct. A total of three microdissections 
were sampled from this duct but no support for over 500 of Cluster 36-associated 
mutations is found in the two more peripheral samples. The ductal distance between 
these microdissections was 140 µm. (B) Cluster 21 from the left-hand side glandular 
subunit contributes to over 50% of the sampled cells in a single peripheral 
microdissection. No evidence for over 300 mutations associated with Cluster 21 could 
be observed in the adjacent microdissection despite similar clonality in these samples. 
The ductal distance between these microdissections was 250 µm. 
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A Prostate Cancer Driver Mutation is Associated with Spatial Expansion of an 
Adult Clone 
With the exception of all but two observed coalescence events, ancestral clones that 
were widely distributed across the ductal network, were likely to be linked to embryonic 
or pubertal development. However, Cluster 118 and Cluster 36, which was nested 
underneath Cluster 118, were found in the glandular subunit of the right-hand side and 
represented ancestral clones with a total burden of 981 and 1,248 mutations, 
respectively. The clade defined by Cluster 118 was nested underneath the embryonic 
clone Cluster 98 and the pubertal clone Cluster 85 was found in parallel (Figure 48).  
 
In contrast to the limited spatial distribution of other adult clones across few 
microdissections within one or few spatially related ducts, cellular contribution of 
Cluster 118 was prominent in 13 microdissections covering one main peripheral duct 
with four outgoing branches. Cellular contribution of Cluster 118 ranged between 40 – 
80% in these microdissections. Cluster 36 was present in most of these 
microdissections as well but its cellular contribution only exceeded 20% in 6 
microdissections in two spatially related side branches. Cluster 118 displayed greater 
spatial distribution than the parallel pubertal clone Cluster 85 and covered most of the 
spatial territory of its embryonic clone Cluster 98 (Figure 52). 
 
As explained during description of the lineage trees, Cluster 118 contained a prostate 
cancer driver mutation in FOXA1. Considering the distance to the closest followed 
branching points before substantial contribution of Cluster 118 was detected, a total 
of about 4 mm of spatially contiguous and histologically normal glandular tissue was 
implied to carry this driver mutation. This suggested that the presence of driver 
mutations can result in substantial clonal expansion within normal prostatic ductal 
tissue during adult tissue homeostasis. 
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Figure 52: An Adult Clone Carrying a Prostate Cancer Driver Mutation Displays 
Great Spatial Distribution Within Normal Glandular Epithelium. The lineage tree 
for the corresponding glandular subunit on the right-hand side is shown in Figure 43. 
(A) The embryonic clone represented by Cluster 98 displays wide spatial distribution 
in two main peripheral ducts. (B) Cluster 118 associated with a FOXA1 driver mutation 
represents an adult clone that occupies most of the territory of its corresponding 
ancestral clone that existed during embryonic development. (C) Cluster 36 is 
subclonal to Cluster 118. (D) The pubertal clone represented by Cluster 85 is a parallel 
branch to Cluster 118 and is shown for comparison of clonal expansion during pubertal 
morphogenesis. 
 
SBS40 is Only Detected in Recent Ancestral Clones  
The mutational landscape in normal prostatic epithelium was shown to be dominated 
by clock-like mutational signatures. Notably, mutational signatures were slightly more 
diverse in microdissections from older prostate tissue donors. SBS40 was the only 
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additional signature identified in prostatic tissue from two donors with higher 
contribution in the older donor (Figure 41). In addition to comparison of the mutational 
signatures across donors, the phylogenetic trees of glandular subunits allowed for the 
investigation of changing mutational signatures with time within the same patient. 
Mutational signatures were extracted for all clusters that could be placed in the 
phylogenetic trees and SBS1, SBS5 and SBS40 were identified for both glandular 
subunits. Notably, SBS40 was only identified in two terminal branches for the glandular 
subunit on the left-hand side and in eleven terminal branches for the respective subunit 
on the right-hand side of the prostate. In these thirteen terminal branches, SBS40 
contributed to a median of 50% of the associated mutations with SBS1 accounting for 
a median of 11% and SBS5 for a median of 39%. For the remaining branches, median 
contributions of SBS1 of 14% and SBS5 of 86% were observed (Figure 53). Hence, 
SBS40 was only observed in more recent clones that were not associated with 
embryonic or pubertal development. However, not all terminal branches displayed a 
contribution of SBS40, indicating a more complex relationship than the switch from 
development to tissue maintenance. 
 
 
Figure 53: Contribution of SBS40 is Only Detected in More Recent Common 
Ancestors. Mutational signatures were extracted for all ancestral clones that were 
placed on the lineage trees for two glandular subunits. The clock-like mutational 
signatures SBS1, SBS5 and SBS40 were identified in both structures. Notably, SBS40 
was only detected in more terminal branches. These terminal branches were 




The presented work highlights multiple insights into the mutational landscape of 
normal prostate epithelium with relevance to prostate cancer. Mutations were 
demonstrated to accumulate with age as well as throughout the ductal network of 
individual glandular subunits with increasing distance from the peri-urethral ducts 
(Figure 40 and 45A). These observations align well with the strongly increased 
prostate cancer risk in older men in general and in glandular acini in particular as these 
represent the most distal parts of the glandular network 307,311.  
 
The spatial effect of a proximal to distal increase in mutational burden could only be 
considered for the donor of the whole prostate sample, where morphological 
reconstruction of individual glandular subunits was possible (Figure 42 - 44). For the 
remaining donors, small prostate biopsies were obtained without information about 
their original anatomic location. While primarily small terminal ducts and acini were 
sampled for WGS for these donors, a precise localisation within individual glandular 
subunits was impossible. To improve the estimates for age-dependent accumulation 
of mutation, sampling within morphologically reconstructed glandular tissue would be 
essential to account for the substantial intra-individual variation observed in the 
presented data set. Despite these limitations, a significant linear correlation of 
mutation accumulation with age could be shown (Figure 40). The proposed model 
estimated an increase of 16 mutations per year with an offset of 150 mutations. 
Notably, the considered age range was between 22 and 78 years of age. Therefore, 
all considered donors had completed pubertal development, which is associated with 
extensive morphogenesis 299,300,303-305. Extending the considered age range to pre-
pubertal stages would allow to estimate a potential difference in mutation rates before 
and after finalisation of prostatic development, which is suggested by the substantial 
offset. However, access to pre-pubertal human prostate samples is extremely limited. 
Consequently, the estimated mutation rate of 16 per year should be limited to the 
phase of adult tissue maintenance. 
 
This mutation rate is lower than in several other adult human tissues such as small 
intestine, colon, liver, endometrium or oesophagus with estimated rates between 
23 – 42 mutations per year 68,70,84,92. However, it is well in line with the mutation rates 
for satellite cells in skeletal muscle, which were estimated to acquire 13 mutations per 
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year 274. Remarkably, both satellite cells in skeletal muscle as well as adult prostate 
epithelium are quiescent cell and tissue types 324,345. Therefore, the lower mutation 
rates in these tissues potentially mirror a reduced cellular turnover. 
 
The pronounced interdependence between cell division and mutation accumulation in 
normal glandular epithelium of the prostate was suggested by the significant 
relationship between telomere length and mutational burden as well as the dominance 
of clock-like mutational processes (Figure 45B and 41) 66. SBS1 and SBS5 contributed 
to the majority of mutations in all donors and SBS40 in two of the older donors 
(Figure 41). Remarkably, presence of SBS40 could only be detected in terminal 
branches on the lineage trees that represent more recent clones for both 
morphologically reconstructed glandular subunits (Figure 53). Collectively, these 
observations suggest that additional mutational processes are active in the aging 
prostate. Given the strong age-dependence of prostate cancer and observation of 
SBS40 in corresponding genomes, this highlights a potential disease relevance of 
these mutational processes 36. 
 
In addition to the insights into the mutational landscape of normal prostatic glandular 
epithelium, the observed mutations and their distribution across individual glandular 
subunits allowed for exploration of the clonal dynamics within the human prostate. 
Individual mutations were clustered to identify ancestral clones that could be placed 
onto phylogenetic trees (Figure 46 - 48). Using information about the temporal 
sequence of existence of these clones and their corresponding mutational burden, 
clones were associated with embryonic and pubertal development as well as with adult 
tissue maintenance. Through combination of this phylogenetic information with the 
spatial distribution of these clones within morphologically reconstructed glandular 
subunits, several features of development and tissue maintenance could be inferred 
(Figure 49 - 52). 
 
Only few embryonic clones could be observed but these provided high cellular 
contributions to nearly all microdissections sampled throughout the ductal network 
(Figure 49). This highlights that only small numbers, maybe as few as four to six, 
embryonic cells give rise to whole glandular subunits during embryonic development. 
Notably, embryonic clones displayed a contiguous distribution throughout the ductal 
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network and could be found in proximity to other embryonic clones. However, their 
contribution to individual microdissections was largely mutually exclusive (Figure 49). 
These findings are in line with anatomic observations during embryonic development 
and corroborate the suggested stochasticity during branching 
morphogenesis 290,301,302. Budding tips extend from the urethra-proximal prostate to 
generate the immature ductal network and the cells present at budding tip formation 
give rise to the whole glandular subunit. Stochastic branching of a subset of the cells 
within each budding tip explain the overall wide distribution throughout the glandular 
subunit but mutually exclusive contribution to smaller terminal side branches. Such a 
stochastic and long-ranging model of clonal distribution during embryonic 
development is also in line with the in-situ lineage tracking of COX-deficient clones in 
prostatic glandular epithelium 295,331,332. 
 
Following the phase of embryonic development, a second group of ancestral clones 
was associated with pubertal development in accordance to the model considering 
age-related accumulation of mutations and through similarity of their mutational 
burden with the one observed in microdissections from a 22-year-old donor 
(Figure 40). Notably, the bimodal clustering of coalescences implied to occur during 
embryonic and pubertal development, respectively, aligns well with the described 
quiescence between these periods and distinct morphogenic bursts 299,303,305. Pubertal 
clones displayed a contiguous but more spatially confined distribution than embryonic 
clones. When a pubertal clone could be associated with an embryonic clone, the 
pubertal clone was always observed within the area covered by the embryonic clone. 
Some pubertal clones covered several sampled side ducts but their corresponding 
branching points were always in very close distance to each other (Figure 49 and 50). 
Commonly, the cellular contribution of pubertal clones implied at least bipotent lineage 
potential. These observations can be explained through the second burst of branching 
morphogenesis during adolescence 299,303,305. Budding tips are still observed 
throughout the ductal network of the pubertal prostate and are enriched at branching 
points 300. Directed morphogenesis in proximal to distal direction similar to embryonic 
development gives rise to the more complex adult glandular network 299,300,303. 
However, the presented data implies that scattered stem cells within budding tips can 
initiate this branching morphogenesis throughout the ductal network and contribution 
from a peri-urethral stem cell compartment is not strictly necessary.  
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Subsequent to adolescence, the prostate enters a stage of adult tissue homeostasis. 
Notably, the human prostate is a comparatively quiescent organ and the time for 
epithelial cell turnover is estimated to be around 200 days 324. Despite the low 
proliferation rates, several clones that have existed during the period of adult tissue 
maintenance could be identified. These clones displayed an even more spatially 
confined distribution than pubertal clones and significant cellular contribution was 
usually only observed in one or few adjacent microdissections. Remarkably, despite 
the long cellular turnover times, adult clones featured hundreds of private mutations 
that were commonly not detectable in adjacent microdissections. Cellular contribution 
of adult clones often increased in proximal to distal direction but few examples of the 
most substantial contribution in more proximal microdissections were also observed. 
The cellular contribution for several of these clones indicated at least a bipotent 
lineage potential (Figure 51). 
 
The observation that hundreds of mutations are acquired in common ancestors for 
basal and luminal epithelium across a distance of a few hundred micrometres, 
suggests a localised population of cells that is long-lived, has high proliferative 
capacity and multipotent lineage potential. This aligns well with the previous 
identification of small and isolated cell populations that were scattered throughout the 
ductal network and display stem cell markers 324-328. While the previously published 
model of continuous directed migration of basal stem cells from a peri-urethral niche 
to distal parts of the glandular network cannot be ruled out with the presented data, 
any directed migration is suggested to be an extremely slow process 295. Nearly the 
full mutational burden per microdissection that is dated to adult tissue maintenance is 
private to a ductal area of few hundred micrometres. Therefore, the presented data 
primarily supports a model of scattered ASCs during tissue maintenance and the 
detection of directed long-ranging COX-deficient clones would be attributed to 
morphogenesis during pre- and post-natal development. To further corroborate this 
model, a more precise and location-specific determination of the epithelial cell turnover 
time and the corresponding mutation rate would be needed. Additionally, targeted 
deep-sequencing of the previously identified mutations and more extensive 
microdissection sampling throughout the ductal system would allow for a more precise 
definition of clonal territories to estimate the contribution of residual directed migration 
during the adult life stage more accurately. 
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A model of local proliferation of a stem-cell like population during adult tissue 
maintenance is further supported by the fact that the only adult clones that displayed 
greater spatial distribution were linked to a prostate cancer driver mutation. 
Cluster 118 included the R219S mutation in FOXA1 and displayed greater spatial 
distribution than a parallel pubertal clone that originated from the same embryonic 
clone (Figure 52). FOXA1 mutations are used as molecular classification marker in 
prostate cancer and were demonstrated to substantially increase cellular proliferation 
rates 341-343. Cluster 118 was observed throughout 13 contiguous microdissections 
covering a main peripheral duct and several corresponding side branches (Figure 52). 
Notably, substantial subclonal evolution within this local area was suggested by three 
further clones that derived from cellular progeny of Cluster 118 (Figure 48 and 52). 
This extensive subclonal evolution during the adult life stage within a localised area of 
a peripheral duct is another strong indication of a long-lived but localised cell 
population that is responsible for tissue maintenance. 
 
Furthermore, the spatial expansion of a clone carrying a proliferation-enhancing 
prostate cancer driver mutation within normal glandular epithelium highlights the 
selective advantage of these mutations within normal tissues 137,343. While high 
prevalence of driver mutation-associated clones was demonstrated within normal skin, 
oesophagus and endometrium, clonal expansion of the FOXA1-associated clone was 
the only one observed in the presented data and no global signals of positive selection 
could be detected 68-70,92,93. However, the mutational burden in prostate cancer is 
comparatively low, the driver landscape heterogeneous and only the most prevalent 
rearrangements were considered in this study 307,317,319. Therefore, additional disease-
relevant mutations could have been missed. Still, the remaining clonal expansions 
were potentially linked to developmental morphogenesis, which supports a primarily 
neutral genomic background in histologically normal glandular epithelium of the 
human prostate. 
 
The proposed model can be summarised as directed morphogenesis during 
development followed by an adult phase dominated by proliferation of scattered 
progenitor cells with rare expansions of driver mutation-associated clones that can 
display extensive subclonal evolution. This model aligns the previously reported 
observations of distinct stem cell populations throughout the ductal networks with the 
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long-ranging COX-deficient clones reported from in-situ lineage tracking 295,324-
328,331,332. Moreover, it provides an explanation for the observation of multiple prostate 
cancer foci, which are implied to share some of their mutational history but are 
suggested to have eventually derived from distinct clones 313-316.  
 
In summary, the presented work highlights mutational processes in normal glandular 
epithelium that are relevant to our understanding of prostate cancer development. 
Moreover, this is the first description of clonal dynamics within prostatic glandular 
subunits based on a whole-genome scale. Differences between developmental and 
tissue maintenance stages are implied and a model that aligns previous insights into 







Somatic mutation is a natural process that starts at fertilization and continues to shape 
tissue and cell heterogeneity throughout life. In the presented thesis, various 
techniques are advanced or applied to study the relevance of somatic mutation in the 
context of health and disease. Furthermore, the continuity of somatic mutation is 
utilised to retrospectively analyse the clonal dynamics within a human tissue, avoiding 
the need for artificial markers or model organisms. 
 
The mutational landscapes of human tissues are diverse and can instruct us about 
their cellular biology. Here, the mutational spectrum of somatic base substitutions was 
reported for cortical neurons that exist in a post-mitotic state for several decades and 
a direct link to active transcription was established. In contrast, the mutational burden 
acquired through substantial cellular proliferation during two distinct morphogenic 
bursts identified potentially neutral and long-ranging clonal expansion in the human 
prostate during embryonic and pubertal development. 
 
While somatic mutation is common in normal human tissue, distinct alterations or 
combinations thereof can lead to severe tissue malfunction and disease. Recent 
surveys have started to explore the mutational processes in the corresponding normal 
tissues and most of the work presented in this thesis is placed within this context. 
While especially meta-analyses of the rich data available for the diseased state will 
continue to further our understanding of aberrant processes as demonstrated in one 
of the presented chapters, deeper insights into the mutational landscape and somatic 
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ASC Adult Stem Cell 
ASE Allele-specific Expression 
ASMD Median Alignment Score 
AUROC Area Under Receiver Operating Characteristic 
BLCA Bladder Urothelial Cancer 
bp Base Pair 
BPH Benign Prostate Hyperplasia 
cDNA Copy DNA 
CML Chronic Myeloid Leukaemia 
CPM Counts per Million Mapped Reads 
DHT Dihydrotestosterone 
DSB Double-strand Break 
FACS Fluorescence-activated Cell Sorting 
FISH Fluorescence in-situ Hybridisation 
GBM Glioblastoma 
gDNA Genomic DNA 
GenomiPhi Single Cell GenomiPhi DNA Amplification Kit from GE Healthcare 
Life Sciences 
gHet Germline Heterozygous SNP 
GLM Generalised Linear Model 
GO Gene Ontology 
H&E Haematoxylin and Eosin Staining 
HCC Hepatocellular Carcinoma  
ICGC International Cancer Genome Consortium 
IPC Intermediate Progenitor Cell 
iPSC Induced-pluripotent Stem Cell 
kb Kilobase 
LCM Laser-Capture Microscopy 
Mb Megabase 
MDA Multiple Displacement Amplification 
MDS Multidimensional Scaling 
MRCA Most Recent Common Ancestor 
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mRNA Messenger RNA 
n-HDP N-Dimensional Hierarchical Dirichlet Process 
NE Neuroendocrine Cells 
NEC Neuroepithelial Cells 
OLS Ordinary Least Squares Regression  
OSC Ovarian Serous Carcinoma  
PCA Principal Component Analysis 
PCAWG Pan-Cancer Analysis of Whole Genomes Project 
QC Quality Control 
RepliG Repli-g Single Cell Kit from Qiagen  
ROS Reactive Oxygen Species 
RT Reverse Transcription 
Sanger 
Pipelines 
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scRNA-seq Single Cell RNA-seq 
SMG Significantly Mutated Gene 
SNCT Somatic Nuclear Cell Transfer 
SNP Single Nucleotide Polymorphism 
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SVZ Subventricular Zone 
TCGA The Cancer Genome Atlas 
Trueprime Trueprime Whole Genome Amplification Kit from Expedeon 
TSS Transcription Start Site 
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VAF Variant Allele Fraction 
VZ Ventricular Zone 
WGA Whole-genome Amplification 
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